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1. Introduction 
1.1. Transporters 
Transporters are the gatekeepers for all cells and organelles, facilitating influx and efflux of 
crucial compounds such as sugars, amino acids, nucleotides, inorganic ions and drugs. 
Transporters can be divided into passive and active transporters (Figure 1.1). Passive 
transporters, allow passage of solutes (e.g., glucose, amino acid, urea) across membranes 
down their electrochemical gradients. Active transporters create ion/solute gradients across 
membranes, utilizing diverse energy-coupling mechanisms. These active transporters are 
classified as primary- or secondary-active transporters according to the directness of coupling 
to cellular energy (e.g., ATP hydrolysis, or ion gradients). 
 
 
Figure 1.1 Cartoon showing a cell with different transporters. Solute carrier (SLC)- and non-SLC 
transporters expressed in the plasma membrane or in intracellular compartment membranes are shown. 
Primary-active, ATP-dependent transporters include members of the ATP-binding cassette 
(ABC) transporter family and ion pumps (ATPases). Mammalian ABC transporters [e.g., P-
glycoprotein/multi-drug resistance (MDR) proteins and transporter associated with antigen 
processing (TAP)] bind or hydrolyze ATP as a control gate for the transport of a variety of 
substances such as ions, carbohydrates, lipids, xenobiotics and drugs, out of cells or into 
organelles (Borst and Elferink, 2002). Ion pumps hydrolyze ATP to pump ions such as Na+, 
K+, H+, Ca2+ and Cu2+ out of cells or into organelles, for review see (Dunbar and Caplan, 
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2000; Muller and Gruber, 2003). These pumps also generate and maintain electrochemical ion 
gradients across membrane, and are thus called active transporters. Such ion gradients are 
used in turn by secondary-active, ion-coupled transporters to drive uphill transport of nutrients 
across biological membranes. 
Similar to transporter, channels allow movement of solute down their electrochemical 
gradients, for review see (Armstrong, 2003; Chen, 2003; Decoursey, 2003; Jiang et al., 2003; 
Yu and Catterall, 2003). Transporters typically have a fixed stoichiometry of ion/solute 
movement per translocation cycle. Ion or solute flow through channels, on the other hand, is 
controlled by open probability of the channel via gating mechanisms. 
1.2. Solute carrier (SLC) families of transporters 
The solute carrier (SLC) series includes genes encoding passive transporters, ion compled 
transporters and exchangers (Hediger et al., 2004; Wright and Turk, 2004). A transporter has 
been assigned to a specific SLC family if it has at least 20-25% amino acid sequence identity 
to other members of that family (Turk and Wright, 1997). The list of currently approved SLC 
human gene symbols is shown in Table 1.1. The table comprises 43 different SLC transporter 
families of the SLC series and the number of members in each family. 
 
Table 1.1 List of currently approved solute carrier (SLC) families. 
              The HUGO SLC Family Series Total  
The high-affinity glutamate and neutral amino acid transporter 
family 
7 SLC1 
SLC2 
The facilitative GLUT transporter family 14 
SLC3 The heavy subunits of the heteromeric amino acid transporters 2 
SLC4 The bicarbonate transporter family 10 
SLC5 The Na+/glucose cotransporter family 8 
SLC6 The sodium- and chloride-dependent neurotransmitter transporter 
family  
16 
SLC7 The cationic amino acid transporter/glycoprotein-associated 
amino-acid transporter family 
14 
SLC8 The Na+/Ca2+ exchanger family 3 
SLC9 The Na+/H+ exchanger family 8 
SLC10 The sodium bile salt cotransport family 6 
SLC11 The proton-coupled metal ion transporter family 2 
SLC12 The electroneutral cation-Cl cotransporter family 9 
SLC13 The human Na+-sulfate/carboxylate cotransporter family 5 
SLC14 The urea transporter family 2 
SLC15 The proton oligopeptide cotransporter family 4 
SLC16 The monocarboxylate transporter family 14 
SLC17 The vesicular glutamate transporter family 8 
SLC18 The vesicular amine transporter family 3 
SLC19 The folate/thiamine transporter family 3 
SLC20 The type-III Na+-phosphate cotransporter family 2 
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SLC21/SLCO The organic anion transporting family 11 
SLC22 The organic cation/anion/zwitterion transporter family 18 
SLC23 The Na+-dependent ascorbic acid transporter family  4 
SLC24 The Na+/(Ca2+-K+) exchanger family 5 
SLC25 The mitochondrial carrier family 27 
SLC26 The multifunctional anion exchanger family 10 
SLC27 The fatty acid transport protein family 6 
SLC28 The Na+-coupled nucleoside transport family 3 
SLC29 The facilitative nucleoside transporter family 4 
SLC30 The zinc efflux family 9 
SLC31 The copper transporter family 2 
SLC32 The vesicular inhibitory amino acid transporter family 1 
SLC33 The acetyl-CoA transporter family 1 
SLC34 The type-II Na+-phosphate cotransporter family 3 
SLC35 The nucleoside-sugar transporter family 17 
SLC36 The proton-coupled amino acid transporter family 4 
SLC37 The sugar-phosphate/phosphate exchanger family 4 
SLC38 The System A and N, sodium-coupled neutral amino acid 
transporter family 
6 
SLC39 The metal ion transporter family 14 
SLC40 The basolateral iron transporter family 1 
SLC41 The MgtE-like magnesium transporter family 3 
SLC42 The Rh ammonium transporter family (pending) 3 
SLC 43 The Na+-independent, system-L-like amino acid transporter 
family 
2 
Total  298 
 
In general the genes are named using the root symbol SLC, followed by a numeral (e.g., 
SLC1, solute carrier family 1), the letter A (which act as a divider between the numerals) and 
finally the number of the individual transporter (e.g., SLC5A1, sodium/glucose cotransporter 
protein). These general rules of SLC gene nomenclature have been elaborated further for a 
couple of families. In the nucleotide-sugar transporter family SLC35, the letter between 
SLC35 and family member number has been exploited to specify specific subfamilies, called 
A, B, C, D and E (Ishida and Kawakita, 2004). In another family, originally named SLC21, 
encoding the organic anion-transporting (OATP) proteins, the “21” and the “A” have been 
replaced by the letter “O”, which stands for organic transporter. This modification has 
occurred to accommodate a unique, species-independent classification and naming system that 
has been introduced, because this family has been the subject of rapid evolution, giving rise to 
new isoforms within a given species (Hagenbuch and Meier, 2004). 
1.2.1. Sodium/glucose cotransporter family (SLC5) 
The sodium/glucose cotransporter family (SLC5) has 220 members in animal and bacterial 
cells (Wright and Turk, 2004). An unrooted phylogenetic tree of 11 human members of the 
SLC5 family of cotransporters and two other vertebrate members of known function is shown 
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in Figure 1.2. The 11 human genes (Table 1.2) are expressed in tissues such as the small 
intestine, kidney, brain, muscle, and thyroid gland. Despite the homology among the proteins 
(21-70% amino acid identity to SGLT1) there is diversity in gene structure: in eight of ten 
genes mapped the coding sequences are found in 14-15 exons (SGLT1-6, NIS, and the Na+-
dependent multivitamin transporter SMVT) (Turk et al., 1994; Wang et al., 1999). On the 
other hand the coding sequences for the choline transporter (CHT) and SMIT are contained in 
eight and one exons respectively (Mallee et al., 1997; Okuda et al., 2000). In SGLT4-6 and 
SMIT there is evidence for alternative splicing (Roll et al., 2002). 
 
 
Figure 1.2 Unrooted phylogenetic tree of the 11 human members of the SLC5 family of cotransporters and 
two other vertebrate members of known function. Members for which transport functions have been 
demonstrated experimentally are shown in red. Members shown in black have yet to have their function 
determined. In a pairwise basic local alignment search tool (BLAST) analysis the amino acid identities relative to 
SGLT1 were 59% SGLT2, 70% SGLT3, 56% SGLT4, 57% SGLT5, 50% SGLT6, 55% SMIT, 24% SMVT, 
24% CHT, and 21% NIS (SGLT Na+/glucose transporter, SMIT Na+/myo-inositol transporter, SMVT 
Na+/multivitamin transporter, CHT choline transporter, AIT apical iodide transporter, NIS Na+/iodide 
transporter). 
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1.2.2. Sodium/glucose cotransporter protein (SGLT1) 
SGLT1 (SLC5A1) was expression-cloned in 1987 (Hediger et al., 1987). SGLT1 is expressed 
primarily in the brush border membrane of mature enterocytes in the small intestine where it 
plays a central role for the homeostasis of glucose, galactose, salt and water (Kinne, 1976; 
Wright et al., 1994; Wright and Loo, 2000; Wright et al., 2001). The most well known genetic 
disease caused by SGLT1 is glucose-galactose malabsorption (GGM) (Kasahara et al., 2001; 
Lam et al., 1999; Martin et al., 1997; Martin et al., 1996; Turk et al., 1991; Wright et al., 
2001; Wright et al., 2002). This is a rare autosomal recessive disease (Online Mendelian 
Inheritance in Man database accession No. OMIM 182380) that presents in newborn infants as 
a life-threatening diarrhea. The diarrhea ceases promptly on removing dietary glucose, 
galactose and lactose, but returns immediately on reintroducing one of the offending sugars 
into the child’s diet. In some 46 patients tested sofar mutations have been identified in the 
SGLT1 gene that cause the defect in sugar transport. These include missense, nonsense, 
frame-shift, and splice-site mutations. The missense mutations were studied using the oocytes 
expression system, where the defect in transport in 22 out of 23 mutants was due to missorting 
of the protein in the cell. Surprisingly, some very conservative GGM mutations cause the 
trafficking defect; e.g., four are alanine to valine trafficking mutants. Normal trafficking is 
restored when valine is replaced by cysteine, suggesting that slight conformational changes in 
the protein interfere with interactions between the transport vesicles containing SGLT1 and 
motor proteins responsible for delivery of the vesicle to plasma membrane. 
Human isoforms of SGLT1 are 664 amino acids long with 14 transmembrane α-helices and 
both the N- and C-terminals facing the extracellular fluid (Turk and Wright, 1997) (Figure 
1.3). A secondary structure model as shown in Figure 1.3 is indicating position of loop 13 as 
intracellular (Turk and Wright, 1997), while our group (Lin et al., 1999) results with 6× 
Histidine tagged mutant in COS-7 cells indicates that the last large group (loop13) towards the 
C-terminal end faces the cell exterior where it might be involved in substrate recognition. 
However both the secondary structure models are not able to explain all the functional 
properties of SGLT1, so both models are not 100% correct, but it might be the case that this 
loop exists in dynamic equilibrium between extracellular and intracellular orientations, which 
takes place during the interaction with substrates. 
Extensive molecular biological and biophysical studies of hSGLT1 in Xenopus laevis oocytes 
revealed that the N-terminal half of the protein contains the Na+-binding sites (Meinild et al., 
2001) while the solutes and inhibitors binding sites lies in the C-terminal half of protein 
(Panayotova-Heiermann et al., 1997; Panayotova-Heiermann et al., 1996). Further studies in 
this direction indicate that residue Gln-457, Thr-460 (Diez-Sampedro et al., 2001; Napoli et 
al., 1995) and negative charge at residue Asp-454 form the sugar-binding and translocation 
pathway (Diez-Sampedro et al., 2004). The mechanism by which SGLT1 couple their 
substrates across the cell membrane is still unknown. A commonly proposed kinetic model for 
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sodium/glucose cotransport is a six-state ordered kinetic model (Loo et al., 1993; Loo et al., 
1998; Parent et al., 1992a; Parent et al., 1992b; Peerce and Wright, 1984). The model 
describes sodium/glucose cotransport as a series of ligand-induced conformational changes 
(Figure 1.4). On the external surface of the membrane, two Na+ ions bind to the transporter 
before sugar. The empty transporter C (states 1 and 6), Na+-loaded transporter CNa2 (states 2 
and 5), and the sugar-loaded transporter CNa2S (states 3 and 4) can “cross” the membrane. 
Membrane voltage affects Na+-binding and translocation of the empty transporter. 
 
 
Figure 1.3 Tentative secondary structure model of hSGLT1. hSGLT1 consists of 14 α-helical transmembrane 
domains (shaded columns) with the N- and C-terminal located on the extracellular phase of membrane. The N-
glycosylation site (Asn-248; N) is indicated (Quick and Wright, 2002). 
Heterologous expression of hSGLT1 has been described in Xenopus laevis oocytes (Hediger 
et al., 1987), COS-7 cells (Birnir et al., 1990), CHO cells (Lin et al., 1998), Sf9 cells (Smith et 
al., 1992), and Escherichia coli (Quick and Wright, 2002) and has increased our knowledge 
about functions of transporter significantly but the amount of protein produced in the above 
mentioned systems is not sufficient for most of the biochemical, biophysical and structural 
studies which need tens or some times hundreds of milligrams of highly purified protein. In 
view of these difficulties our group’s previous success in the expression and purification of 
different fragments of SGLT1 (Raja et al., 2003; Xia et al., 2003) and their subsequent use as 
a model for the identification of phlorizin-binding site and alkyl glucosides-binding site as 
studied by fluorescence spectroscopy and affinity labeling (Raja et al., 2004; Raja et al., 2003; 
Tyagi and Kinne, 2003; Xia et al., 2003) provided valuable information about different 
inhibitors mechanism. However there lies an urgent need to express hSGLT1 in full-length 
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and sufficient quantity. To achieve high-level expression of hSGLT1 we chose to use the 
methyltropic yeast Pichia pastoris because in the last 15 years this expression system has 
emerged as the most successful expression system for the heterologous expression of a wide 
variety of foreign proteins (Cereghino and Cregg, 2000; Cregg et al., 2000; Higgins and 
Cregg, 1998), especially membrane proteins, which were either not possible to express in E. 
coli or if possible, express in very low amounts often with loss of functionality. 
 
Figure 1.4 Cartoon of the 6-state ordered kinetic model for sodium/glucose cotransport. States 1-3 face the 
external and states 4-6 internal membrane surfaces, respectively. In the absence of ligands, the transporter exists 
in 2 states (1 and 6). At the external surface, 2 Na+  ions bind to the transporter to form the complex CNa2 (state 
2). The fully loaded transporter CNa2S (state 3) undergoes a conformational change (states 3 to 4) resulting in 
sodium/glucose cotransport. The reaction from state 2 to 5 represents a uniport (“leak”) pathway for the sugar 
(Loo et al., 1998). 
1.3. Pichia pastoris as an expression host 
Pichia pastoris has become a highly successful system for the expression of heterologous 
genes. Several factors have contributed to its rapid acceptance, the most important of which 
include: 
1. A promoter derived from the alcohol oxidase I (AOX1) gene of P. pastoris that is 
uniquely suited for the controlled expression of foreign genes; 
2. The similarity of techniques needed for the molecular genetic manipulation of P. 
pastoris to those of Saccharomyces cerevisiae, one of the most well-characterized 
experimental systems in modern biology; 
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3. The strong preference of P. pastoris for respiratory growth, a key physiological trait 
that greatly facilitates its culturing at high cell densities relative to fermentative yeasts; 
and 
4. A 1993 decision by Phillips Petroleum Company to release the P. pastoris expression 
system to academic research laboratories, the consequences of which has been an 
explosion in the knowledge base of the system. 
As a yeast, P. pastoris is a single-celled microorganism that is easy to manipulate and to 
culture. However, it is also a eukaryote and capable of many of the posttranslational 
modifications performed by higher eukaryotic cells, such as proteolytic processing, protein 
folding, and disulfide bond formation. Thus many proteins that end up as inactive inclusion 
bodies in E. coli are produced as biologically active molecules in P. pastoris. The P. pastoris 
system is also generally regarded as being faster, easier, and less expensive to use than 
expression systems derived from higher eukaryotes, such as insect and mammalian tissue 
culture cell systems, and usually gives higher expression levels. 
A second role played by P. pastoris in research is not directly related to its use as a protein 
expression system. P. pastoris serves as a useful model system to investigate certain areas of 
modern cell biology, including the molecular mechanisms involved in import and assembly of 
peroxisomes, the selective autophagic degradation of peroxisomes, and the organization and 
function of the secretory pathway in eukaryotes. More detailed information on the P. pastoris 
system can be found in the numerous reviews describing the system (Cereghino and Cregg, 
2000; Cregg et al., 2000; Higgins and Cregg, 1998) and the Pichia Expression Kit Manual 
(Invitrogen Corporation, Carlsbad, CA, USA). The DNA sequence of many P. pastoris 
expression vectors and other useful information can be found on the Invitrogen web site 
(http:// www.invitrogen.com). 
In the last few years the following membrane proteins have been successfully expressed in P. 
pastoris, Na+, K+-ATPase (Strugatsky et al., 2003), multidrug resistance protein1 (Cai et al., 
2001), ATP-binding cassette transporter (Cai and Gros, 2003), NOP-1 (Bieszke et al., 1999), 
mammalian intestinal peptide transporter (Doring et al., 1998), human µ-opioid receptor 
(Talmont et al., 1996) and 5HT5A-serotoninergic receptor (Weiss et al., 1998). 
1.4. Photoaffinity labeling 
Photoaffinity labeling and cross-linking refer to a variety of important biochemical techniques 
that are used to investigate structural and functional properties of biological systems, for 
review see (Bayley, 1983; Bayley and Knowles, 1977; Brunner, 1993; Dorman and Prestwich, 
2000). These techniques make use of reagents, which, after targeting to a biological system or 
component, can be activated with UV light to generate highly reactive intermediates capable 
of forming covalent bonds with adjacent molecules. Labeling reagents can be divided into 
three main classes: first, probes designed to report on general properties of a system (for 
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example, small apolar molecules and lipids which partition into membranes and, upon 
activation, label selectively integral membrane proteins) (Brunner et al., 1980; Do et al., 1996; 
D'Silva and Lala, 2000; Heinrich et al., 2000; Mothes et al., 1997), second, affinity labeling 
reagents intended to interact with and label components (receptors, cotransporters, and 
channels) in a specific, functionally relevant manner (Addona et al., 2002; Jahn et al., 2002; 
Kipp et al., 1997; Leite et al., 2003; Thiele et al., 2000; Tyagi and Kinne, 2003), and third, 
heterobifunctional photo cross-linkers, containing a photactivatable and a conventional 
(thermal) reactive functional group, preferentially connected via a cleavable linker. These 
later reagents are primarily used to study the spatial relationship between components in 
complex systems. 
Several successful examples of photoaffinity labeling of membrane proteins have been 
reported; among these are the glucose transporters in the plasma membrane of erythrocytes 
and of adipocytes (Trosper and Levy, 1977), the β-galactoside transport in E. coli membrane 
vesicles (Rudnick et al., 1975), the dipeptide and oligopetides transporters in E. coli (Staros 
and Knowles, 1978), rhodopsin (Borhan et al., 2000), the ATP-binding cassette transporter 
LmrA (van Veen et al., 2000), fatty acid binding proteins in E. coli (Mangroo and Gerber, 
1992), alpha 1-adrenegic receptors of rat heart (Terman and Insel, 1986), anion channel-1 in 
rat brain (Darbandi-Tonkabon et al., 2003), the ion channel of F-ATP synthase (von Ballmoos 
et al., 2004), the synaptic vesicle protein SV2A (Lynch et al., 2004),  the bovine γ-
aminobutyric acid type receptor (Sawyer et al., 2002), and nicotinic acetylcholine receptor 
(Chiara et al., 2003; Pratt et al., 2000; Wang et al., 2000; Ziebell et al., 2004). 
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2. Aim of the study 
Large-scale purification of recombinant human membrane proteins represents a rate-limiting 
step towards understanding their role in health and disease. There are only four mammalian 
membrane proteins of known structure and these were isolated from natural sources. 
However, heterologous expression of hSGLT1 has been described in Xenopus laevis oocytes, 
COS-7, CHO, Sf9 cells, and Escherichia coli but the amount of protein produced in the above 
mentioned systems is not sufficient for most of the biochemical, biophysical and structural 
studies. In order to shed more light on the structure-functions of hSGLT we intend to express 
full-length transporter in high yield to fulfill our requirements of protein amount, which is 
necessary for most of the biochemical and biophysical experiments.  
The elucidation of molecular interactions leading to transport of sugar and its translocation 
pathway through SGLT1 is a major objective of this work. Different methods have been 
widely used for the identification of sugar translocation pathway into SGLT1, but all methods 
were unable to provide an insight into protein structure at molecular level. To overcome this 
problem we proposed the use of photoaffinity labeling of functional domains of SGLT1 with 
different ligands and inhibitors based photoaffinity probes for the identification of sugar 
translocation pathway and inhibitor binding sites. To achieve this aim we proposed the 
synthesis and application of four new photoaffinity probes.  
Therefore the main objectives of this work are: 
1. To achieve high-level heterologous expression, purification and reconstitution of full-
length functional hSGLT1. 
2. Functional characterization of recombinant hSGLT1 by sugar uptake assays. 
3. Synthesis of sugar and phlorizin based photoaffinity probes for the identification of sugar 
translocation pathways and inhibitor binding sites. 
4. Photoaffinity labeling of loop 13 with [(2’-Iodo-4’-(3’’-trifluoromethyldiazirinyl) 
phenoxy]-D-glucopyranoside (TIPDG), [(4’-Benzoyl) phenoxy)]-D-glucopyranoside 
(BzG), and 3-Azidophlorizin (3-AP).  
5. Photoaffinity labeling of recombinant full-length hSGLT1. 
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3. Materials and methods 
Protocols were adapted from standard methods (Sambrook and Russell, 2001) unless 
otherwise mentioned. 
All solutions and media were prepared with ultra-pure water (Milli-Q Plus ultra purification 
pak, Milli-RO Plus purification pak; Millipore, Molsheim, France). 
3.1. General equipments 
Autoclave Autoclave 23; MELAG Medizintechnick (Berlin, Germany) 
Bioclav; Schütt Labortechnik GmbH (Göttingen, Germany) 
Centrifuges Biofuge pico, Omnifuge 2.OR, Megafuge 1.ORS, Heraeus 
(Osterode, Germany) Centrikon H-401, with Rotors A8.24 and 
A6.9; Kontron-Hermle (Gosheim, Germany) 
Chromatography System Automated Econo System; Biorad (Hercules, CA) 
Electroporation apparatus Gene pulser II; Biorad (Hercules, CA) 
Freezer, -70°C ULT1706; Revco Scientific (Asheville, NC),  
Gel documentation camera Polaroid MP-4 land camera; Polaroid USA 
Gel Electrophoresis   Biorad (Hercules, CA) 
Incubators   WTB Binder (Tuttlingen, Germany), Forma Scientific (USA) 
JULABO Labortechnik GmbH 
Liquid nitrogen tank  BT40; L’air liquide (Champigny, France) 
Magnetic stirrer  MR3001; heidolph (Kelheim, Germany) 
MALDI-MS   PE-Biosystems, Shelton, USA 
Microscope   IX50; Olympus Optical GmbH (Hamburg, Germany) 
Oriel photochemical  Oriel, Stratford, CT, USA 
reactor 
Rayonet photochemical  Southern New England, Branford, CT, USA 
reactor 
pH meter   Model 765 Calimatic; Knick (Berlin, Germany) 
Scales    Model BP 2100S; Sartorius (Göttingen, Germany) 
Sonicator   SONOPLUS Bandelin electronic GmbH (Berlin, Germany) 
Spectrophotometer  UVICON 930; Kontron instruments (Echingen, Germany) 
Thermocycler   Mastercycler gradient; Eppendorf (Hamburg, Germany) 
Thermomixer   Thermomixer compact; Eppendorf (Hamburg, Germany) 
Ultracentrifuge OptimaTM TLX, with rotor TLA 100.4; BeckMan Instruments 
Fullerton, CA 
Vortexer   REAX top; Heidolph (Kelheim, Germany) 
Water baths   GFL GmbH (Burgwedel, Germany) 
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Densitometer   Pharmacia LKB (Sweden) 
UV illuminator  Model N90M; UniEquip (Martinsried, Germany) 
3.2. Materials 
3.2.1. Chemicals 
Acryl/Bis 37.5:1; 40% (w/v) Solution AMRESCO Inc. USA 
α-D-Acetobromoglucose   Mo Bio Laboratories, USA 
Agar       Mo Bio Laboratories, USA 
Agarose      Sigma, Munich, Germany 
Ammonium persulphate    Sigma, Munich, Germany 
Ampicillin     Sigma, Munich, Germany 
Bromophenol blue     Sigma, Munich, Germany 
4-Bromoanisol    Sigma, Munich, Germany 
BSA (bovine serum albumin)   Sigma, Munich, Germany 
G250 Brilliant Blue     Serva, Heidelberg, Germany 
α-Cyano-4-hydroxycinnamic acid  Sigma, Munich, Germany 
Dideoxynucleotides    Stratagene Inc USA 
2,5-dihydroxybenzoic acid   Sigma, Munich, Germany 
3,5-Dimethoxy-4-hydroxycinnamic acid Sigma, Munich, Germany 
DMSO      Sigma, Munich, Germany 
DTT       Sigma, Munich, Germany  
EDTA       Sigma, Munich, Germany 
Ethidium Bromide     Sigma, Munich, Germany 
Formamide      Fluka AG, Neu-Ulm, Germany 
FosCholine-12    Anatrace, Maumee, OH, USA 
D-[6-3H] Glucose    Perkin-Elmer, LAS, Germany 
Glycerol     Merck, Darmstadt, Germany 
HEPES      Sigma, Taufkirchen, Germany 
4-Hydroxybenzophenone   Sigma, Munich, Germany 
IPTG       peqLab Biotechnologie, Erlangen, Germany 
Methyl-α-D-[14C] glucopyranoside  Perkin-Elmer, LAS, Germany 
SDS       Sigma, Munich, Germany 
Sodium Azide     Serva, Heidelberg 
Phlorizin     Sigma, Munich, Germany 
TEMED      Sigma, Munich, Germany 
Triton X-100      Sigma, Munich, Germany 
Tryptone      Sigma, Munich, Germany 
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Tween 20      Sigma, Munich, Germany 
Yeast extracts      Sigma, Munich, Germany 
Zeocin      Invitrogen, Carlsad, USA 
All other Chemicals were of analytical grade and obtained from commercial sources. 
3.2.2. Enzymes and reagents for molecular biology 
Restriction enzymes   New England Biolabs GmbH, Frankfurt, Germany  
Taq DNA polymerase   New England Biolabs GmbH, Frankfurt, Germany  
Pfu Ultra HF DNA polymerase Stratagene, Netherlands 
Thermoscript reverse transcriptase Invitrogen GmbH, Karsruhe, Germany 
Calf Intestine alkaline phosphatase Roche Diagnostic, Mannheim, Germany 
T4 DNA ligase   New England Biolabs GmbH, Frankfurt, Germany 
RNaseA     Sigma, Munich, Germany 
DNase I    Roche Diagnostic, Mannheim, Germany 
DNase (Rnase free)   Qiagen, Hiden, Germany 
Lysozyme    Sigma, Munich, Germany 
dNTP     Stratagene, Netherlands 
T4 Polynucleotide kinase  New England Biolabs GmbH, Frankfurt, Germany 
3.2.3. Antibodies 
Anti-FLAG M2 monoclonal antibody peroxidase conjugate  Sigma, Munich, Germany 
Mouse anti-His-tag (27E8) monoclonal antibody              Cell Signaling Technology 
Baverly, USA 
Rabbit anti-human SGLT1 antibody      Acrirs Antibodies, 
Hiddenhausen, Germany 
3.2.4. Commercial Kits and other materials 
QIAquickTM PCR-Purification kit   Qiagen, Hiden, Germany 
QIAquickTM Gel-extraction kit   Qiagen, Hiden, Germany 
QIA®Spin Miniprep kit    Qiagen, Hiden, Germany 
QuickChange® XL Site directed mutagensis kit Stratagene, Netherlands 
Rapid DNA ligation kit    Roche Diagnostic, Mannheim, Germany 
Expend High Fidelity PCR system   Roche Diagnostic, Mannheim, Germany 
Easy SelectTM Pichia Expression Kit   Invitrogen, Carlsbad, USA 
Lowry Protein assay kit    Sigma, Munich, Germany 
HybondTM-C extra blotting membrane  Amersham Biosciences, Germany 
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SuperSignal®West Pico chemiluminiscent   Pierce, Rockland, USA 
Substrate   
Photographic film     Polapan; Polaroid, Offenbach, Germany 
3.2.5. Primers for preparation of cDNA inserts 
Primer Sequence Type, 
restriction site 
SGLT_F TATTGAATTCGATGGACAGTAGCACCTG Sense, EcoR1 
SGLT_R AATACTCGAGGGCAAAATATGCATGGC Antisense, 
Xho1 
∆N12-377SGLT_F CTGCGAGGCCTGATGCTATCAGTCATGCTG Sense 
∆N12-377SGLT_R GGTGGTCTTGGGGCTCCAGGTGCTACTGTC Antisense 
Spacer_His_SGLT_F GGTGGTAGCCCGGGTCACCACCACCACCAC
CACTGAGAT 
Sense 
Spacer_His_SGLT_R GCTTTTATACAGCACGGCAAAATATGCATGG
CAAAAGAC 
Antisense 
T7 promoter_F TAATACGACTCACTATAGGG Sense 
Unc-F_R TTTATTACAGTTCAGCGACAAG Antisense 
SGLT_FLAG_F GACGACGATAAGATCCAAGAAGGCCCTAAG
GAGAC 
Sense 
SGLT_FLAG_R 
 
PBAD_SGLT_R 
ATCCTTGTAATCCAGGTCAATACGCTCCTCT
TTGC    
TAATTAAGCTTTTAGGCAAAATATGCA 
 TGG 
Antisense 
 
Antisense, 
Hind III 
pPICZ_SGLT_F TATTGAATTCAAAATGGACAGTAGCACCTG Sense, EcoR1 
pPICZα_SGLT_R ATTATTGCGGCCGCGGCAAAATATGCATGCC Antisense, Not1
3.2.6. Plasmids 
3.2.6.1. Original plasmids 
Plasmid Description Reference 
pET22b Expression vector, T7-lac promoter, Signal 
sequence at N-terminal of gene, at C-terminal 
His tag, AmpR, origin of replication pBR322. 
Novagen, San Diego, CA, USA 
pBAD24 PBAD promoter, His tag at C-terminal of gene, 
AmpR, pUC origin of replication. 
Invitrogen, Carlsbad, CA, USA 
pPICZB AOX1 promoter, His-tag at the C-terminal of 
gene, ZeoR; CoLE1 origin of replication. 
Invitrogen, Carlsbad, CA, USA 
pPICZαA AOX1 promoter, α-factor secretion signal at the 
N-terminal of gene, His-tag at the C-terminal of 
gene, ZeoR; CoLE1 origin of replication. 
Invitrogen, Carlsbad, CA, USA 
Materials and methods 18
3.2.6.2. Plasmid with insert 
Plasmid Description Reference 
DKFZp686N20230Q2 Plasmid containing full-length hSGLT1 gene RZPD, Berlin, 
Germany 
pET22b-hSGLT1 hSGLT1 gene cloned in pET22b This study 
pET22b-hSGLT1-
Spacer 
hSGLT1 gene cloned in pET22b with DNA 
sequence encoding for a 10 amino acids long 
spacer at the C-terminal of gene 
This study 
pET22b-∆N12-377 
hSGLT1 
hSGLT1 gene cloned into pET22b after deletion 
of DNA sequence encoding amino acids 12-377 
This study 
pET22b-∆N12-377 
hSGLT1-Spacer 
Clone pET22b-∆N12-377 hSGLT1 with DNA 
sequence encoding for a 10 amino acids long 
spacer at the C-terminal of gene 
This study 
pET22b-Unc-F Unc-F gene encodes β-subunit of E. coli ATPase 
under the control of bacteriophage T7 promoter 
This study 
pET22b-Unc-F-hSGLT1 Unc-F gene cloned in pET22b plasmid encoding 
full-length hSGLT1 
This study 
pET22b-Unc-F-
hSGLT1-Spacer 
Unc-F gene cloned in pET22b plasmid encoding 
full-length hSGLT1 with C-terminal spacer 
This study 
pET22b-Unc-F-∆N12-
377 hSGLT1 
Unc-F gene cloned in pET22b plasmid encoding 
hSGLT1 gene shorten at N-terminal from 12-377 
amino acids  
This study 
pET22b-hSGLT1-
FLAG-Spacer 
pET22b vector containing full-length hSGLT1 
gene with C-terminal spacer and FLAG tag at 
position D574. 
This study 
pBAD24-hSGLT1-
FLAG-Spacer 
pBAD24 vector containing full-length hSGLT1 
gene with C-terminal spacer and FLAG tag at 
position D574. 
This study 
pBAD24-∆N12-377 
hSGLT1-FLAG-Spacer 
pBAD24 plasmid encoding hSGLT1 gene shorten 
at N-terminal from 12-377 amino acids and FLAG 
tag at position D574 
This study 
pPICZB-hSGLT1 P. pastoris plasmid pPICZB containing full-
length hSGLT1 gene with FLAG tag at D574  
This study 
 
pPICZαA-hSGLT1 P. pastoris plasmid pPICZαA containing full-
length hSGLT1 gene with FLAG tag at D574 
This study 
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3.3. Work with E.coli 
3.3.1. E.coli strains 
Strain Genotype Source 
C41 (DE3) BL21 (DE3) derivative with uncharacterized mutations Avidis 
C43 (DE3) BL21 (DE3) derivative with uncharacterized mutations Avidis 
C43 (DE3) Rosetta C43 (DE3) and Rosetta derivative This study 
DH5α F−φ80dlacZ∆M15 ∆(lacZYA-argF)U169 deoR 
recA1endA1 hsdR17(rk−, mk+) phoA supE44λ−thi-1 
 
Origami (DE3) ∆ (ara-leu)7697∆ lacX 74∆phoA PvuII phoR 
araD139ahpC galK rpsL F´[lac+ lacIq pro] (DE3) gor522:: 
Tn 10trx (KanR, StrR, TetR) 
Novagen 
RosettaTM (DE3) F− ompT hsdSB (rB- mB-) gal dcm (DE3) pRARE (CamR) Novagen 
XL10-Gold TetR ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZ∆M15 Tn10 (TetR) Amy CamR] 
Stratagene 
TOP10F- F´proAB, lacIq, lacZ∆M15, Tn10 (TetR) mcrA, ∆(mrr-
hsdRMS-mcrBC), φ80lacZ∆M15, ∆lacX74, deoR, recA1, 
λ-araD139, ∆(ara-leu) 7697, galU, galK, rpsL, (strR), 
endA1, nupG 
Invitrogen 
3.3.2. Media for bacterial culture 
LB-medium     1.0% tryptone 
0.5% yeast extract 
1.0% NaCl 
pH 7.2 
 
Terrific Broth   1.2% tryptone 
     2.4% yeast extract 
     0.4% glycerol 
17 mM KH2PO4  
72 mM K2HPO4 
1.5% agar was added to the media for production of agar plates.  
The following concentrations of the antibiotics were used if required: 
Table 3.1 Antibiotic stock solutions and its working concentration. 
Antibiotic Stock solution  Working concentration 
Ampicillin 
Chloramphenicol 
Zeocin    
Tetracycline 
100 mg/ml in water 
30 mg/ml in ethanol 
100 mg/ml in water 
5 mg/ml in ethanol 
 
 
 
 
100 µg/ml 
30 µg/ml 
100 µg/ml 
10 µg/ml 
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3.3.3. General 
E. coli were cultured at 37°C with LB medium or terrific broth. Bacteria transformed with an 
antibiotic resistance-conferring plasmid were selectively propagated by supplementing the LB 
medium with respective antibiotic (see Table 3.1). All solutions and supplements used for 
work with E. coli were autoclaved for 20 min at 121°C or filter-sterilized. Bacterial strains for 
long-term were stored at –70°C in LB medium supplemented with glycerol to a final 
concentration of 15 %. 
3.3.4. Transformation of plasmid in E.coli 
3.3.4.1. Preparation of competent cells by CaCl2 method 
LB medium (100 ml ) was inoculated with an overnight culture of E. coli DH5α and grown at 
37°C with shaking to an OD600 of 0.4. This culture was transfer to sterile, disposable, ice-cold 
50-ml plastic tubes and store on ice for 10 minutes. After incubation, cells were centrifuged at 
4,000 rpm for 15 min at 4°C. The pellet was resuspended in 50 ml ice-cold 100 mM MgCl2, 
incubated for 30 min on ice, and centrifuged at 4°C. The cells were resuspended in 2 ml ice-
cold 100 mM CaCl2, incubated for 24 h at 4°C, supplemented with ice-cold 0.6 ml glycerol 
and 2.4 ml 100 mM CaCl2 and stored in 200µl aliquots at –70°C. 
3.3.4.2. Heat shock transformation of the plasmid 
Treatment of competent bacterial cells with a brief heat shock enables transformation of 
DNA. Plasmid DNA or a plasmid ligation reaction (not more than 15ng or in a volume 2.5µL) 
was mixed with 50µl thawed competent bacteria and incubated for 30 min on ice. The bacteria 
were treated for 90s by heat shock of 42°C, placed on ice for 1-2 min, diluted with 950 µl LB 
medium and incubated for 1 h at 37°C with shaking. An aliquot of 50-200 µl or resuspended 
pellet was spread on LB/antibiotic agar plate and incubated overnight at 37°C to select for 
transformed bacteria. In case of ligation mixture, the transformed cells were pelleted by 
centrifugation at 13,000 rpm for 30 seconds, and the pellet was resuspended in 100µl of LB 
medium. The whole suspension was spread on the agar plate. 
3.4. Work with P. pastoris 
3.4.1. P. pastoris strains 
Strain Genotype Phenotype 
X-33 Wild-type Mut+ 
GS115 his4 His-, Mut+ 
KM71H arg4 aox1::ARG4 MutS, Arg+ 
GS115/Albumin His4 MutS 
GS115/pPICZ/lacZ his4 His-, Mut+ 
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3.4.2. Media for P. pastoris culture 
Low Salt LB (Luria-Bertani) Medium   1.0 % tryptone 
0.5% yeast extract 
1.0% NaCl 
pH 7.0 
Low salt LB medium is needed for use with Zeocin antibiotic. 
Low salt LB agar plates were made by the addition of 1.5% agar before autoclaving. 
 
Yeast Extract Peptone Dextrose Medium (YPD or YEPD)  
% yeast extract 
2% peptone 
2% dextrose (glucose)  
 
Yeast Extract Peptone Dextrose Medium (YPD ± Zeocin)  
1% yeast extract 
2% peptone 
2% dextrose (glucose)  
± 2% agar 
± 100 µg/ml Zeocin 
 
Buffered Glycerol/ Methanol complex Medium (BMGY and BMMY) 
                                                                          1% yeast extract 
                                                                          2% peptone 
                                                                          100mM KH2PO4, pH 6.0 
                                                                          1.34% YNB   
                                                                          4× 10-5% biotin 
                                                                         1% glycerol or 1% methanol  
 
Breaking Buffer                                              50 mM KH2PO4, pH 6.0 
                                                                          Protease inhibitors cocktails 
                                                                          10% glycerol 
3.4.3. General 
P. pastoris was grown at 28-30°C in YPD medium. Cells transformed with pPICZB-hSGLT1 
plasmid were selectively propagated by supplementing the YPD medium with Zeocin 
antibiotic (see Table 3.1). For protein expression pPICZB-hSGLT1 plasmid transformed cells 
were grown in BMGY medium supplemented with Zeocin. P.pastoris cells for long-term 
were stored at –70°C in YPD medium supplemented with glycerol to a final concentration of 
15 %. 
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3.4.4. Electroporation of P. pastoris with plasmid pPICZB or pPICZB-
hSGLT1 
The purified DNA samples of pPICZB and pPICZB-hSGLT1 were linearized by PmeI 
digestion at 37°C for 3 h and the linearized plasmids DNA were purified by enzyme removal 
column.  
YPD medium (100 ml) was inoculated in a 1-liter flask with 0.2 ml of overnight culture of P. 
pastoris strain GS115 and the cells were grown at 28°C overnight to an OD600 of 2-4. 
Overnight grown culture was centrifuged at 1500 × g at 4°C for 5 min. The supernatant was 
removed and the pellet was resuspended with 25 ml of ice-cold sterile water. The resuspended 
cells were centrifuged again as above and the pellet was resuspended in 8 ml of ice-cold 
sterile 1 M sorbitol. The cells were centrifuged as above and then the pellet was resuspended 
with 1 ml of ice-cold sterile 1 M sorbitol. The suspension of competent cells was kept on ice 
and used the same day. 
The suspension of competent cells (40 µl) and of linearized DNA (10 µl, 10 µg) were mixed 
and transferred to an ice-cold electroporation cuvette. The cuvette with the mixture of cells 
and DNA was incubated on ice for 5 min. The cells were pulsed at 1.5 kV, 50 µF and 200 Ω 
and 1 ml of ice-cold 1 M sorbitol was added to the cuvette. The cuvette contents were 
transferred to a sterile 15 ml tube and incubated at 30°C without shaking for 2 h. 200 µl of 
these cells were plated on YPD medium with 100, 500, and 1000 µg/ml Zeocin and incubated 
at 30°C for 2 days. 
3.5. Recombinant DNA processing and manipulation 
3.5.1. Buffers and solutions 
TBE buffer (5X)   Tris-base 54 g 
(Working solution 0.5X)  boric acid 27.5 g 
     EDTA 20 ml of 0.5 M, pH 8.0       Final volume 1 Liter 
TE     10mM Tris (pH 7.6), ImM EDTA (pH8.0) 
 
DNA loading buffer (6X)  0,25% (w/v) bromophenol blue 
     0,25% (w/v) xylene cyanol 
     30% (v/v) glycerol 
     50 mM EDTA 
Ethidium bromide   1% (w/v) in water 
DNA standard    SmartLadderTM Eurogentec GmbH, Germany 
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3.5.2. Restriction endonuclease digestion of DNA 
For preparative purposes, 1-5 µg DNA was digested with 1-20 U of restriction enzyme in a 
volume of 10-50 µl of reaction buffer. Complete digestion was confirmed by agarose gel 
electrophoresis. For analytical purposes, 0.2-1 µg DNA were digested with 1-5 U enzyme in a 
volume of 10-20 µl of reaction buffer. In both cases digests were incubated for 3h at 37°C. 
Reaction buffers were supplied by the manufacturer. Enzymes were heat-inactivated as 
recommended by the supplier or removed by purification of the digested DNA by column 
chromatography. 
3.5.3. Purification of the digested DNA 
To inactivate and remove the proteins e.g. restriction enzymes, digested DNA was purified by 
using the QIAquick PCR purification kit (Qiagen) according to the manufacturer’s 
instructions with slight modification. Buffers were provided in the kit and all centrifugation 
steps were carried out at 13,000 rpm at RT in a tabletop microcentrifuge. The 5 volume of the 
buffer PB and one volume of isopropanol were added to the DNA solution. The sample was 
then applied to QIAquick spin column (Qiagen) and centrifuged for 1 min in order to bind 
DNA to the column. For washing of DNA on the column, 0.75 ml of buffer PE was added to 
the column and spun down for 1 min. The flow-through was removed and the column was 
centrifuged for an additional 1 min to remove the residual ethanol. The column was then 
placed into a clean 1.5 ml tube and the DNA was eluted by the addition of 30-50 µl of buffer 
EB (10 mM Tris/HCl, pH 8.5) or dH2O to the column followed by centrifuging for 1 min. If 
needed the DNA could be concentrated by precipitating with ethanol. 
3.5.4. Ethanol precipitation of DNA 
5 M NaCl solution was added to the DNA sample to a final concentration of 250 mM. Three 
volumes of ethanol (-20°C) were added to the solution and stored on ice for 30 min and then 
centrifuged at 13,000 rpm for 15 min at 4°C. The pellet was washed with one volume of ice-
cold 70 % ethanol, recentrifuged for 5 min and dried at room temperature on desk. The DNA 
was dissolved in water or TE (pH 8) for 20 min at 37°C at an appropriate concentration. 
3.5.5. Dephosphorylation of linearized plasmid DNA by CIP 
In order to prevent self-ligation of vector ends in cloning strategies linearized plasmid DNA 
was treated with calf intestine alkaline phosphatase (CIP). CIP catalyzes the hydrolysis of 5'-
phosphate residues to 5'-hydroxyl ends. Since T4 DNA ligase requires 5'-phosphate residues 
to catalyze new phosphodiester bonds, ligation is only possible between vector ends and 
inserts, but not between vector ends themselves. Dephosphorylation was carried out directly 
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following plasmid linearization. CIP was added to the digestion mixture at a concentration of 
1 U per pmol linearized vector DNA. After 45 min incubation at 37°C, CIP and the restriction 
enzymes were removed as described previously. 
3.5.6. Ligation of DNA fragments 
Ligation was carried out using Rapid DNA ligation kit according to the manufacturer’s 
instructions with slight modification. All the buffers were provided with the kit. The insert 
DNA was employed at a 2-5 molar excess relative to the linearized and dephosphorylated 
vector DNA. The vector DNA and insert mixture were diluted in dilution buffer to a final 
volume of 10µl. 10µl of ligation buffer was added in diluted DNA mixture. 5unit of T4 DNA 
ligase was added and mix thoroughly. The ligation reaction mixture was incubated 5-10 
minutes at 15-25°C. The 5µl of ligation reaction mixture was used directly for transformation 
of the 200µl competent cells. 
3.5.7. Miniprep: small-scale preparation of plasmid DNA 
Plasmid DNA was purified from bacteria cultures by alkaline lysis of the bacterial cells by 
using QIAprep Spin miniprep kit according to the manufacture instructions. In brief, A small 
culture (10ml) of bacteria was grown in order to amplify in vivo the plasmid of interest. The 
bacteria were harvested by centrifugation at 13,000 rpm for 1 min at room temperature. This 
pellet was resuspended in 250µl buffer P1 (50 mM Tis·Cl pH 8.0, 10 mM EDTA, 100 µg/ml 
RNase A). 250µl lysis buffer P2 (0.2 N NaOH, 1 % SDS) was added in resuspended pellet 
followed by gently mixing and incubated for 5 minutes at room temperature. It causes 
denaturation of the DNA by NaOH and of the bacterial proteins by SDS. The alkaline mixture 
was neutralized by 350µl of buffer N3 (containing guanidine hydrochloride, 3M potassium 
acetate, pH 5.5) causing reannealing of plasmid DNA and precipitation of SDS. The white 
precipitate, containing Proteins, chromosomal DNA, SDS and cell debris was removed by 
centrifugation for 10 minutes at 13,000 rpm while the plasmid DNA wasleft in the solution. 
The supernatant was passed through the spin column by centrifugation at 13,000 rpm for 1 
minute. After washing of the column with 0.75ml buffer PE, the column was additionally 
centrifuged for 1 minute to remove residual buffer. The DNA was eluted by adding 50µl 
water or TE and centrifugation of the column at 13,000 rpm for 1 min. 
3.5.8. Large scale preparation of plasmid DNA 
100 ml of bacterial culture was centrifuged at 4,000 rpm for 15 min at 4°C. The pellet was 
resuspended in 10 ml of P1 (50mM Tris.Cl, pH 8.0; 10mM EDTA; 100µg/ml Rnase A). 
Resuspended pellet was lysed with 10 ml P2 (200mM NaOH, 1% SDS) by incubating for 5 
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min at room temperature. The lysis was stopped by adding 10 ml ice-cold P3 (3M potassium 
acetate, pH 5.5) and the white precipitated mixture was poured into the barrel of QIAfilter 
cartidge and incubated for 10 min. After 10 minutes, the plunger was inserted into the 
QIAfilter cartidge and filtered the cell lysate into the 50ml tube. The lysate was loaded on an 
equilibrated anion exchange column that was subsequently washed twice with 30 ml of buffer 
QC (1.0M NaCl, 50mM MOPS, pH7.0; 15% isopropanol). The bound DNA was eluted with 
elution buffer QN (1.6M NaCl, 50mM MOPS, pH7.0; 15% isopropanol) by gravity flow. The 
eluted DNA was precipitated by adding 0.7 volumes isopropanol at room temperature and 
subsequent centrifugation at ≥15,000xg for 30 min at 4°C. The pellet was washed with 5 ml 
70 % ethanol, re-centrifuged for 10 min, dried under vacuum and re-dissolved in 1ml of 
endothelial electroporation buffer or TE. 
3.5.9. Qunatification of DNA and RNA solutions 
The concentration of nucleic acid solutions was determined by spectrophotometry. The 
ultraviolet (UV) absorption was measured at a wavelength of 260 nm (OD260) using a quartz 
cuvette of 1 cm width. For double-stranded DNA an OD260 =1.0 corresponds to approximately 
50 µg DNA/ml. For RNA an OD260 = 1.0 corresponds to approximately 40 µg RNA/ml. In 
addition the OD260 was measured to estimate the purity of the nucleic acid sample. A ratio 
OD260/OD280 of significantly less than 1.8-2.0 indicates protein contamination.  
3.5.10. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for analytical and preparative purposes. The method is 
based on the migration of the negatively charged DNA towards the anode in an electric field. 
The fragments migrate through the gel matrix at rates inversely proportional to the logarithm 
(log10) of the number of base pairs. DNA bands were visualized within an agarose gel by 
staining with the intercalating fluorescent dye ethidium bromide and subsequent illumination 
under UV light. The length of a DNA fragment is determined by comparison of its mobility to 
that of DNA standards. For casting gel, 1-2 % (w/v) agarose was melted in 0.5xTBE 
electrophoresis buffer and supplemented with 0.5 µg/ml ethidium bromide and cast in casting 
tray of desired size. The gel was placed in an electrophoresis tank and submerged in 0.5xTBE 
buffer. The DNA samples were mixed with DNA loading buffer and loaded into the gel wells. 
In addition 5 µl of a DNA standard was loaded in parallel with the samples. Horizontal 
electrophoresis was carried out at approximately 100 V. The stained gel was photographed 
under UV light. 
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3.5.11. DNA recovery from agarose gel 
For preparative purposes DNA fragments of interest were cut out from stained agarose gels 
with a razor blade under UV illumination. The gel slices were solubilized and DNA was 
purified by using the QIAquick Gel extraction kit (Qiagen) according to the manufacturer’s 
instructions. 
Agarose gel slices were weighed (= 1 volume) and dissolved each slice in 3 volumes of 
solubilization buffer QG by incubation for 10 min at 50°C. 1 volume isopropanol was added 
and the solution was applied to a silica-gel QIAquick spin column. The column was 
centrifuged at 13,000 rpm for 1 min, washed with washing buffer PE and centrifuged again. 
The extra centrifugation was done to remove residual buffer. DNA was eluted by adding 30-
50µl water or TE on the column and centrifugation of the column at 13,000 rpm for 1 min. All 
the buffers were provided by the manufacturer. 
3.5.12. DNA sequencing 
The sequence of specific target regions in recombinant plasmid DNA was determined by a 
commercial sequencing service (Agowa GmbH Berlin, Germany). The sequence data were 
verified on the basis of the corresponding fluorescence electropherogram and subjected to 
computer analysis. 
3.5.13. DNA amplification of hSGLT1 gene by PCR for cloning into 
different expression systems 
Primers for PCR amplification of SGLT1 cDNA were commercially synthesized (MWG 
Biotech, Ebersberg, Germany). They were designed corresponding to the DNA segment to be 
amplified, provided with restriction sites for endonuclease digestion. Pairs of primers were 
designed to have equivalent melting temperatures (Tm), calculated according to the formula1 
Tm [°C] = (A+T)·2 + (G+C)·4. The annealing temperature for each PCR was typically 
estimated by experimentally. For preparative DNA amplification as part of cloning strategies, 
High fidelity DNA polymerase was used in preference to Taq DNA polymerase, due to its 
3'→5' proofreading exonuclease activity which minimizes the risk of nucleotide 
misincorporation during elongation. 
 
PCR reaction composition for DNA amplification was as follows: 
Template DNA  20-50ng  
Sense primer (forward) 100 pMoles 
Antisense primer (reverse) 100 pMoles 
                                                 
1 A, T, G, C: number of the 2’-deoxyribonucleosides adenosine (A), thymidine (T)guanosine (G) and cytidine 
(C) with in the primer sequence 
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dNTPs    200µM each 
PCR reaction buffer  1x 
DMSO    5-10% (Optional, to increase yield, specificity, consistency)  
DNA polymerase  1-2.5 units 
Final reaction volume  100µl (preparative PCR), 20-50µl (analytical PCR) 
Th PCR amplified products of hSGLT1 gene were analyzed by agrose gel electrophorsis, they 
were further proceeding for cloning into their respective vectors. 
Thermal cycle parameters for PCR was as follows: 
Lid temperature  105°C 
Initial denaturation  94°C, 5 minutes 
Denaturation   94°C, 30 seconds 
Annealing   50-55°C  (primer pair and template specific), 1minute 
Elongation   72°C, 1 miunte/kb 
Cycles    30 
Final elongation  72°C, 10 minutes 
cDNA sequence encoding full length human SGLT1 was amplified by  using plasmid 
DKFZp686N20230Q2 as a template and subcloned into the EcoR1 and Xho1 sites of the 
bacterial expression vector pET22b. Primers used for the amplification were SGLT1_F and 
SGLT1_R (see section 3.2.5). 
For cloning into pBAD24 bacterial expression vector, pET22b-hSGLT1-FLAG-Spacer 
plasmid (see section 3.5.14.2 for detail) was used as a PCR template. The primers 
pPICZ_SGLT_F and PBAD_SGLT_R containing EcoR1 and HindIII restriction sites 
respectively were used for PCR amplification. 
For cloning hSGLT1 gene into eukaryotic expression system Pichia pastoris, pET22b-
hSGLT1-FLAG-Spacer plasmid (see section 3.5.14.2 for detail) was used as a PCR template. 
hSGLT1-FLAG-Spacer gene product contains a FLAG epitop at postion of 574 amon acid 
and a 10 amino acids spacer  at the end of hSGLT1 gene. The primers used for PCR 
amplification were pPICZ_SGLT_F and pPICZα_SGLT_R primer containing EcoR1 and 
Not1I restriction sites respectively 
3.5.14. Addition or deletion mutagenesis in hSGLT1 gene 
This method is a PCR-based site directed mutagenesis system that eliminates the necessity to 
subclone the amplified mutated DNA fragment. This procedure starts with a supercoiled, 
dsDNA vector with an insert of interest and two synthetic oligonucleotide primers containing 
the desired mutation. The oligonucleotide primers, each complementary to opposite strands of 
the vector, are extended during temperature cycling by PfuUltra® high-fidelity DNA 
polymerase. On incorporation of the oligonucleotide primers, a mutated plasmid is generated. 
After temperature cycling, the product is treated with Dpn I. Dpn I is used to digest the 
parental DNA template and select for the synthesized DNA containing mutations. Since DNA 
isolated from most E. coli strains is dam methylated, it is susceptible to Dpn I digestion, that 
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will cut only fully or hemimethylated 5′-Gm6ATG-3′ DNA sequences2. The nicked vector 
DNA incorporating the desired mutations is then transformed into the commercial XL10-Gold 
cells3. This method is very rapid and generates mutants with the efficiency greater than 80%. 
The specific primer design consideration was applied which are as follows. 
Both the primers must anneal to different strands of the plasmid. 
Primers should be >22 bases in length  
The mismatched portions should be at or near the 5´ end of one or both of the primers with 15 
or more bases of correct sequence on the 3´ end. 
For deletion, the primers should be designed in frame of the coding sequence of the gene. The 
forward primer and reverse primer should be designed at 3′ and 5′end of the deletion sequence 
respectively. For addition of base pairs in the cDNA of hSGLT1 the additional base pairs 
should incorporated at the 5’end of the primers. 
One or both of the primers must be 5´ phosphorylated. T4 polynucleotide kinase used for the 
5´ phosphorylation of an oligonucleotide primers. 
The reaction composition of the phosphorylation reaction is as follows 
Primer    1µl (100pmole) 
Kinase buffer   0.5µl (1x) 
T4 polynucleotide kinase 1µl (10 units) 
Water    2.5µl 
The reaction mixture was incubated for 1 hour. The 1.25µl of the reaction mixture was 
directly used for PCR. 
The mutant strands synthesis reaction was setup for PCR according to the manufacturer’s 
instructions. The PCR reaction composition and PCR cycling parameter were as follows: 
Template DNA   30ng 
Sense primer4 (forward)  125ng 
Antisense primer (reverse)  125ng 
dNTPs     200µM each or 1µl(supplied with the kit) 
PCR reaction buffer   1x 
Quik solution reagent   3µl (supplied with the kit) 
Water was added to a final volume of 50µl 
Then 1µl of PfuUltra HF DNA polymerase was added and PCR was done with the following 
thermal cycling parameters. 
 
Lid temperature  105°C 
Initial denaturation  94°C, 2 minutes 
Denaturation   94°C, 50 seconds 
Annealing   60°C, 1minute 
                                                 
2 While plasmid DNA isolated from almost all the commonly used E.coli strains such as DH5α (dam+) is 
methylated and is suitable for mutagenesis, plasmid DNA isolated from the exceptional dam- E.coli strains, 
including JM110 and SCS11, is not suitable. 
3The DH5α chemical competent cells prepared in our lab are also worked well with this protocol. 
4 The primers were design according to the mutagenic primer design rules, which were given in instruction 
manual. 
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Elongation   68°C, 1 miunte/kb 
Cycles    18 
Final elongation  68°C, 10 minutes 
After the PCR the reaction mixture was cooled to ≤37°C on ice. 1µl of Dpn I was added 
directly to reaction mixture and kept for 2 hours for digestion at 37°C. The PCR product was 
purified by PCR purification kit as described before. The 5µl of purified PCR product was 
ligated with rapid DNA ligation kit and transformed into DH5α cells. The positive clone was 
confirmed by DNA sequencing. 
3.5.14.1. Addition of 30 base pairs long spacer at the C-terminal of hSGLT1 gene 
cDNA sequence encoding a 10 amino acids long spacer (VLYKSGGSPG) was introduced at 
the C-terminal of hSGLT1 gene. For the addition of spacer sequence, two primers (each 
containing 5 additional amino acids coding base pairs). The primers used for this mutation 
were Spacer_SGLT_His_F and Spacer_SGLT_His_R (see section 3.2.5) and designed as 
shown in Figure 3.1. The resultant plasmid was designated as pET22b-hSGLT1-Spacer.  
 
 
 
 
 
 
 
Figure 3.1 Positions of the mutation primers in pET22b-hSGLT1 plasmid. 15 base pairs were added to each 
primers. After Ligation 30 bps were incorporated between hSGLT1 gene and His tag. 
3.5.14.2. Addition of FLAG tag in hSGLT-spacer gene 
For better immunological detection and to provide ease in the purification process, the FLAG 
epitope was introduced in hSGLT1 by mutating the native hSGLT1 sequence D574 AEEEN to 
D574YKDDDDK. In pET22b-hSGLT1-Spacer plasmid 21 base pairs endcoding the FLAG tag 
were inserted at the postion 574. During this mutation 15 base pairs encoding wildtype 5 
amino acids (574-579) were deleted. The forward primer (SGLT1_FLAG_F) and reverse 
primer  (SGLT1_FLAG_R) were designed similarly as shown in Figure 3.1. The resultant 
plasmid was designated as pET22b-hSGLT1-FLAG-Spacer. 
3.5.14.3. Deletion of N-terminal half of hSGLT1 gene 
To construct N-terminal truncated hSGLT1 gene, the base pairs 34 to 1131 (Amino acids 12-
377) were deleted by deletion mutagenesis as described above. The primers ∆N12-
377_SGLT_F and ∆N12-377_SGLT_FR were designed with a similar approach as describe in 
section 3.5.14.1 following the primer design rules as described in section 3.5.14. 
Spacer_SGLT_His_R 
Spacer_SGLT_His_F 
pET22b pET22b 
3’ 
3’ 5’ 
hSGLT1 His tag 
5’ 
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3.5.15. Addition of Unc-F gene at the N-terminal of hSGLT1 gene 
pAVD10 vector (Avidis, Saint-Beauzire, France) encodes for the intra membrane inducer 
Unc-F gene product (i.e. the β-subunit of the E. coli ATPase) under the control of the 
bacteriophage T7 promoter. Unc-F gene was subcloned into pET22b vector pAVD10 plasmid 
was digested with XbaI enzyme and purified on agarose gel. The purified Unc-F gene 
fragment was ligated into similarly treated dephosphorylated pET22b and pET22b-hSGLT1 
plasmids. After ligation 5 µl of ligated mixture was transformed into DH5α cells and positive 
clones were identified by XbaI digestion.  In order to further confirm the correct orientation of 
Unc-F gene in pET22b-Unc-F and pET22b-Unc-F-hSGLT1 clones PCR reaction of these 
clones were performed with following primer: T7 promoter, sense, 5´-
TAATACGACTCACTATAGGG-3´and Unc-F primer, antisense, 5´-TTTATTACAGTTCAG 
CGACAAG-3´. 
3.6. Protein expression and analysis 
3.6.1. Growth conditions of E.coli for hSGLT1 expression 
Each clone was tested for protein expression in different conditions: 
                  Types of E. coli cells Clone name 
DH5α Rosetta C41 C43 C43 Rosetta 
Expression conditions*
pET22b-
hSGLT1 
Yes Yes Yes Yes Yes Condition 1, 2, 3, 4, 5 
and 6 in Rosetta, C43 
and C43R cells 
pET22b-
hSGLT1-Spacer 
Yes Yes Yes Yes Yes Same 
pET22b-∆N12-
377 hSGLT1 
Yes Yes Yes Yes Yes Same 
pET22b-∆N12-
377 hSGLT1 
Spacer 
Yes Yes Yes Yes Yes Same 
pET22b-Unc-F Yes Yes No Yes Yes Same 
pET22b-Unc-F-
hSGLT1 
Yes Yes No Yes Yes Same 
pET22b-Unc-F-
hSGLT1-Spacer 
Yes Yes No Yes Yes Same 
pET22b-Unc-F-
∆N12-377 
hSGLT1 
Yes Yes No Yes Yes Same 
pET22b-
hSGLT1-
FLAG-Spacer 
Yes Yes Yes Yes Yes Same 
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pBAD24-
hSGLT1-
FLAG-Spacer 
Yes Yes Yes Yes Yes Conditions 7 and 8 in 
Rosetta, C43 and C43R 
cells  
pBAD24-∆N12-
377 hSGLT1-
FLAG-Spacer 
Yes Yes Yes Yes Yes Same 
*Specification of different expression conditions; 
1. LB medium, 1 mM IPTG, 37°C growing temperature. 
2. LB medium, 1 mM IPTG, 37°C growing temperature with 45 min heat shock before induction of IPTG. 
3. LB medium, 1 mM IPTG, 22°C growing temperature with 45 min heat shock before induction of IPTG. 
4. LB medium, 0.5 mM IPTG, 16°C growing temperature with 45 min heat shock before induction of IPTG. 
5. TB medium, 0.5 mM IPTG, 16°C growing temperature with 45 min heat shock before induction of IPTG. 
6. TB medium with 1 M sorbitol, 0.5mM IPTG, 22°C growing temperature with 45 min heat shock before 
induction of IPTG. 
7. LB medium, 0.2% L- (+) arabinose, 22°C growing temperature. 
8. LB medium, 0.2% L- (+) arabinose, 22°C growing temperature with 45 min heat shock before Arabinose 
induction. 
3.6.2. Growth condition of P. pastoris for hSGLT1 expression 
In pilot experiments, single colonies of transformed cells were used to inoculate 2.5 ml of 
BMGY medium (1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate, 
pH 7.0, 1.34% (w/v) yeast nitrogen base, 4×10-5% (w/v) biotin, and 1% (v/v) glycerol). After 
16-20 h of incubation at 30°C, the cells were pelleted at 1000 × g and were resuspended in 
BMMY medium (BMGY medium in which the glycerol was replaced by 1% (v/v) methanol) 
to induce protein expression.  The positive colonies for recombinant protein expression were 
identified by Western blot analysis by using anti-FLAG antibody (Sigma). The clone with the 
highest protein yield was selected for medium-scale protein expression in 2-liters flasks. In all 
subsequent preparations, the cells were harvested at ~24 h of methanol induction.  
3.6.3. hSGLT1 purification from P. pastoris 
Membranes were prepared from P. pastoris cells as described below in the functional analysis 
of recombinant hSGLT1 section. Peripheral proteins and proteins adhering to the membrane 
were removed by washing with 4 M urea in breaking buffer containing protease inhibitor 
cocktail (Roche) at 4°C for 2 h and resulting membranes were centrifuged at 100,000 × g at 
4°C for 40 min. The stripped membranes were solublized in buffer TG [20 mM Tris.Cl, pH 
8/1 M NaCl/20% (v/v) glycerol] supplemented by 1.2% FosCholine-12 (Anatrace, Maumee, 
OH) and protease inhibitor cocktail, resulted membrane solution was shaken at 4°C, 
overnight. After removal of insoluble fraction by ultracentrifugation at 100,000 × g for 40 min 
at 4°C, the clear supernatant was bound to the preequilibrated Protino Ni 2000 prepacked  
(Macherey-Nagel) polyhistidine-tag purification column at 4°C, unbound proteins were 
removed by washing with 3 column volume of buffer TG plus 0.2% FosCholine-12.  
Recombinant hSGLT1 was eluted with 9 ml of buffer TG plus 0.2% FosCholine-12 
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supplemented with 250 mM imidazole and protease inhibitor cocktail. The purified protein 
containing fractions were concentrated to 0.35 ml by ultrafiltration in Centricon YM100 
devices (Millipore) and stored at -20°C for further use. 
3.7. Protein analysis 
3.7.1. Buffers and solutions 
SDS sample buffer (2x)   100 mM Tris·HCl (pH 6.8) 
20 % (v/v) glycerol 
4 % (w/v) SDS 
0.01 % (w/v) bromphenol blue 
10% β-mercaptoethanol 
acrylamide/bis-acrylamide 40% (w/v) acrylamide/bis-acrylamide ratio 37.5:1 
(Amersco) 
Stacking gel buffer 0.5 M Tris-HCl, pH 6.8 
Resolving gel buffer 1.5 M Tris-HCl, pH 8.8 
APS 10% (w/v) APS in water, aliquots were stored at -20°C 
SDS     10% (w/v) SDS in water 
Electrophoresis Buffer (10x)  30g Tris-base 
     142g glycine 
     10g SDS  
     Water was up to 1 liter  
Transfer buffer   5.82g (48mM) Tris-base 
     2.93g (39mM) glycine 
     200ml methanol 
     Water was added up to 1 liter 
TBST buffer    10mM Tris-base (pH 7.6) 
     150mM NaCl 
     0.05% (v/v) Tween 20 
Blocking solution   5% blocking milk (BioRad) in TBST 
     Phosphatase cocktail (1:100) 
     0.1% SDS 
Coomassie staining solution  0.25% coomassie Brilliant Blue R-250 
     10%Acetic acid  
     40% methanol in water (filtered) 
Coomassie destaining solution 10%Acetic acid  
     40% methanol  in water 
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3.7.2. Measurement of protein concentration 
3.7.2.1. Enhanced alkaline copper (Lowry) protein assay 
The method is based on Peterson’s modification of the micro-Lowery method (Peterson, 
1977). An alkaline cupric tartrate reagent (Lowery reagent) complexes with the peptide bonds 
of proteins and becomes reduced to cuprous (Cu+). The Cu+ as well as the R groups of 
tyrosine, tryptophan, and cysteine residues then react with the Folin reagent. The reagent 
reacts by first producing an unstable product which is slowly reduce to become 
molybdenum/tungsten blue color complex. The absorbance is read at a suitable wavelength 
between 500 nm and 800 nm (preferably 750nm) for spectroscopic quantification of proteins 
in aqueous solution.  
Lowry protein assay kit (Sigma) was used for protein quantification according to the 
manufacturer instructions. Using BSA stock solution (400 µg/ml), a set of protein standards 
with 0-300 µg/ml was prepared. The protein samples were dilute to 1.0 ml with water. To 
each set of protein standards and samples, 1 ml of Lowry reagent was added and incubated for 
20 minutes at room temperature. With rapid and immediate mixing, 0.5 ml of Folin & 
Ciocalteu’s phenol reagent was added in each tube and allowed color to develop for 30 
minutes. The absorbance was measured at the wavelength of 750 nm in a spectrophotometer. 
Based on the absorption values of the protein standards a calibration curve was calculated and 
used for determination of the protein concentrations in the samples. All protein standards and 
samples were prepared in duplicate. 
3.7.3. SDS-PAGE 
Table 3.2 Compostion of staking and resolving gel.  
Components Stacking gel 5% 
(5ml final vol.) 
Resolving gel 10% 
(10ml final Vol) 
Resolving gel 12% 
(10ml final vol.) 
Water 
Acrylamide mix 
1.5M Tris (pH8.8) 
1.0M Tris (pH6.8) 
10% SDS 
10% ammonium persulphate 
TEMED 
3.2ml 
0.83 ml 
 
0.63 ml 
0.05 ml 
0.05 ml 
0.005 ml 
4ml 
3.3ml 
2.5ml 
 
0.1ml 
0.1ml 
0.004ml 
3.3ml 
4ml 
2.5ml 
 
0.1 ml 
0.1 ml 
0.004 ml 
Protein samples were resolved for analytical purposes by polyacrylamide gel electrophoresis 
(PAGE). The use of the anionic detergent sodium dodecyl sulfate (SDS) enables separation 
according to the molecular weight of the proteins. It binds to the polypeptides and confers a 
negative charge, which is in direct proportion to their size. The gel matrix is prepared by 
polymerization of acrylamide and N,N'-methylenebisacrylamide via free radicals. Initial 
radicals arise from chemical decay of ammonium persulfate (APS) catalyzed byN,N,N',N'-
tetramethylethylenediamine (TEMED). The electrophoresis towards the anode is carried out 
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in a discontinuous buffer system that first concentrates SDS-protein complexes within a 
stacking gel before they migrate into the resolving gel. The size of proteins is determined by 
comparing their mobility with that of a protein standard. 
The resolving gel solution was prepared, poured between two clean glass plates and overlaid 
with water or butanol. After polymerization, the top of the gel was washed with water and the 
residual water was removed by filter paper. Freshly prepared stacking gel solution was filled 
and allowed to polymerize. The plastic comb was inserted in poured stacking gel to prepare 
the wells for sample loading. After polymerization comb was removed and the wells were 
washed with water to remove un polymerized acrylamide Subsequently the gel was placed in 
a vertical electrophoresis apparatus filled with 1x electrophoresis buffer. SDS-PAGE protein 
samples were prepared by mixing protein samples with 2x SDS sample buffer in the ratio of 
1:1, if not already prepared with 1x SDS sample buffer. The SDS-PAGE protein samples and 
a protein standard were denatured at 95°C for 5 min and loaded onto the gel. Electrophoresis 
was carried out at 200 V. The resolving gel was subsequently subjected to western blot 
analysis or gel staining. 
3.7.4. Coomasie staining of the polyacrylamide gels 
Coomassie Brilliant Blue is an aminotriarylmethane dye that forms strong covalent cpmplexs 
with proteins, most probably by a combination of van der Waals forces and electrostatic 
interactions with NH3+ groups. The uptake of dye is approximately proportional to the amount 
of protein.  
The polyacrylamide gel was immersed in at least 5 volumes of the coomassie staining solution 
and placed on a slowly rotating plateform for 15-30 minutes at room temperature. The gel was 
destained in coomassie destaining solution on a slowly rotating plateforms, changing the 
destaining solution three to four times. The rapid destaing can also achevied by keeping the 
staining gel in hot water (80°C). The reaming background was removed by leaving the gel 
overnight in water. 
3.7.5. Western blot analysis 
Western blotting consists of the transfer of electrophoretically separated proteins from a SDS-
PAGE gel to a nitrocellulose membrane by electoblotting. The membrane-immobilized target 
protein is identified by an appropriate primary antibody and a horseradish peroxidase (HRP)-
conjugated secondary antibody directed against the primary antibody. Detection of the 
antigen-antibody-antibody complex occurs by HRP-mediated oxidation of the chemilumin 
escent substrate luminol, a cyclic diacylhydrazide. The reaction product exhibits an excited 
state which decays to ground state via a light emitting pathway, and is detectable by exposure 
of the membrane to an autoradiography film. 
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After SDS-PAGE, the gel, nitrocellulose membrane pads and electrode papers were 
equibilirated with pre chilled transfer buffer. The gel cassette was placed with the gray side 
down on a clean surface. The fiber pad, electroblotting papers (7papers on each side), gel and 
nitrocelloluse membrane were arranged in the cassette. 
The firmly closed cassette was put into the blotting module and then placed into the  
electroblotting buffer tank with ice cooling unit. The proteins were transferred to the 
membrane towards the anode at 200 mA for 1 h at 4°C in ice-cooled transfer buffer with 
continuous stirring. Non-specific binding sites on the blotted membrane were blocked by 
shaking in blocking solution for 2 h at room temperature. After blocking, the membrane was 
washed thrice with TBST for 5 minutes each wash. The washed membrane was sealed in 
polybag along with the primary antibody and incubated at 4°C for over night with an end-to-
end shaking. The membrane was washed thrice for minutes each washing and incubated with 
the secondary antibody in blocking solution for 45 minutes. The membrane was washed thrice 
for 5 minutes each washing. The freshly prepared chemiluminescent substrate working 
solution was added to the surface of the membrane (approx. 0.2 ml/cm
2
) and incubated for 4 
min at room temperature. The membrane was wrapped in plastic foil and exposed in the 
darkroom for 10 s - 30 min to an autoradiographic film that was subsequently developed in 
dark room conditions. 
3.8. Functional analysis of recombinant hSGLT1 
Sugar uptake assays were carried out in membranes prepared from Pichia GS115 cells 
harboring pPICZB-hSGLT1 plasmid and with purified recombinant hSGLT1 reconstituted 
into liposomes. 
3.8.1. Membrane preparations for transport studies 
Cells cultured in BMMY medium were harvested at O.D600 of 4-6/ml by centrifugation at 
3000 × g at 4°C for 10 min, washed once with ice-cold breaking buffer (50 mM sodium 
phosphate, pH 7.4, 10% glycerol) and resuspended in breaking buffer supplemented with 
protease inhibitor cocktail. An equal volume of acid- washed chilled glass beads (0.5 mm 
diameter) was added to the suspension, and cells were disrupted by vigorous vortexing ten 
times for 1 min, with intervening 1 min incubations on ice. Unbroken cells were removed by 
centrifugation at 2000 × g at 4°C for 5 min. Membranes were pelleted at 100,000 × g at 4°C 
for 30 min and resuspended in membrane suspension buffer (100 mM Mannitol, 20 mM 
HEPES- Tris, pH 7.4) with protease inhibitor cocktail. Aliquots were snap-frozen and stored 
at -80°C. The protein concentration of the membrane preparation was determined by using a 
micro-BCA kit. 
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3.8.2. Reconstitution of recombinant hSGLT1 
Proteoliposomes were made using Triton X-100 destabilized liposomes (Jung et al., 1998; 
Heiermann et al., 1999; Rigaud and Daniel, 2003). Liposomes were composed of 90% (w/v) 
asolectin soy lecithin and 10% (w/v) cholesterol. 10 mg cholesterol and 90 mg asolectin soy 
lecithin were dissolved in 5 ml of chloroform in a beaker. The solvent was evaporated under a 
stream of argon to obtain a thin layer of dry lipids. Last traces of solvent were removed under 
vacuum in a desiccator overnight. Before each reconstitution the lipids were suspended in 5 
ml of 100 mM potassium phosphate, pH 7.5/2 mM β-mercaptoethanol to yield a lipid 
concentration of 20 mg/ml and subsequently sonicated in argon atmosphere in a tip probe 
sonicator (until the suspension became slightly clear), and resulting liposomes were stored in 
liquid nitrogen. Triton X-100 was added at concentrations corresponding to the onset and or 
total solublization of lipids as determined by turbidity measurements (Rigaud et al., 1995). 
Detergent-destabilized liposomes were mixed with purified protein in a 400:1 (w/w) and 
incubated at room temperature under gentle agitation for 10 min. Detergent was removed by 
adding Bio-Beads SM-2 activated according to (Holloway, 1973) at a wet weight beads: 
detergent ratio of 6:1. After 1 h of incubation at room temperature, fresh Bio-Beads were 
added, and incubation was continued for an additional hour. After the third addition of Bio-
Beads, incubation was continued overnight at 4°C. Bio-Beads were removed by filtration on 
glass silk. Proteoliposomes were concentrated by centrifugation at 300,000 × g for 45 min and 
stored in liquid nitrogen. Proteoliposomes pellet for sugar uptake assay were resuspended in 
100 mM potassium phosphate, pH 7.5/2 mM β-mercaptoethanol for final protein 
concentration of 0.1 µg/ml. 
3.8.3. Transport assay of hSGLT1 in membranes and in proteoliposomes 
Sugar uptake by right-side-out membrane vesicles was performed as described for E. coli 
right-side-out membrane vesicles (Jung et al., 1998; Turk et al., 2000).  Proteoliposomes 
(preloaded with 100 mM potassium phosphate, pH 7.5/2 mM β- mercaptoethanol) were 
subjected to three sonication/freeze/thaw cycles before uptake assays at 22°C. Uptake was 
initiated by mixing 10 µl of proteoliposomes with 10 µl of transport buffer 2X (200 mM 
choline.Cl, 50 mM NaCl, 100 mM mannitol, 20 mM Tris, 20 mM HEPES, 300 mM KCl, 6 
mM MgSO4, 2 mM CaCl2) with methyl α-D- [14C] glucopyranoside ([14C] α-MDG). Each 
reaction was stopped by with 1 ml of ice-cold stop solution  (10 mM Tris, 10 mM HEPES, 
100 mM mannitol, 150 mM KCl, 50 mM choline.Cl, 50 mM NaCl, 3 mM MgSO4, 1 mM 
CaCl2, 0.2 mM phlorizin), applied centrally to a 0.22 µm nitrocellulose filter GSWP 
(Millipore) over vacuum and washed with 3 ml of ice-cold stop solution, and the filter was 
assayed by scintillation counting.  All experiments were performed at least in triplicate, and 
errors indicate the SE of the mean values. 
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3.9. Chemical synthesis of photoaffinity probes 
TIPDG, BzG, 3-AP and 6-AG were synthesized according to schemes given in Figure 3.2, 
Figure 3.3, Figure 3.4 and Figure 3.5. 
3.9.1. [(2’-Iodo-4’-(3’’-trifluoromethyldiazirinyl) phenoxy]-D-
glucopyranoside (TIPDG) 
3.9.1.1. 4-Methoxytrifluoroacetophenone (1) 
The titled compound in (Figure 3.2) was synthesized as previously reported (Delfino et al., 
1993; Hatanaka et al., 1994) in 95% yield. 
3.9.1.2. 3-Iodo-4-methoxytrifluoroacetophenone (2) 
A mixture of 10 g (0.5 mol) of 1, 21.6 g (1.0 mol) of HgO, 5 ml of concentrated H2SO4, and 
12.7 g (0.5 mol) of iodine in 250 ml of CCl4 was heated to reflux with vigorous stirring for 4 
h. The reaction mixture was cooled to room temperature, and then filtered through a pad of 
celite. The filtrate was washed with 2 N aqueous sodium thiosulfate solution and brine, and 
dried over Na2SO4. The residue obtained after evaporation was purified by column 
chromatography (hexane: EA = 9:1) to give 13.87 g (85%) of 2 as a white solid; mp 52-54ºC. 
1H NMR (CDCl3, 400MHz): δ = 3.98 (s, 3H), 6.89 (d, 1H, J  = 8.8Hz), 8.04 (d, 1H, J = 
8.8Hz), 8.47 (s, 1H). 13C NMR (CDCl3, 100MHz): δ = 56.9, 86.5, 110.3, 116.6, 124.3, 132.7, 
141.7, 163.6, 177.9. 
3.9.1.3. 4-Hydroxy-3-iodo-trifluoroacetophenone (3) 
O-Demethylation of 2 was carried out as follows. A mixture of 6.70 g (20 mmol) of 2 and 2.6 
g (62 mmol) of LiCl in 50 ml of DMF was heated at reflux under argon for 2 h. The reaction 
mixture was cooled to room temperature, poured into water (200 ml) and acidified with 10% 
HCl. The product was extracted with Et2O .The ethereal layer was washed with brine twice, 
dried over MgSO4, and the residue obtained after evaporation of solvent was purified by 
column chromatography (CH2Cl2) affording 5.59 g (88%) of 3 as a white solid; mp 87-88ºC. 
1H NMR (CDCl3, 400MHz): δ = 6.13 (s, 1H), 7.09 (d, 1H, J = 8.8Hz), 7.98 (d, 1H, J = 
8.6Hz), 8.40 (d, 1H, J = 0.4Hz). 13C NMR (CDCl3, 100MHz): δ = 86.3, 115.3, 118.0, 124.6, 
125.9, 132.9, 141.2, 160.8, 178.4. DEI-MS 316 (M+); HRMS calcd for (C8H4F3IO2)+ 
315.9208, found 315.9208. 
3.9.1.4. [(2´-Iodo-4´-trifluoroacetyl) phenoxy]-2,3,4,6-tetra-O-acetyl-D- glucopyranoside 
(5) 
To a solution of α-D-acetobromoglucose 4, 4.0 g (9.73 mmol) in 80 ml of dry benzene-nitro 
methane 1:1, 3.07 g (9.71 mmol) of compound 3, 2.45 g (9.73 mmol) mercuric cyanide, and 
3.0 g molecular sieves (4Å) were added. The resulting suspension was stirred for 12 h at 50ºC. 
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The solvent was evaporated in vacuum and the residue was purified by column 
chromatography (EA: P.E = 3:1) to yield 4.71 g (75%) compound 5. 1H NMR (CDCl3, 
400MHz): δ = 2.01, 2.03, 2.07, 2.09 (s, 3H, H-Ac), 4.01-4.16 (m, 1H, H-5), 4.20-4.28 (m, 2H, 
H-6), 4.88 (dd, 1H, J1, 2  = 4.5Hz, H-1), 5.07 (t, 1H, J  = 11.7Hz, H-4), 5.18-5.33 (m, 1H, H-2), 
5.53 (t, 1H, J3, 4  = 11.7Hz, H-3), 7.03 (d, 1H, J = 10.75Hz, Ar-H), 7.92-7.96 (m, 1H, Ar-H), 
8.41 (s, 1H, Ar-H).  13C NMR(CDCl3, 100MHz): δ = 21.05, 21.16, 21.17, 21.23, 62.40, 67.43, 
68.87, 70.27, 71.46, 95.73, 115.36, 118.25, 124.39, 132.84, 141.81, 161.71, 169.92, 170.41, 
170.49, 171.19, 177.57, 177.70, 178.05, 178.83. FAB-MS 646.09 (M-H)-, 670.04 (M+Na)+, 
HRMS calcd for (C22H23O11F3NaI)+ 670.0134, found 670.0122. 
3.9.1.5. [(2´-Iodo-4´-trifluoroacetyloxime) phenoxy]-2,3,4,6-tetra-O-acetyl-D- 
glucopyranoside (6) 
A solution of 5, 4.0 g (6.18 mmol) and hydroxylamine hydrochloride 1.27 g (18.28 mmol) in 
10 ml absolute ethanol and 30 ml dry pyridine was stirred at 60ºC for 8 h. After evaporation 
of the solvent, the residue was partitioned between water and ether. The organic layer was 
washed with 1 N HCl and dried over MgSO4. After evaporation of the solvent, the crude 
oxime was purified by column chromatography on silica gel (CH2Cl2: MeOH = 10:1) to leave 
3.68 g (90%) of a colorless syrupy product 6.  1H NMR (CDCl3, 400MHz): δ = 2.01, 2.04, 
2.06, 2.09 (s, 3H, H-Ac), 4.09-4.15 (m, 1H, H-5), 4.22-4.30 (m, 2H, 2H-6), 4.88 (dd, 1H, J1, 2  
= 4.5Hz, H-1), 5.08 (t, 1H, J  = 11.7Hz, H-4), 5.20-5.34 (m, 1H, H-2), 5.54 (t, 1H, J3, 4  = 
11.7Hz, H-3), 7.04 (d, 1H, J = 10.75Hz, Ar-H), 7.92-7.96 (m, 1H, ArH), 8.36 (s, 1H, NOH), 
8.41 (s, 1H, ArH). 13C NMR (CDCl3, 100MHz): δ = 21.06, 21.15, 21.18, 21.24, 62.33, 67.36, 
68.89, 70.33, 71.49, 95.73, 115.38, 118.25, 124.40, 132.84,141.41, 141.83, 161.71, 169.92, 
170.49, 177.58, 177.70, 178.15, 178.83 . FAB-MS 661.96 (M+H)+, 683.94 (M+Na)+, HRMS 
calcd for (C22H24NO11F3I)+ 662.0347, found 662.0356, calcd for (C22H23NO11F3NaI)+ 
684.0165, found 684.0197. 
3.9.1.6. [(2´-Iodo-4´-(3´´-trifluoromethyldiaziridinyl) phenoxy]-2,3,4,6-tetra-O-acetyl-D- 
glucopyranoside (7) 
To a solution of oxime 6, 3.5 g (5.28 mmol), triethylamine 1.44 g (10.54 mmol) and (N,N-
dimethylamino) pyridine 25 mg (0.02 mmol) in 20 ml CH2Cl2 at 0ºC, was added p-
toluenesulfonyl chloride 1.0 g (5.28 mmol) portion wise with stirring. After the addition, the 
reaction mixture was stirred at room temperature for 45 min. The mixture was washed with 
water, and the organic phase was dried over MgSO4. After evaporation of the solvent, the 
crude oxime tosylate was dissolved in 20 ml dry CH2Cl2, and the solution is cooled to –78 ºC 
in a sealed tube. Liquid ammonia 3 ml was added and the mixture was stirred at room 
temperature for 16 h in a sealed tube. The excess ammonia was allowed to evaporate at room 
temperature. The residue was partitioned between water and CH2Cl2, and the organic layer 
was dried over MgSO4. After evaporation of the solvent, the residual syrupy product was 
purified by column chromatography on neutral alumina (CH2Cl2) to give 2.27 g (65%) of a 
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pale yellow syrupy compound 7. 1H NMR (CDCl3, 400MHz): δ = 2.00, 2.01, 2.06, 2.08 (s, 
3H, H-Ac), 4.00- 4.28 (m, 5H, H-5, H-6, NH), 4.78 (dd, 1H, J1, 2 = 4.4Hz, H-1), 5.02 (t, 1H, J 
= 11.6Hz, H-4), 5.12-5.27 (m, 1H, H-2), 5.43 (d, 1H, J3, 4 = 11.7Hz, H-3), 7.02 (d, 1H, J = 
10.75, Ar-H), 7.90-7.96 (m, 1H, Ar-H), 8.41 (s, 1H, Ar-H). 
FAB-MS 659.73 (M)+, 661.06 (M+H)+, 683.08 (M+Na)+, HRMS calcd for (C22H24N2O10F3I)+ 
661.3408, found 661.0506, calcd for (C22H24N2O10F3NaI)+ 683.3226, found 683.0297 
3.9.1.7. [(2´-Iodo-4´-(3´´-trifluoromethyldiazirinyl) phenoxy]-2,3,4,6-tetra-O-acetyl-D- 
glucopyranoside (8) 
To a vigorously stirred solution of 7, 1.0 g (1.51 mmol) and triethylamine 0.3 g (3.0 mmol) in 
10 ml MeOH was added portionwise I2 total 0.39 g (1.54 mmol). After being stirred for 30 
min at room temperature, the dark brown reaction mixture was partitioned between Et2O and 
saturated aqueous citric acid. The Et2O phase was washed with solutions of citric acid, sodium 
hydrogen sulfite and finally with water. The organic layer was dried over MgSO4 and 
concentrated in vacuo to give syrupy residue, which was purified by column chromatography 
on silica (CH2Cl2) to give 0.9 g (91%) yellow color syrupy compound 8. 1H NMR (CDCl3, 
400MHz): δ = 2.00, 2.01, 2.06, 2.08 (s, 3H, H-Ac), 4.00-4.10 (m, 1H, H-5), 4.18-4.24 (m, 2H, 
H-6), 4.76 (dd, 1H, J1, 2 = 4.4Hz, H-1), 5.02 (t, 1H, J = 11.6Hz, H-4), 5.12-5.26 (m, 1H, H-2), 
5.40 (d, 1H, J3, 4 = 11.7Hz, H-3), 7.00 (d, 1H, J = 10.75, Ar-H), 7.90-7.96 (m, 1H, Ar-H), 8.40 
(s, 1H, Ar-H). 
FAB-MS 658.00 (M)+, 681.04 (M+Na)+, HRMS calcd for (C22H22O10N2F3NaI)+ 681.0168, 
found 681.0159. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Reaction scheme for the synthesis of TIPDG 9. The reagents were (a) I2, HgO, conc. H2SO4, CCl4; 
(b) LiCl, DMF; 3,4-hydroxy-3-iodo-trifluoroacetophenone; (c) Hg(CN)2, nitro methane, benzene; (d) 
NH2OH.HCl, EtOH, pyridine; (e) tosyl chloride, DMAP, Et3N, DCM, NH3; (f) I2, Et3N, MeOH; (g) NaOMe. 
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3.9.1.8. [(2´-Iodo-4´-(3´´-trifluoromethyldiazirinyl) phenoxy]-D-glucopyranoside (9) 
Compound 8, 0.5 g (0.75 mmol) was deacylated by stirring with 10 ml dry MeOH containing 
0.9 g (22.5 mmol) NaOH for 2 h at room temperature. The solution was neutralized with ion 
exchange resin (Amberlite IR 120, H+), the solvent was evaporated in vacuo and the residue 
was purified on a silica column (CHCl3: MeOH = 9:1) to yield 0.36 g (98%) 9, λmax (ME) = 
358 nm (ε = 290 M-1.cm-1). 1H NMR (CD3OD, 400MHz): δ = 3.25 (dd, 1H, J = 7.7Hz,H-2), 
3.30-3.39 (m, 3H, H-3, H-4, H-5), 3.70-3.82 (dd, 1H, J = 6.0Hz, H-6), 3.88-3.91 (dd, 1H, J = 
1.6Hz, H-6), 4.27 (d, 1H, J = 7.8Hz, H-1), 7.06 (d, 1H, J = 10.8, Ar-H), 7.94-7.98 (m, 1H, Ar-
H), 8.41 (s, 1H, Ar-H). 
 13C NMR (CD3OD, 100MHz): δ = 71.51, 71.56, 75.15, 78.03, 78.15, 103.0, 117.37, 120.52, 
126.92, 134.82, 171.20, 176.67, 178.07, 179.05, 179.93.FAB-MS 489.98 (M)+, 490.99 
(M+H)+, HRMS calcd for (C14H14N2O6F3I)+ 489.9846, found 489.9846, calcd for 
(C14H15N2O6F3I)+ 490.9925, found 490.9927. 
3.9.2. [(4´-Benzoyl) phenoxy]-D- glucopyranoside (BzG) 
3.9.2.1. [4´-Benzoyl) phenoxy] –2,3,4,6-tetra-O-acetyl-D- glucopyranoside (11) 
A solution of α-D-Acetobromoglucose 4, 5.0 g (12.16 mmol) in 50 ml of benzene and in 50 
ml of nitro methane was mixed with 4-hydroxybenzophenone 10, 2.41 g (12.16 mmol), 
mercuric cyanide 3.07 g (12.16 mmol) and 3.9 g of molecular sieves (4Å) and the resulting 
mixture was stirred at 60ºC for 15 h. The reaction mixture was partitioned in between water 
and Et2O and the resulting organic phase was washed with brine and dried over MgSO4. After 
evaporation of the solvent in vacuo, the resulting residue was purified by column 
chromatography on silica (EA: PE = 1:1) to yield 4.36 g (68%) white solid compound 11. 1H 
NMR (CDCl3, 400MHz): δ = 2.01, 2.02, 2.06, 2.07 (s, 3H, H-Ac), 4.08-4.11 (m, 1H, H-5), 
4.21-4.26 (m, 2H, H-6), 4.88 (dd, 1H, J1, 2  = 4.5Hz, H-1), 5.06 (t, 1H, J  = 11.7Hz, H-4), 5.20-
5.28 (m, 1H, H-2), 5.53 (t, 1H, J3, 4  = 9.4Hz, H-3), 6.80 (dd, 2H, J = 8.42 and 2.45Hz, Ar-H), 
7.43-7.47 (m, 2H, Ar-H), 7.52-7.56 (m, 1H, Ar-H), 7.70-7.75 (m, 4H, Ar-H). 
 13C NMR (CDCl3, 100MHz): δ = 21.08, 21.16, 21.18, 21.22, 67.34, 68.89, 70.36, 71.51, 
95.67, 115.51, 128.42, 129.55, 132.27, 133.23, 138.26, 161.15, 169.99, 170.50, 170.58, 
171.30, 196.61. 
3.9.2.2. [(4´-Benzoyl) phenoxy]-D- glucopyranoside (12) 
Deacetylation of compound 11 was carried out as follows. A mixture of 2.0 g (3.78 mmol) of 
11 and 4.53 g (151.2 mmol) NaOH in 20 ml dry methanol was stirred at room temperature for 
5 h. After completion of reaction the resulting reaction mixture was neutralized with ion 
exchange resin (Amberlite IR 120, H+), the solvent was evaporated in vacuo and crude 
product was purified by column chromatography on silica (CHCl3: MeOH = 3:1) to yield 1.22 
g (90%) white solid compound 12; mp 163 ºC; λmax (ME) = 293 nm (ε = 290 M-1.cm-1). 1H 
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NMR (CD3OD, 400MHz): δ = 3.22 (dd, 1H, J = 7.6Hz, H-2), 3.27-3.38 (m, 3H, H-3, H-4, H-
5), 3.68-3.71 (dd, 1H, J = 5.9Hz, H-6), 3.87-3.90 (dd, 1H, J = 1.6Hz, H-6), 4.27 (d, 1H, J = 
7.8Hz, H-1), 7.51 (t, 2H, J = 7.8Hz, Ar-H), 7.62 (tt, 1H, J = 1.7 and 6.4Hz, Ar-H), 7.69 (d, 
2H, J = 8.1Hz, Ar-H), 7.83 (m, 4H, Ar-H). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Synthesis of BzG 12. The reagents were (a) Hg(CN)2, nitro methane, benzene; (b) NaOMe. 
3.9.3. 3-Azidophlorizin (3-AP) 
3.9.3.1. 3-Nitrophlorizin (14) 
472 mg Phlorizin 13 was dissolved in 10 ml of glacial acetic acid. The temperature of the 
solution was brought to 15°C. 75 µl of nitric acid (specific gravity 1.4) was added dropwise to 
the solution under vigorous stirring. At the end of the reaction, the color of the solution turned 
to red-brown. The solution was then poured onto 20 g ice. The green precipitates were 
collected and dried under vacuum. For further purification, the dry precipitates were dissolved 
in tetrahydrofurane. The solution was passed through a neutral aluminum oxide column. The 
yellow solution was then concentrated and a small amount of petroleum ether 30-60°C was 
added until the solution became slightly turbid. After some time crystals developed. Melting 
point 217-218°C. 
3.9.3.2. 3-Aminophorizin (15) 
482 mg 3-Nitrophlorizin 14 was dissolved in 5 ml ethanol and mixed with 150 mg 
palladium/carbon (10% Pd). Hydrogen gas was introduced into the solution gently for a 
period of 1 h at room temperature. The catalyst was then removed by filtration. The ethanolic 
solution was diluted with 10 ml of deoxygenated water and frozen immediately. Solid 3-
Aminophlorizin was obtained by freeze-drying. The yield of reduction product was almost 
100%. Melting point 91-93°C. During the whole procedure the reaction mixture was protected 
from light by aluminum foil. 
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Figure 3.4 Reaction scheme for the synthesis of 3-AP. The reagents were (a) HNO3, CH3COOH; (b) H2, Pd/C, 
EtOH; (c) NaNO2, NaN3. 
3.9.3.3. 3-Azidophlorizin (16) 
45 mg of 3-Aminophlorizin were dissolved in 3 ml of 0.5 N ice-cold hydrochloric acid. The 
solution was cooled down to -5°C. To this solution 0.5 ml 0.2 M cold sodium nitrite was 
added. The reaction was allowed to proceed at -5 °C for 10 min. A deep green color 
developed. Subsequently, 0.5 ml of 0.2 M sodium acetate was added. The solution changed its 
color rapidly to red brown while bubbling occurred because of nitrogen release. A gel-like 
precipitate was obtained by centrifugation (low speed). The dry precipitate was then dissolved 
in an excess of THF. The deep brown solution was decolored by passing through a short silica 
gel column. After part of THF had been evaporated, a few drops of water were added to 
obtain 3-Azidophlorizin precipitate. Melting point 85°C (decomposed). 
3.9.4. n-Methyl-6C- (Azimethyl)-D- glucopyranoside (6-AG) 
3.9.4.1. Methyl-2,3,4-tri-O-benzyl-7-deoxy-DL-glycero-D-glucohepta-1,5- pyranoside (18) 
Compound 17, 11.5 g (25 mmol) (Lehmann and Thieme, 1986) dissolved in 200 ml dry ether 
was added at room temperature over a period of 45 min to a stirred solution of 
methylmagnesium iodide prepared from 5.4 g (0.18 mol) magnesium turnings and 24.8 g 
(0.18 mol) methyl iodide in 310 ml dry ether. The mixture was stirred for 1 h at room 
temperature and poured on 400 g ice, and saturated aqueous NH4Cl was added until 
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precipitated magnesium salts dissolve. The organic phase was separated and the aqueous layer 
was extracted three times with 150 ml ether. The combined ether extracts were washed with 
water, dried with MgSO4, evaporated in vacuo to yield 11.5 g (97%) as syrup. The crude 
product was used without further purification in next step. 
3.9.4.2. Methyl-2,3,4-tri-O-benzyl-7-deoxy-D-glucohepto-1,5-pyranoside-6-ulose (19) 
Compound 18, 11.5 g (24 mmol), 14.0 g (69 mmol) DCC, and 1.0 g anhydrous phosphoric 
acid were dissolved in 170 ml anhydrous dimethyl sulxfoside and the mixture was stirred for 
19 h at room temperature. The suspension was added slowly with stirring to an ice-cold 
solution of 9.5 g (0.11 mol) oxalic acid in 20 ml methanol within 15 min; the mixture was 
stirred for 30 min and diluted with 350 ml saturated aqueous NaCl. After stirring for a further 
30 min, the precipitated solid was filtered and stirred two times with 250 ml ether and filtered 
again. The combined ether extracts were neutralized with saturated aqueous NaHCO3, washed 
with water, dried with MgSO4, and evaporated in vacuo. The syrupy crude product was 
dissolved in boiling ethyl acetate (40 ml) and after addition of 40 ml petroleum ether it was 
crystallized at -20°C to yield 5.5 g (48%) 19, melting point 97°C. 
1H NMR (CDCl3, 500MHz): δ = 2.16 (s, 3H, H-7), 3.39 (s, 3H, OCH3), 3.54 (dd, 1H, H-2, J2, 
3 = 9.6Hz), 3.62 (t, 1H, H-4, J4, 5 = 9.9Hz), 4.01 (t, 1H, H-3, J3, 4 = 9.5Hz), 4.12 (d, 1H, H-5), 
4.61 (d, 1H, H-1, J1, 2 = 3.5Hz), 4.60-5.00 (m, 6H, H-Bn), 7.72-7.36 (m, 15H, H-Ph). 
13C NMR (CDCl3, 125.8MHz): δ = 27.85, 55.55, 74.22, 73.46, 74.84, 75.79, 78.59, 79.57, 
81.77, 98.53, 127.58-128.43, 137.84, 137.96, 138.55, 204.36. 
3.9.4.3. Methyl- 7- deoxy-D-glucohepta- 1, 5- pyranoside-6- ulose (20) 
Compound 19, 5.8 g (12 mmol) dissolved in 200 ml methanol-ethyl acetate was debenzylated 
in the presence of 3.0 g palladium (10% C) by catalytic hydrogenation for 5 h with shaking 
using a hydrogen pressure of 3 bar at room temperature. The suspension was filtered from the 
catalyst and evaporated in vacuo to yield 2.5 g (100%) 20 as syrup. 
For further characterization 0.86 g (4.2 mmol) 17 was per-O-acetylated by stirring with 30 ml 
pyridine-acetic anhydride (2:1) for 15 h at room temperature. The mixture was poured on 250 
g ice, stirred for 30 min, and extracted three times with 50 ml dichloromethane. The combined 
organic extracts were washed with water, dried with MgSO4, and concentrated in vacuo.  The 
resulting syrup was purified on silica gel column to yield 0.97 g (67%) acetylated compound 
21. 
1H NMR (CDCl3, 500MHz): δ = 2.01, 2.02, 2.09 (s, 3H, H-Ac), 2.26 (s, 3H, H-7), 3.45 (s, 3H, 
OCH3), 4.09 (d, 1H, H-5), 4.89 (dd, 1H, H-2, J2, 3 = 10.2Hz), 5.03 (d, 1H, H-1, J1, 2 = 3.6Hz), 
5.10 (t, 1H, H-4, J4, 5 = 10.3Hz), 5.50 (t, 1H, H-3, J3, 4 = 9.8Hz). 
13C NMR (CDCl3, 125.8MHz): δ = 20.51- 20.63, 25.82, 55.85, 68.93, 69.47, 70.72, 73.32, 
97.03, 169.64, 169.79, 170.09, 203.65. 
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3.9.4.4. n-Methyl-6C-(Azimethyl)-D-glucopyranoside (22) 
A stream of dry NH3 was introduced into a solution of 2.5 g (12 mmol) 20 in 100 ml dry 
methanol at -30°C until the volume increased about 20%. Then 2.0 g (17 mmol) hydroxyl-O-
sulfonic acid was added in small portions over a time period of 1 h to the vigorously stirred 
mixture. The suspension was stirred for 3 h at -30°C, allowed to attain room temperature 
overnight, filtered, and concentrated in vacuum. A solution of the residue in 100 ml dry 
methanol containing 20 ml Et3N was cooled to 0°C and iodine was added until the red color 
persisted.  The solution was then concentrated and the residue was purified on a silica gel 
column to give 1.6 g (61%) pure compound 22. λmax (Methanol) = 335 nm (ε = 52 M-1. cm-1). 
For further characterization of compound 22, 0.2 g of it was per-O-acetylated as described for 
compound 20, to yield 0.16 g (76%) compound 23. 
1H NMR (CDCl3, 500MHz): δ = 1.08 (s, 3H, H-7), 2.02, 2.07, 2.15 (s, 3H, H-Ac), 3.02 (d, 
1H, H-5), 3.39 (s, 3H, OCH3), 4.82 (dd, 1H, H-2, J2, 3 = 10.2Hz), 4.96 (d, 1H, H-1, J1, 2 = 
3.6Hz), 5.03 (t, 1H, H-4, J4,5 = 10.3Hz), 5.37 (t, 1H, H-3, J3, 4 = 10.1Hz). 
13C NMR (CDCl3, 125.8MHz): δ = 15.15, 20.47-20.83, 25.09, 55.33, 68.58, 69.52, 70.48, 
71.19, 96.56, 169.54, 169.72, 169.90. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Synthesis of 6-AG. The reagents were (a) MeMgI, H2O; (b) Me2SO, N, N´-
dicyclohexylcarbodiimide; (c) H2, Pd/C, EtOH; (d) Ac2O, pyridine; (e) NH3, hydroxylamine-O-sulfonic acid, I2; 
(f) Ac2O, pyridine. 
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3.10. Photoaffinity labeling of loop 13 
Truncated loop 13 protein used in this study was a gift from Mobeen Raja. Before using these 
photoprobes as a label for truncated loop 13 we performed transport assays of these probes 
with rabbit small intestine brush border membrane vesicles. 
3.10.1. Isolation of small intestine brush border membrane vesicles (BBMV) 
Rabbit small intestines were obtained immediately after sacrifice of the animals. Brush border 
membrane vesicles (BBMV) from rabbit small intestine epithelial scratching were prepared by 
the magnesium precipitation method of Booth and Kenny (Booth and Kenny, 1974). Final 
BBMV were suspended at a concentration of 16 mg protein/ml in mannitol-Hepes-Tris 
(MHT) buffer (100 mmol/l mannitol, 20 mmol/l Hepes-Tris, pH 7.4, and protease inhibitor: 
Aprotinin 20 µg/ml, leupeptin 20 µg/ml, pepstatin 5 µg/ml, and chymostatin 5 µg/ml). The 
purity of the preparation was routinely determined by assaying the marker enzyme alkaline 
phosphatase (E.C.3.1.3.1), which was enriched 8 to 10 fold. BBMV were stored at -70°C until 
use and diluted to the concentration of 5 mg protein/ml with MHT buffer for transport studies. 
3.10.2. Transport measurements 
Uptake of radioactive substrate was determined at 22°C with the rapid filtration technique as 
described initially by Hopfer (Hopfer et al., 1973). The uptake was initiated by adding 20 µl 
BBMV suspension (100 µg protein) to 50 µl incubation media to give 100 mmol/l mannitol, 
20 mmol/l Hepes-Tris (pH 7.4), 100 mmol/l NaSCN or KSCN, 0.1 mmol/l substrate 5µCi D-
[3H] glucose, and the indicated inhibitor concentrations. The incubation was terminated after 5 
s by adding 1 ml ice-cold stop solution (100 mmol/l NaCl, 100 mmol/l mannitol, 20 mmol/l 
Hepes-Tris and 0.2 mmol/l phlorizin, pH 7.4) followed by rapid filtration of the suspension 
through prewetted 0.45 µm nitrocellulose filters. After rinsing with 3.5 ml ice-cold stop 
solution the wet filters were dissolved in 7 ml scintillation cocktail and counted for 
radioactivity in a liquid scintillation counter. 
Substrate uptakes presented are mean values ± S.E from at least three independent 
experiments, each performed in duplicate or triplicate. For statistical comparisons, Student’s t-
test was used. 
3.10.3. Photoaffinity labeling of truncated loop 13 protein with TIPDG or 
BzG 
The photolabeling experiments were carried out in 200 µl PBS buffer (140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) containing 200 µg truncated loop 13 
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protein and 1 mM TIPDG or with 0.5 mM BzG. The mixture was preincubated at room 
temperature in the dark for 5 min. After incubation, photolysis was carried out in a Rayonet 
photochemical reactor RPR-100, fitted with 16, 3500Å lamps at 22°C for 5 min for TIPDG 
and for BzG an Oriel photochemical reactor, fitted with 200 W medium pressure Hg lamp at 
25°C for 30 min. As a control, the photoprobe was first exposed to UV light and then added to 
the protein. No labeling was observed in the absence of UV light. We also performed 
photoaffinity labeling of truncated loop 13 with 1 mM TIPDG in the presence of 100 µM 
arbutin and with 0.5 mM BzG in the presence of 15 µM phlorizin under the same conditions 
that were employed in the other photolabeling experiments. After photoaffinity labeling the 
protein was precipitated with chloroform methanol (v/v 2:1). The protein pellet was 
solublized with 0.1% TFA in 50% acetonitrile for MALDI-TOF mass spectrometry analysis. 
 Mass spectra were acquired in the positive ion, linear mode on a Voyager DE-PRO MALDI 
(PE- Biosystems, Shelton, USA). After mixing the solublized protein with sinapinic acid 
matrix (saturated sinapinic acid solution in 0.1% TFA in 50% acetonitrile), samples were 
deposited on a MALDI plate and dried at room temperature. 
3.10.4. Photoaffinity labeling of truncated loop 13 protein with 3-AP 
Photoaffinity labeling was performed with the photolabile phlorizin analogue 3-
Azidophlorizin. The photolabeling experiments were carried out in 200 µl PBS buffer (pH 
7.3) containing 200 µg truncated loop 13 protein and 1 mM 3-Azidophlorizin. The mixture 
was preincubated at room temperature in the dark for 5 min. After incubation, photolysis was 
carried out in a Rayonet photochemical reactor RPR-100, fitted with sixteen, 2800Å lamps at 
22° C for 10 min. As a control, the photoprobe was first exposed to UV light and then added 
to the protein. No labeling was observed in the absence of UV light. After photoaffinity 
labeling the protein was precipitated with chloroform methanol (v/v 2:1). A small part of the 
protein pellet was solublized with 0.1% TFA in 50% acetonitrile for MALDI-TOF mass 
spectrometry analysis and the rest of the protein pellet was dissolved in sample buffer for 
SDS-PAGE. Proteins were separated by SDS-PAGE using NuPAGE 4-12% Bis-Tris gels 
(Invitrogen). Gels were stained with Coomassie Brilliant Blue G-250 (Neuhoff et al., 1985). 
Bands of interest were excised from gel with a clean razor blade, sliced into 1 mm3 cubes and 
incubated over night at room temperature with 200 µl of 50 mM NH4HCO3, pH 8.5, 50% 
acetonitrile, then dehydrated with 200 µl acetonitrile and dried in a centrifugal evaporator. Gel 
pieces were rehydrated with a small volume of digestion solution (50 mM NH4HCO3, 5 mM 
CaCl2, and 12.5 ng/µl of trypsin) at 4° C for 30 min. Trypsin was used at an enzyme: substrate 
ratio of ~ 1:100 by weight. Digestion was allowed to proceed overnight at 37° C. Peptides 
were extracted from the gel pieces with 100 µl of 20 mM NH4HCO3 followed by 2 extractions 
of water: acetonitrile (1:1) plus 1% trifluoroacetic acid and finally, 1 extraction with 100 µl of 
acetonitrile. All extracts were combined in a fresh tube, flash frozen and dried in a centrifugal 
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evaporator. Dried extracts were stored at -20° C until analyzed. Mass spectra were acquired in 
the positive ion, linear mode on a Voyager DE-PRO MALDI (PE-Biosystems, Shelton, USA). 
After mixing the solublized protein with 2,5-dihydroxybenzoic acid matrix (saturated DHB 
solution in 0.1% TFA in 50% acetonitrile) for intact truncated loop 13 protein, and for 
acquisition of mass spectrometric peptide map of the trypsin digested protein, 0.5 µl aliquots 
of the generated cleavage products were dispensed onto the sample support, followed by 0.5 
µl of CHCA matrix solution (solution of α-Cyno-4-hydroxycinnamic acid in 0.1% TFA in 
50% acetonitrile).  Samples were deposited on a MALDI plate and dried at room temperature 
prior to collecting the spectra. 
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4. Results 
4.1. E.coli as an expression host 
4.1.1. Construction of different clones of hSGLT1 in pET22b vector 
The full-length cDNA sequence of human sodium/D-glucose cotransporter 1 (hSGLT1) was 
amplified by PCR. Agarose gel electrophoresis shows the amplification of 2.0 Kbp fragments 
(Figure 4.1A) as expected, which corresponds to the gene size of hSGLT1. In order to further 
ensure that amplified gene product is hSGLT1 gene we performed its digestion with BamH1 
because hSGLT1 gene contains only one BamH1 restriction site. Therefore, after BamH1 
digestion it would reveal 2 DNA fragments if the PCR amplified product was correct. The 
predicted size of 2 DNA fragments is 1576 and 419 bp (which is in total 1995 bp), 
respectively. Analysis of the digestion mixture revealed that 2 DNA fragments were precisely 
produced by BamHI1digestion (Figure 4.1B).    
The cDNA sequence encoding full-length hSGLT1 was cloned into pET22b E. coli 
expression vector by using EcoR1 and Xho1 restriction enzymes sites. The plasmid was 
transformed into E. coli DH5α strain for further replication. The restriction digestion of this 
clone with EcoR1 and Xho1 obtained the evidence for the successful construction of pET22b-
hSGLT1 plasmid. 
         
Figure 4.1 Different steps for the construction of pET22b-hSGLT1 clone. (A) PCR amplification of hSGLT1 
gene by using EcoR1 and Xho1 restriction sites containing primers from EST clones. Only EST4 clone contains 
full-length hSGLT1 gene. (B) Agarose gel of BamH1 digested hSGLT1 gene resulted in 2 DNA fragments of 
1576 and 419 bp (total 1995 bp).  
In addition to the evidence mentioned above, the construct was also sequenced by using 
appropriate sequencing primer. The full sequence of the construct revealed that the cloning 
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process was successful. Other constructs of hSGLT1 in pET22b expression vector were made 
with help of the same strategy by using their respective set of primers and restriction enzymes. 
Some-times it is difficult to express full-length transporter but the expression of small parts as 
functional domains of the transporters can be favored by using suitable hosts. Domains are 
known as the regions along a single polypeptide chain that can act as independent units. To 
that extent, they can be excised from the chain, still be shown to fold correctly, and often 
exhibit biological activity (Kachalsky et al., 1995; Li de La Sierra et al., 2000). So we tried to 
express the last seven domain of hSGLT (with 11 amino acids N-terminal part) in pET22b 
expression vector. Sequence encoding ∆N12-377hSGLT1 was amplified by 
QuikChangeSite-Directed Mutagenesis method by using ∆N12-377SGLT sense and ∆N12-
377SGLT antisense primers. pET22b-∆N12-377 hSGLT1 clone was confirmed by DNA 
sequencing. The same clones as mentioned in the pET22b series were also prepared using the 
pBAD24 vector. 
4.1.2. Construction of pET22b-Unc-F and pET22b-Unc-F-hSGLT1 clones 
Unc-F gene encodes the subunit β of F0 membrane sector of E. coli ATP synthase (Walker et 
al., 1982). Fusion of Unc-F gene at the N-terminal of gene of interest resulted in a 
polycistronic gene, which encodes two different proteins. Over- expression of β-subunit of the 
E. coli ATP synthase induces a massive proliferation of membranes in E. coli C43 (DE3) 
strain, which helps in the proper insertion of membrane proteins (Arechaga et al., 2000), 
sometimes this means help in the expression of   eukaryotic membrane proteins. To test this 
idea for the expression of hSGLT1 protein, we constructed pET22b-Unc-F (control) and 
pET22b-Unc-F-hSGLT1 clones by the ligation of Xba1 digested purified Unc-F gene 
fragment (511 bp) with similarly treated dephophorylated pET22b and pET22b-hSGLT1 
expression vectors. The resulting expression plasmids pET22b-Unc-F and pET22b-Unc-F-
hSGLT1 were transformed into DH5α cells for replication and for DNA isolation. It is a 
single enzyme ligation so the Unc-F gene can ligate into pET22b and pET22b-hSGLT1 vector 
into two ways, right orientation or reverse orientation.  For the identification of clones 
containing Unc-F gene in the right orientation we performed colony PCR of these clones with 
primers: forward T7 promoter and reverse UncF. Clones with right orientation of Unc-F gene 
only shows amplification of Unc-F fragment (Figure 4.2). 
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Figure 4.2 Agarose gel of PCR amplified Unc-F gene product from the clones pET22b-Unc-F and pET22b-
Unc-F-hSGLT1 for the identification of positive clones with right orientation of Unc-F gene. Lane PU1 and 
SU1 indicate the clone containing Unc-F gene in correct orientation. 
4.1.3. hSGLT1 expression in E.coli 
Since E. coli is the first choice for heterologous expression of any foreign gene, heterologous 
expression of hSGLT1 was tried in E. coli. For the expression of hSGLT1 each clone was 
transformed into following E. coli strains (Rosetta, C41, C43, and C43Rosetta) except 
pET22b-Unc-F-hSGLT1 clone, which was transformed, into C43 and C43Rosetta cells. For 
the analytical purpose each clone was grown in 10 ml culture volume in different expression 
conditions (mentioned in the section 3.6.1 of Material and Methods). When O.D600 of culture 
reached between 0.4-0.6, protein expression was induced by IPTG (in case of pET22b vector) 
and by L- (+) arabinose (pBAD24 vector). 1 ml culture was withdrawn before and after 4 h of 
protein induction and protein expression was probed by Western blot analysis by using anti-
His tag, anti-SGLT1 and anti-FLAG tag antibodies but none of the clones tested positive for 
hSGLT1 expression (Table 4.1). 
Table 4.1 Expression of hSGLT1 in different clones of E. coli 
Clone E. coli strain Outcome 
pET22b-hSGLT1 R, C41, C43 and C43R* Expression not observed 
pET22b-hSGLT1-Spacer Same Same 
pET22b-∆N12-377 hSGLT1 Same Same 
pET22b-∆N12-377 hSGLT1-Spacer Same Same 
pET22b-Unc-F-hSGLT1 C43 and C43R Same 
pET22b-Unc-F-hSGLT1-Spacer Same Same 
pET22b-Unc-F-∆N12-377 hSGLT1 Same Same 
pET22b-hSGLT1-FLAG-Spacer R, C41, C43 and C43R Same 
pBAD24-hSGLT1-FLAG-Spacer R, C41, C43 and C43R Same 
pBAD24-∆N12-377 hSGLT1-
FLAG-Spacer 
R, C41, C43 and C43R Same 
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R, Rosetta; C41, C41 (DE3); C43, C43 (DE3); C43R, C43 (DE3) Rosetta.Conditions for 
expression are described in Material and Methods. 
However in all Western blot probed by anti- His tag antibody a specific band around 72 kDa 
(expected molecular weight region of hSGLT1) appears but this band is also present in control 
as well as in uninduced samples. 
The rationale for preparing the various plasmids is briefly summarised in the following 
paragraph. First we constructed full-length hSGLT1 clone in pET22b vector  (pET22b-
hSGLT1 series), in which the sequence encoding His tag was just after C-terminal of hSGLT1 
gene but in this case we could not see any expression of hSGLT1. Thus we were thinking 
about highly charged His tag might interfere with the proper insertion of newly synthesized 
protein into the membrane, which would result in degradation of protein. In order to test this 
possibility we constructed a second series of clones in pET22b vector (pET22b-hSGLT1-
spacer series), in which we added a 10 amino acids long spacer between hSGLT1 gene and 
the His tag, but also in this case protein expression results were negative. 
Because bacterial cotransporter posses significantly shorter N-terminal hydrophilic extensions 
than those in eukaryotes (Turk and Wright, 1997), we deleted the first seven helices  
(pET22b-∆N12-377hSGLT1 series) but also in vain. Taking into consideration a possible 
advantage associated with co-expression of outer membrane protein Unc-F with our gene of 
interest, we constructed a new series of expression plasmid in pET22b vector (pET22b-Unc-
F-hSGLT1). Results of hSGLT1 expression in this type of clones were also negative. 
4.1.4. β-subunit of E.coli ATPase expression in pET22b-Unc-F and pET22b-
Unc-F-hSGLT1 plasmids 
We tested pET22b-Unc-F and pET22b-Unc-F-hSGLT1 plasmids for the expression of β-
subunit of E. coli ATPase in C43 and C43Rosetta strains (Unc-F is toxic for other strains of E. 
coli). In this case we could not detect expression of hSGLT1 but SDS-PAGE analysis of 
uninduced and induced samples from pET22b-Unc-F and pET22b-Unc-F-hSGLT1 indicates 
quite interesting and unique band pattern  (Figure 4.3). pET22b-Unc-F clone indicates very 
good expression of the β-subunit of E. coli ATPase around 20 kDa in the induced sample 
(lane 3) while as expected there was no protein band detected in the uninduced sample (lane 
2) at this molecular weight.  To our surprise this protein band was completely absent in case 
of pET22b-Unc-F-hSGLT1 clone, uninduced (lane 4) and induced (lane 5).  The most 
interesting thing with these results is that we constructed a polycistronic gene in which protein 
translation is independent from each other but in one case we are getting expression of β-
subunit of E. coli ATPase but when we fused the Unc-F gene with hSGLT1 gene the 
expression of β-subunit of E. coli ATPase was completely abolished. These results lets 
assume that mRNA of hSGLT1 might be unstable in E. coli and that therefore when expressed 
simultaneously also the mRNA of the Unc-F gene is destroyed. 
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Figure 4.3 Coomassie- stained SDS-PAGE gel for the expression of β- subunit of E. coli ATPase in 
pET22b-Unc-F and pET22b-Unc-F-hSGLT1 plasmids. M, marker protein; PU0, pET22b-Unc-F uninduced; 
PU1, pET22b-Unc-F induced by 0.5 mM IPTG after 4 h of induction (position of arrow is indicating expression 
of β- subunit of E. coli ATPase around 20 kDa); SU0, pET22b-Unc-F-hSGLT1 uninduced; SU1, pET22b-Unc-
F-hSGLT1 induce by 0.5 mM IPTG after 4 h of induction. 
4.1.5. Messenger RNA stability of hSGLT1 in E.coli 
In order to further shed light on mRNA stability of hSGLT1 and its possible implication in 
heterologous expression of hSGLT1 in E. coli, we performed computational analysis of 
hSGLT1 mRNA by RNAdraw V1.1B program, which predicts secondary structure and 
minimum energy (Figure 4.4). Calculated secondary structure of hSGLT1 mRNA shows 
energy of –541.99 kCal at 37°C with 323 CG pairs, 225 AU pairs and 96 GU pairs. 
Computational analysis revealed that hSGLT1 mRNA sequence contains 5 potential RNase E 
sites at nucleotide sequence 576, 600, 1488, 1500, and 1558 (Table 4.2). RNase E is an 
endoribonuclease, which degrades mRNA from 5´- to 3´ direction (Mackie, 1998). RNase E is 
known to cleave mRNA substrates in single stranded regions that are proceeded or followed 
by a stable stem-loop structure (Carpousis et al., 1994; Lin-Chao and Cohen, 1991; Melefors 
and von Gabain, 1988). Moreover, the stem-loop structures adjacent to the cleavages site do 
not affect the specificity of cleavages but can influence the rate of cleavage indirectly 
(McDowall et al., 1995). 
While originally suggested that an RNase E cleavages site encompasses a 10 nucleotide 
region (ACAGA/UAUUUG) (Tomcsanyi and Apirion, 1985), subsequent analysis of many 
more sites indicate that RNase E prefers single-stranded regions that are typically, but not 
always A-U rich (Coburn and Mackie, 1999). Additionally, it is known that RNase E is a 5´-
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end-dependent endoribonuclease (Mackie, 1998) that prefer substrates with 
monophosphorylated 5´ ends to triphosphorylated termini (Lin-Chao and Cohen, 1991). The 
predicted RNase E sites in the mRNA of hSGLT1 are thus at positions 1488, 1500, and 1558 
(see Table 4.2) and the discussion section. 
 
Table 4.2 Predicted RNase E sites in the mRNA of hSGLT1 
Cleavage site Nucleotide sequence Stem-loop structure adjacent to cleavage site 
 
576 
 
ACAAUUACAG 
 
Absent  
600 GUGAUUUACA Absent 
1488 GGGAUUUCAC Present 
1500 UAUGAUUACU Present 
1558 GAUUAUCUGU Present 
   
 
Figure 4.4 Secondary structure of hSGLT1 mRNA as calculated by RNAdraw V1.1B program. 
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4.2. Pichia pastoris as an expression host 
4.2.1. Construction of expression plasmid pPICZB-hSGLT1 
hSGLT1 gene was PCR amplified using an EST clone (DKFZp686N20230Q2) as a template. 
The cDNA coding for the human sodium/glucose cotransporter hSGLT1 was cloned into the 
plasmid pPICZB that uses the AOX promoter, which is able to drive over-expression of the 
hSGLT1 gene in P. pastoris. hSGLT1 was cloned into pPICZB vector under ´AOX´ promoter. 
EcoR1 and NotI restriction sites were introduced upstream and downstream of the hSGLT1 
gene by PCR and the EcoR1 and Not1 containing gene fragment was cloned into the 
respective sites of the pPICZB vector (Figure 4.5). To facilitate immunological detection and 
protein purification, the FLAG epitope and 6His tag were attached to the C-terminus of the 
hSGLT1. In order to resolve the potential effect of 6 His tag on the proper targeting of 
hSGLT1 in the membrane we placed a 10 amino acids long spacer (VLYKSGGSPG) between 
the His tag and the hSGLT1 gene sequence. In the resulting expression vector pPICZB-
hSGLT1 the hSGLT1 gene was under the transcriptional control of the AOX1 promoter, 
which is inducible by methanol (Figure 4.5). For further propagation and growth this plasmid 
was transformed into TOP10F- E. coli strain and five colonies were grown in 10 ml low salt 
LB with 100 µg/ml Zeocin and 10 µg/ml Tetracycline for 12 h at 37°C for plasmid isolation, 
which was used for the identification of positive clones by EcoR1 and Not1 restriction 
digestion (Figure 4.6) and by DNA sequencing. 
 
 
 
 
Figure 4.5 hSGLT1 expression construct. cDNA sequence encoding full-length hSGLT1 cloned into pPICZB 
vector in EcoR1 and NotI restriction sites in the multiple cloning site (MCS), for the expression of hSGLT1. 
 
Figure 4.6 EcoR1 and Not1 restriction digestion for the identification of positive colony of pPICZB-
hSGLT1 clone. Lane pPICZB E/N, pPICZB vector digested by EcoRI and NotI restriction enzymes; Lane1-5, 
colonies of pPICZB-hSGLT1 clone digested by EcoR1 and Not1 restriction enzymes. Only positive colonies (1, 
2, 3, and 5) yield fragments of 2000 bp after EcoR1 and Not1 restriction digestion. 
MCS        hSGLIT-FLAG-Spacer-His                   MCS 
EcoR1 Not1 
AOX1 pPICZB
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4.2.2. Identification of positive clones of hSGLT1 showing protein 
expression 
Recombinant derivates of plasmid pPICZB linearized by digestion with Pme1 typically 
integrate at the AOX locus as a single copy, but multiple copy integration occurs with a 
frequency of 1 to 10%. Resistance to higher levels of Zeocin correlates with higher copy 
number for the integrated plasmid, which usually (Romanos et al., 1998) but not always 
(Clare et al., 1991) correlates with higher levels of expression of the recombinant protein of 
interest. In our case clones selected on 1000 µg/ml Zeocin concentration give the highest yield 
of hSGLT1 as judged by Western blot analysis by anti-FLAG antibody (Figure 4.7), so for 
further expression we used the clone of this plate. 
 
 
Figure 4.7 Western blot analysis by anti-FLAG antibody for the identification of positive clones for 
hSGLT1 expression. Clones 1 and 2 were selected from 500 µg/ml Zeocin plate whereas 3 and 4 were selected 
from 1000 µg/ml Zeocin plate. Clones 1, 2, 3, and 4 show expression of hSGLT1. Clones from 1000 µg/ml 
Zeocin plate shows highest expression of hSGLT1. 
4.2.3. Optimization of feeding and induction in the shake flask cultures 
For expression of proteins using the AOX1 promoter it is important to keep the methanol level 
within a relatively narrow range. In bioreactors this can be achieved by different control 
methods (Cereghino and Cregg, 2000). For expression in shake flasks Guarna (Guarna et al., 
1997) introduced a technique for on-line monitoring of methanol concentration. This still 
requires significant technical effort. Our aim was to empirically optimize a feeding protocol 
for our host strain (GS115, methanol using genotype), which works without any measuring 
devices and is, therefore, suitable for optimization. Sofar most expression protocols for shake 
flask scale are based on the recommendations by Invitrogen Corporation, USA, where 0.5% 
methanol (v/v) are added to start induction and the rest addition of 0.5% (v/v) methanol 
occurs after 24 h. 
To determine the optimum course of methanol feeding we varied the amount of methanol 
added to the culture. We decided to add methanol twice a day instead of 24 h to minimize 
concentration shifts in the medium. The medium used was BMMY. Our results shows that 
after 24 h of induction a methanol feed of 1% twice a day led to a 2 times higher protein 
expression than a methanol feed of 0.5% (v/v) twice a day as judged by Western blot by anti-
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FLAG antibody (Figure 4.8). Sofar induction with 1% (v/v) methanol and feeding with 1% 
(v/v) methanol twice a day gave optimal results in our expression system. 
 
 
Figure 4.8 Western blot analysis by anti-FLAG antibody for the optimization of feeding and induction in 
shake flasks. Clones from 1000 µg/ml Zeocin plate were grown in the same condition but induced in different 
conditions. 1, 2, 3 induced and feed with 1% methanol twice in 24 h. 4, 5, 6 same clones (1, 2, 3) induced and 
feed with 0.5% methanol once in 24 h. 
4.2.4. Purification of hSGLT1 from Pichia pastoris 
The clone with the highest protein yield was grown in BMGY medium supplemented by 100 
µg/ml Zeocin for 30-36 h at 28°C for O.D600 of 2-4/ml and then transferred to methanol 
containing medium (BMMY with 100 µg/ml Zeocin) to induce protein expression for 24 h. 
After expression, cells were disrupted in breaking buffer containing protease inhibitor cocktail 
with vigorous vortexing with acid washed chilled 0.5 mm glass beads. The cell pellet obtained 
by high-speed ultra centrifugation was washed with 4 M urea to remove peripheral membrane 
proteins. The stripped membranes were solublized in 1.2% FosCholine-12 in TG buffer at 4°C 
overnight and the solublized material was removed by high-speed centrifugation. The clear 
supernatant was applied to a preequilibrated Protino Ni-resin column for the purification of 
hSGLT1 by using buffer TG with 250 mM imidazole. The obtained protein was more than 
95% pure as judged from Coomassie stained SDS gels (Figure 4.9A).  Western blot analysis 
of different steps of hSGLT1 purification by anti-FLAG antibody (Figure 4.9B, lane I, L1, P1, 
and S4) reveal some proteolytic degradation of the recombinant transporter (protein bands 
around 30 kDa range), even though all purification steps were carried out at 0-4°C. These 
degradation products were completely absent in purified hSGLT1 (Figure 4.9B, lane 
hSGLT1). 
Purified hSGLT1 migrates on SDS-PAGE at an apparent mass of 55 kDa (Figure 4.9A, lane 
hSGLT1), which corresponds to that of the nonglycosylated transporter (Firnges et al., 2001; 
Panayotova-Heiermann et al., 1997; Quick and Wright, 2002) and is recognized by anti-
FLAG antibody (Figure 4.9B) and by anti-hSGLT1 and anti-His tag antibodies. The 1-liter 
culture of P. pastoris gives 3 mg of purified protein. 
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Figure 4.9 Coomassie- stained SDS-PAGE gel and immunoblot of it with anti-FLAG antibody during 
different stages of hSGLT1 purification. (A) M, protein marker; UI, uninduced sample; I, induced sample after 
induction of 1% methanol; L, whole cell lysate after lysis of Pichia pastoris cells expressing hSGLT1; S1, 
supernatant; P1, pellet after high-speed centrifugation; UW, washing obtained after 4 M urea wash to pellet P1; 
S4, supernatant obtained after solublization of   urea wash pellet in 1.2% FosCholine-12; and hSGLT1, Protino 
column purified hSGLT1 which shows an apparent molecular mass of 55 kDa (marked by arrow). (B) Western 
blot of above mentioned SDS-PAGE gel with anti-FLAG antibody. 
4.2.5. Functional analysis of recombinant hSGLT1 in right-side-out 
membrane vesicles 
Functionality of hSGLT1 was confirmed by determining sugar uptake (50 µM α-MDG) by 
right-side-out vesicles of P. pastoris GS115 producing hSGLT1, shown in Figure 4.10, when 
stimulated by sodium a rate of 273 ± 11 nmol × mg of membrane protein-1 × min-1 is 
observed. The uptake is almost completely blocked by phlorizin (29 ± 4 nmol × mg of 
membrane protein-1 × min-1). For the control vesicles, there was no significant difference in 
sugar uptake in the presence or absence of Na+ (33 ± 3 nmol × mg of membrane protein-1 × 
min-1), transport was also not affected by the addition of phlorizin. 
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Figure 4.10 Sugar uptake by right-side-out vesicles of P. pastoris expressing hSGLT1. 50 µM α-MDG 
uptake by right-side-out vesicles of P. pastoris GS115 producing hSGLT1 is stimulated by sodium (Na+, 100 
mM) and inhibited by phlorizin (Phlz, 10 µM). No sodium-dependent, phlorizin-sensitive uptakes were observed 
with vesicles of GS115 harboring plasmid pPICZB as a control. For the control vesicles, there was no significant 
difference in sugar uptake in the presence or absence of Na+ (33 ± 3 nmol × mg of membrane protein-1 × min-1), 
transport was also not affected by the addition of phlorizin. 
4.2.6. Functional analysis of recombinant hSGLT1 in prteoliposomes 
For reconstitution of purified hSGLT1, performed liposomes made of 90% (w/v) asolectin soy 
lecithin and 10% (w/v) cholesterol were titrated with Triton X-100 and solublization was 
followed by turbidity measurements. The detergent concentration was adjusted to the onset or 
total solublization of lipid. After mixing of the detergent-destabilized liposomes with the 
purified transporter, detergent was removed by addition of Bio-Beads SM-2 in three steps, 
first two steps at room temperature and third step at 4°C overnight. 
The time course of 10 µM α-MDG uptake into the proteoliposomes in the presence and 
absence 100 mM Na+, and in the presence of 100 µM phlorizin is shown in Figure 4.11. In the 
presence of 100 mM Na+, sugar transport peaked within 30 min at 313 ± 13 nmol α-MDG per 
mg of recombinant hSGLT1 before falling to the concentration equilibrium of about 60 nmol 
α-MDG per mg of recombinant hSGLT1 in more than 5 h time. The time course of α-MDG 
uptake in proteoliposomes demonstrated a classical overshoot (Kinne, 1976; Lucke et al., 
1978) in the presence of Na+, indicating that sugar was concentrated within the 
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proteoliposomes and that uptake was energised by the Na+electrochemical gradient via 
secondary active cotransport. The overshoot is absent if there is no sodium gradient across the 
membrane. These finding indicate a coupling of sodium flux to glucose flux. 
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Figure 4.11 Time course of sugar uptake into proteoliposomes containing purified recombinant hSGLT1. 
The time course of 10 µM α-MDG in the presence of 100 mM sodium (—) shows a 35 fold of increase in the 
initial rate of sugar uptake before reaching concentration equilibrium in 5 h. After addition of 100 µM phlorizin 
() or removal of Na+ (W), the initial rate was identical to control liposomes (•) and sugar accumulation above 
the equilibrium was not observed. 
In order to further check the functionality of purified recombinant hSGLT1, we performed 
sugar uptake in the proteoliposomes composed of hSGLT1 asolectin soy lecithin and 
cholesterol. Proteoliposomes take-up 1874 ± 65 nmol × mg-1hSGLT1 × min-1 (Figure 4.12) as 
compared to 125 ± 24 nmol × mg-1hSGLT1 × min-1 by liposomes alone. Sodium-dependent 
α-MDG uptake was completely blocked by 10 µM phlorizin (Figure 4.12). 
Phlorizin is a potent high-affinity competitive inhibitor of sugar transport by SGLT1 in native 
tissue, brush border membrane vesicles, Xenopus oocytes, and reconstituted in 
proteoliposomes (Diedrich, 1966; Diez-Sampedro et al., 2001; Ikeda et al., 1989; Quick and 
Wright, 2002; Schultz and Curran, 1970) with a half-maximum inhibition constant (KiPhlorizin) 
in the micromoler range. In our study, 10 µM phlorizin inhibited the initial rate of α-MDG 
transport in membrane vesicles by 89% (Figure 4.10), whereas the same concentration of 
phlorizin in proteoliposomes inhibits uptake by 86% (Figure 4.12). 
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Figure 4.12 Sugar uptake kinetics of proteoliposomes containing purified recombinant hSGLT1. 50 µM α-
MDG uptake by proteoliposomes made of purified hSGLT1 transport 1874 ± 65 nmol × mg of hSGLT1-1 × min-1 
in a sodium-dependent manner (when 100 mM Na+ was replaced by 100 mM K+ transport slows down to 598 ± 3 
nmol × mg of hSGLT1-1 × min-1) and 10 µM phlorizin inhibited sugar transport upto 251 ± 39 nmol × mg of 
hSGLT1-1 × min-1), whereas liposomes (control) transported only 125 ± 24 nmol × mg of hSGLT1-1 × min-1. 
The sugar selectivity of recombinant hSGLT1 in proteoliposomes was measured by 
determining the uptake of 100 µM α-MDG in the presence of 10 mM D-Glucose (D-Glc), D-
Galactose (D-Gal), 2-Deoxy-D-Glucose (2Doglc), Mannose (Man), Allose (All), L- Glucose 
(L-Glc), and 100 µM phlorizin (Phlz) in the presence of 100 mM Na+. High-affinity substrates 
of hSGLT1 D-Glc and D-Gal inhibited Na+-dependent α-MDG by 70% and 72%, while low 
affinity substrates 2Doglc, Man, All, and L-Glc inhibited sugar uptake 44%, 18%, 15%, and 
2% respectively and in the presence of 100 µM phlorizin the Na+-dependent sugar uptake was 
reduced to 84% of   original value (Figure 4.13, Table 4.3). hSGLT1 in proteoliposomes 
exhibits substrate specificity in the following order, Phlz >> α-MDG ≈ D-Glc ≈ D-Gal >> 
2Doglc > Man > All > L-Glc. 
Recombinant reconstituted hSGLT1 shows sterospecificity as it preferred D-Glu over L-Glu, 
D-Glu inhibited 75% α-MDG uptake L-Glu, inhibited only 2%. Furthermore, the sugar 
selectivity of the reconstituted recombinant hSGLT1 appears to be similar to that reported for 
transporter in different systems (Diez-Sampedro et al., 2000; Firnges et al., 2001; Kinne, 
1976; Quick and Wright, 2002). The equatorial orientation of the OH-group at the positions 
C-2 and C-3 of the D-glucose seems to be important for its recognition by hSGLT1 since in 
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the presence of mannose, 2-Deoxy-D-glucose and allose the significant inhibitory effect on α-
MDG uptake was observed. The importance of the equatorial OH-group orientation at the C-2 
and C-3 was also reported for the renal SGLT1 (Burckhardt and Kinne, 1992). The 78% 
inhibition of α-MDG uptake in the presence of D-galactose indicates that the orientation of 
OH-group at C-4 (equatorial in D-glucose and axial in D-galactose) is not that important for 
the recognition by cotransporter because D-Glu and D-Gal inhibited sugar uptake by 
transporter upto equal extent (Table 4.3), Phlz inhibited 84% of α-MDG uptake in 
proteoliposomes. 
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Figure 4.13 Sugar uptake kinetics of proteoliposomes containing purified recombinant hSGLT1. Uptake of 
100 µM α-MDG is inhibited by high-affinity substrates or inhibitors of hSGLT1 (10 mM D-glucose, D-Glc; 10 
mM D-galactose, D-Gal; 100 µM phlorizin, Phlz) but not by low-affinity substrates (e.g., 10 mM 2-deoxy-D-
glucose, 2Doglc; 10 mM mannose, Man; 10 mM allose, All; 10 mM L- glucose, L-Glc). 
Table 4.3 Effect of various substrates and inhibitors on the uptake of 100 µM α-MDG as shown in Figure 
4.13. 
Substrate/ Inhibitor           Concentration used               % of α-MDG uptake inhibition 
None                                     100 µM                                      0 
D- Glu                                   10 mM                                      75 
D- Gal                                   10 mM                                      78 
2- Doglc                               10 mM                                       44 
Man                                      10 mM                                      18 
All                                        10 mM                                      15 
L- Glu                                   10 mM                                        2      
Phlz                                      100 µM                                      84 
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For the determination of sugar uptake kinetics parameters, 1 min α-MDG uptake assays were 
performed by varying α-MDG concentration from 0.01 to 25 mM. A half–saturation constant 
(Km sugar) of 0.4 ± 0.05 mM/L and a maximum velocity (Vmax) of 3.4 ± 0.34 µmol × mg 
hSGLT1-1 × min-1 was observed (Figure 4.14). The carrier catalytic turnover number (King et 
al., 1993; Napoli et al., 1995), an index of number of sugar molecules transported per 
transporter was calculated by dividing the sugar transport Vmax by the total number of 
transporter present in the proteoliposomes.  Catalytic turnover of hSGLT1 based on the Vmax 
of 3.4 µmol × mg hSGLT1-1 × min-1 is 6 s-1 (Table 4.4), which is in good agreement with that 
obtained in previous studies (Quick and Wright, 2002) and other Na+-dependent transporter 
[e.g., the Na+/glucose transporter of Vibrio parahaemolyticus (vSGLT) (Turk et al., 2000), 
and the Na+/ proline transporter of Escherichia coli (PutP) (Jung et al., 1998)]. 
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Figure 4.14 Sugar uptake kinetics of proteoliposomes containing purified recombinant hSGLT1. 
Concentration dependence of the initial-rate sugar uptake shows a half-saturation constant ((Km sugar) of 0.4 ± 
0.05 mM/L and maximum velocity (Vmax) of 3.4 ± 0.34 µmol × mg hSGLT1-1 × min-1. 
Table 4.4 Kinetics of hSGLT1 in different systems.  
Xenopus oocytes∗ Proteoliposomes• Proteoliposomes 
This study 
Kinetic parameters 
hSGLT1                      hSGLT1∆N-GFP              hSGLT1 
Km sugar, mM/L              0.41 ± 0.03              0.38 ± 0.1                          0.4 ± 0.05 
Turnover number, s-1         50                            4                                        6 
•Reported values in previous studies(Quick and Wright, 2002). 
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4.3. Synthesis and Characterization of different photoaffinity 
probes 
In order to study the functional domains of SGLT1 photoaffinity labels were synthesized. 
They were derived from phlorizin a non-transported inhibitor, from arbutin, a transported 
inhibitor of SGLT1 and a D-glucose based label. The aim of these studies is to obtain 
information about the important contact points within the transporter at different depth and in 
various conformations. 
In the following section we describe the synthesis, photochemical properties, stability, effects 
of these probes on SGLT1 mediated glucose uptake in natural membranes and photoaffinity 
labeling of an isolated recombinant functional domain of SGLT1. In the future above labels 
will be employed for the photoaffinity labeling of whole recombinant hSGLT1. 
4.3.1. Synthesis of labels BzG and 3-AP for the identification of phlorizin 
interaction sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Chemical structure of photoaffinity probes and their sibling. (A) Phlorizin highest-affinity 
inhibitor of sugar uptake by SGLT1,  (B) [(4´-Benzoyl) phenoxy]-D- glucopyranoside (BzG), (C) 3-
Azidophlorizin (3-AP).  
BzG and 3-AP were synthesized to identify phlorizin interactions sites in the cotransporter. 
The scheme for BzG synthesis (compound 12) is given in Figure 3.3. Compound 11 was 
obtained by the reaction of α-D-acetobromoglucose 4 with 4-hydroxybenzophenone 10 in the 
presence of mercuric cyanide, which was further deacetylated to give final compound 12 in 
98% yield.   
The synthesis scheme for 3-AP (compound 16) was shown in Figure 3.4. 3-Nitrophlorizin 
(compound 14) was obtained by simple nitration of phlorizin, which was subsequently 
A 
B C
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reduced to 3-aminophlorizin  (compound 15). The transformation of 3-aminophlorizin into 3-
azidophlorizin by reacting it in the cold with dilute hydrochloric acid and sodium nitrite 
followed by addition of sodium azide to the diazonated phlorizin represents a classical 
reaction in organic chemistry. The infrared absorption at 2170 cm-1 of the final product is 
characteristics for the azido group. 
4.3.2. Synthesis of label TIPDG for the identification of arbutin ineraction 
sites 
In order to get information about arbutin binding sites in cotransporter we have synthesized 
TIPDG. The reaction scheme for the synthesis of TIPDG 9 is presented in Figure 3.2. The 
coupling of α-D-acetobromoglucose 4 with 4-hydroxy-3-iodo-trifluoroacetophenone 3 gave 
the corresponding keto compound 5, in 75% yield.  Keto compound 5 on reaction with 
hydroxylamine hydrochloride gave oxime 6, which was finally converted into aceto TIPDG 8 
by the reaction of oxime 6 with triethylamine, DMAP, P-toluenesulfonyl chloride, and NH3 
and oxidation of diaziridine 7 with iodine. TIPDG 9 was obtained after deacetylation of 
compound 8. 
 
 
 
 
 
 
 
 
 
Figure 4.16 Chemical structure of photoaffinity probe and its sibling. (A) Arbutin, a high-affinity sibling of 
TIPDG transported by SGLT1, (B) [(2’-Iodo-4’-(3’’-trifluoromethyldiazirinyl) phenoxy]-D-glucopyranoside 
(TIPDG). 
4.3.3. Synthesis of label 6-AG for the identification of D-glucose interaction 
sites 
D-Glucose is a high-affinity transported substrate of SGLT1, in order to identify its binding 
sites in cotransporter we have synthesized 6-AG photoprobe. The synthesis of 6-AG  
(compound 22) is depicted in Figure 3.5. The direct conversion of the debenzylated aldehyde 
17 into the diazirine as described (Lehmann and Thieme, 1986) gave only unsatisfactory 
results. Therefore the aldehyde 17 was converted into the corresponding methyl ketone 19 by 
reacting with methylmagnesium iodide followed by oxidation of the formed secondary 
alcohol. The less-reactive keto compound 19 could be easily converted into the diazirine 
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group with the NH3, Hydroxylamine-O-sulfonic acid reagent and subsequent oxidation of the 
intermediate diaziridine with iodine (Church et al., 1972; Church and Weiss, 1970). 
 
 
 
 
 
 
 
 
 
Figure 4.17 Chemical structure of photoaffinity probe and its sibling. (A) D-glucose transported ligand by 
SGLT1, (B) n-Methyl-6C-(Azimethyl)-D- glucopyranoside (6-AG). 
4.3.4. Photochemical properties and stability of TIPDG, BzG, 3-AP and 6-
AG 
Consistent with the spectral properties of other 3-(trifluoromethyl)-3-phenyldiazirine (Brunner 
et al., 1980; Delfino et al., 1993; Fang et al., 1998; Hatanaka et al., 1994; Nassal, 1984; Platz 
et al., 1991), the TIPDG described here shows a characteristic absorption maximum at 358 nm 
(ε = 290 M-1.cm-1). This is depicted in Figure 4.18 for TIPDG 9 photolysis studies. When a 
0.5 mM solution of 9 in methanol was irradiated in a Rayonet photochemical reactor RPR-100 
fitted with 16, 3500Å lamps at 22°C, the diazirine absorption band at 358 nm decreased with a 
half-life of 20.1 s following apparent first-order kinetics. Upon photolysis, the solution turned 
slightly orange (absorbance maximum at around 460 nm), a result of the well documented 
partial rearrangement of the diazirine to the diazo isomer. 
There have been reports on the reduction of photoactivable reagents containing azido groups 
(Bayley and Knowles, 1978) or 2-diazo-3, 3,3-trifluoropropionyloxy groups (Takagaki et al., 
1983) by commonly used reducing agents like dithiothreitol, 2-mercaptoethanol and reduced 
glutathione. To check the stability of TIPDG in the presence of these reducing agents, a 
methanolic solution of TIPDG was treated with 2- mercaptoethanol and dithiothreitol at an 
equimolar concentration or in the presence of a 5-fold excess of these reagents at 25°C. The 
reaction was followed spectrophotometrically wherein no change was observed up to 1 h. The 
diazirine moiety of TIPDG is also stable under hydrogenation with 10% Pd on carbon, which 
leads to a non-iodinated TIPDG derivative. 
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Figure 4.18 UV spectra of the reaction products from photolysis of TIPDG 9. A solution (0.5 mM) in 
methanol was irradiated for different times (0, 5, 10, 15, 20, 25, 30, 35, 40, and 45 s). The spectra show the 
decay of the characteristic diazirine absorption with a maximum at 358 nm. The half-life of decomposition was 
calculated from a logarithmic plot of the absorbance data against the irradiation time. The half-life t1/2 was 20.1 s. 
BzG shows absorption maximum at 293 nm (ε = 22500 M-1.cm-1) and reveals other 
characteristic features of benzophenone photochemistry (Dorman and Prestwich, 1994; 
Dorman and Prestwich, 2000). The half-life of photolysis of BzG was determined by 
irradiating a 0.5 mM solution in isopropanol in an Oriel photochemical reactor fitted with 200 
W medium pressure Hg lamp at 25°C. The characteristic absorption band of benzophenone in 
BzG at 293 nm disappeared with an approximate half-life of 25.4 min following first order 
reaction kinetics.   
3-AP exhibits photochemical properties similar to other aryl azide compounds. The absorption 
maxima of azide group of 3-AP are at 211 nm (ε = 28150 M-1.cm-1), 258 nm (ε = 6700 M-
1.cm-1), and 288 nm (ε = 16800 M-1.cm-1). Half-life of decomposition of this compound was 
not determined. 
The absorption maximum of the diazirine group of 6-AG is at 330 nm (ε = 45 M-1.cm-1). On 
irradiation with long wavelength UV light (λmax around 350 nm) in a Rayonet photochemical 
reactor, the 6-AG decompose with a half-life of 1.3 min. 
4.3.5. Inhibition of glucose uptake in rabbit small intestine BBMV by BzG 
and 3-AP 
To determine the affinity of BzG towards the SGLT1 cotransporter we measured its inhibitory 
potential on sodium-dependent D-glucose uptake into rabbit intestinal BBMV according to the 
method of Dixon. The effect of BzG on Na+-dependent glucose uptake in small intestine 
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BBMV is shown in Figure 4.19. BzG clearly acts as a fully competitive inhibitor. The 
apparent Ki value 12 ± 2 µM is only slightly higher than the previously reported Ki value of 8 
± 1.2 µM (Evers et al., 1978; Gibbs et al., 1982) phlorizin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 Inhibitory effects of 0, 10, 20, 30, 40, and 50 µM BzG on 5 s sodium-dependent D-glucose uptake 
into rabbit small intestine BBMV measured at two substrate concentrations, 0.1 mM (squares) and 0.2 mM 
(circles) D-glucose according to the method of Dixon. Representative experiments are shown. An inhibition 
constant (Ki) of 12 ± 2 µM was calculated from three independent experiments. 
The affinity of 3-AP for the SGLT1 cotransporter was measured according to method of 
Dixon. 3-AP strictly act as a high affinity inhibitor of sugar uptake by Na+/D-glucose 
cotransporter with a Ki value of 8.6 ± 1.6 µM. The calculated Ki value for 3-AP is exactly 
similar to its parent compound phlorizin (Ki of 8 ± 1.2 µM). 3-AP exhibits all characteristics 
features similar to phlorizin so we used this compound for the identification of phlorizin-
binding sites in truncated loop 13 protein which is predicted to be region involved in inhibitor 
binding (Novakova et al., 2001; Xia et al., 2003). 
4.3.6. Inhibition of glucose uptake in rabbit small intestine BBMV by 
TIPDG 
As shown in Figure 4.20 TIPDG exhibits a fully competitive inhibition with respect to D-
glucose with a Ki of 22 ± 5µM, this affinity is almost identical to the one of its parent 
compound arbutin (25 ± 6 µM). The modification of the phenyl ring OH group into a 
trifluoromethyl diazirine group and the mono iodination of its phenyl ring thus did not 
significantly alter the affinity to the transporter. 
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Figure 4.20 Inhibitory effects of 0, 25, 50, 75, and 100 µM TIPDG on 5 s sodium-dependent D-glucose uptake 
into rabbit small intestine BBMV measured at two substrate concentrations, 0.1 mM (squares) and 0.2 mM 
(circles) D-glucose according to the method of Dixon. Representative experiments are shown. From three 
independent experiments a Ki value of 22 ± 5 µM for TIPDG was calculated. 
4.3.7. Inhibition of glucose uptake in rabbit small intestine BBMV by 6-AG 
The affinity of 6-AG for the SGLT1 cotransporter was also evaluated by measuring its 
inhibitory potential on sodium-dependent D-glucose uptake into rabbit small intestine BBMV 
according to method of Dixon. As shown in Figure 4.21, 6-AG exhibits a fully competitive 
inhibition characteristic with respect to D-glucose with a Ki of 40 ± 5 µM. Compared to the 
inhibitory effect of D-glucose (Ki of 1 mM) the modification of the molecule with the 
photolabile diazirine group and methyl group at position C-6 of the D-glucose moiety 
drastically increase the affinity for the transporter. These results indicate that presence of alkyl 
and diazirine group (hydrophobic interaction) increase the affinity of 6-AG 25 fold as 
compared to its parent compound. 
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Figure 4.21 Inhibitory effect of 0, 100, 150, and 200 µM 6-AG on 5-s D-glucose uptake into rabbit small 
intestine BBMV measured at two substrate concentrations, 0.1 mM (squares) and 0.2 mM (circles) D-glucose 
according to the method of Dixon. Representative experiments are shown. From three independent experiments 
Ki value of 40 ± 5 µM for 6-AG was calculated. 
 
Table 4.5 Photochemical and biochemical properties of different photoaffinity probes. 
Photoaffinity  
probe 
Sibling λmax nm  
(ε = M-1.cm-1) 
Half-life of 
photolysis 
(t1/2) 
Inhibition 
constant (Ki) 
photoaffinity 
probe 
Inhibition 
constant 
(Ki) of 
sibling 
TIPDG ArbutinS 358(290)a 20.1 s 22 ± 5 µM 25 ± 6 µM 
BzG PhlorizinI 293(22500)b  25.4 min 12 ± 2 µM 8 ± 1.2 µM 
3-AP Phlorizin 211(28150)
c 
258(6700)c 
288(16800)c 
NDd 8.6 ± 1.6 µM 8 ± 1.2 µM 
6-AG D-GlucoseS 330 (45 )a 1.3 min 40  ± 5 µM 1 mM 
S Substrate                         I Inhibitor 
 a Methanol                        b Isopropanol                c Ethanol              d not determined 
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4.4. Photoaffinity labeling of truncated loop 13 with TIPDG, BzG, 
and 3-AP 
According to studies employing site-directed mutagenesis (Novakova et al., 2001) and 
molecular recognition atomic force microscopy (Wielert-Badt et al., 2002), the extra-
membranous loop 13 of SGLT1 appears to be involved in substrate and inhibitor recognition 
of SGLT1 (Panayotova-Heiermann et al., 1997; Panayotova-Heiermann et al., 1996; Xia et 
al., 2003). We therefore used this functional domain of SGLT1 (a model system loop 13 in its 
truncated form that has amino acids sequence 564-638 of SGLT1) for the identification of 
substrates and inhibitor sites. 
4.4.1. Photoaffinity labeling of truncated loop 13 with TIPDG and BzG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 MALDI-mass spectrometry of photoaffinity labeled truncated loop 13. (A) Truncated loop 13 
before labeling, (B) Photoaffinity labeling with TIPDG and (C) Photoaffinity labeling with BzG. Truncated loop 
13 protein (200 µg) was incubated with 1 mM TIPDG or with 0.5 mM BzG in 200 µl of PBS buffer for 5 min in 
the dark at room temperature followed by irradiation at 350 nm for 5 min (TIPDG) and 30 min (BzG). After 
separation from noncovalently bound TIPDG or BzG by chloroform/methanol extraction, protein was dissolved 
in SA matrix at a concentration of 50 pmol/µl and subjected to MALDI- mass spectrometry, (A) peak I, 
truncated loop 13 protein; (B) peak I, truncated loop 13 protein; peak II, truncated loop 13 protein cross-linked 
with TIPDG; (C) peak I, truncated loop 13 protein; peak II, truncated loop 13 protein labeled with BzG. 
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Photoincorporation of TIPDG into truncated loop 13 proteins was complete within 1 min of 
light exposure under our condition. Figure 4.22A shows the expected mass peak at m/z 8825.6 
Figure 4.22B demonstrates that after photoaffinity labeling with TIPDG two peaks of m/z 
8825.6 and 9287.5 can be observed. Peak I corresponds to truncated loop 13 protein and peak 
II to the photolabeled truncated loop 13 protein (9287.5). The mass difference between peak I 
and peak II (Figure 4.22B) corresponds to the mass of photolysed TIPDG (461.9). 
MALDI-mass spectra of photolabeled loop 13 proteins with BzG are shown in Figure 4.22C. 
Two intense ion signals at m/z 8825.6 and at m/z 9187.2 are observed. The ion signal at m/z 
9187.2 was absent in the MALDI-mass spectrum of control truncated loop 13 protein Figure 
4.22A. The mass increment of 361.6 amu suggests a simple carbon bond insertion of the 
photoaffinity label BzG into the protein (Figure 4.22C, peak II). 
4.4.2. Photoaffinity labeling of truncated loop 13 with 3- Azidophlorizin 
The reaction product of photolabeling of the truncated loop 13 with 3-azidophlorizin was also 
analysed by MALDI-mass spectrometry. Figure 4.23A shows the expected mass peak for loop 
13 at m/z 8825.60 and in Figure 4.23B the product after photoaffinity labeling of the loop 
with 3-azidophlorizin is depicted. Peak I corresponds to truncated loop 13 (8825.60) and peak 
II to the photolabeled truncated loop 13 protein (9275.10). The mass difference between peak 
I and peak II (Figure 4.23B) corresponds to the mass of photolysed 3-azidophlorizin (449.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 MALDI-mass spectrometry of photoaffinity  labeled truncated loop 13. Protein (200 µg) was 
incubated with 1 mM 3-azidophlorizin in 200 µl of PBS buffer for 5 min in the dark at room temperature 
followed by irradiation at 280 nm for 10 min. After separation from noncovalently bound 3-azidophlorizin by 
chloroform/ methanol extraction, protein was dissolved in DHB matrix at a concentration of 50 pmol/µl and 
subjected to MALDI-mass spectrometry, (A) Control experiment; peak I, truncated loop 13, (B) Products after 
photolabeling; peak I, truncated loop 13; peak II, truncated loop 13 cross-linked with 3-azidophlorizin. 
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4.4.3. Identification of the ligand contact points 
As a next step in identification of the ligand contact points, the photolabeled-truncated loop 
13 was digested in gel with trypsin. After extraction of the peptides from the gel, the resulting 
mixture was analyzed by MALDI-TOF mode with unlabeled-truncated loop 13 as a reference 
(Table 4.6). The only additional peak observed in the labeled probe was at m/z 624.52 (Figure 
4.24B). This can be explained as an adduct peak to m/z 175.11 (corresponding to Arg-602) 
with a difference of 449.41. The latter is equal to the mass of photolysed 3-azidophlorizin. All 
other peaks appear also in the control as shown in Figure 4.24A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
Figure 4.24 MALDI-mass spectrum of in-gel trypsin cleaved truncated loop 13. 200 µg of truncated loop 13 
was photolabeled with 3-azidophlorizin, proteins were separated on SDS-PAGE and protein bands of interest 
were excised, destained and digested in gel with trypsin. The peptides were extracted from the gel pieces with 
acetonitrile. Subsequently 0.5 µl aliquots of the generated cleavage products were dispensed onto the sample 
support, followed by 0.5 µl of CHCA matrix solution and the MALDI- mass spectra were recorded. (A) 
Truncated loop 13 before photoaffinity labeling, (B) truncated loop 13 after photoaffinity labeling with 3-
azidophlorizin. (*) peak indicates the mass shift due to modification of Arg-602 with 3-azidophlorizin. 
A 
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Table 4.6 Theoretical and measured masses of photolabeled truncated loop 13 digested with trypsin as 
shown in Figure 4.24. 
Fragment Amino 
acids 
Sequence Theoretical 
mass 
(M+H)+ 
monoisotopic 
Measured 
    mass 
(M+H)+ 
Additional 
peaks 
1 1-3 PER 401.21 NDa  
2 4-6 NSK 348.18 ND  
3 7-9 EER 433.20 ND  
4 10-33 IDLDAGEEDIQEAPEEATDTEVPK 2614.18 2614.37  
5 34 K 147.11 147.27  
6 35 K 147.11 147.27  
7 36 K 147.11 147.27  
8 37-40 GFFR 526.27 526.11  
9 41 R (602) 175.11 175.35 624.52b 
10 42-53 AYDLFCGLDQDK 1387.61 1387.63  
11 54-56 GPK 301.18 ND  
12 57-59 MTK 379.20 380.85  
13 60-66 EEEAAMK 807.35 807.26  
14 67-68 LK 260.19 ND  
15 69-77 LTDTSEHPL 1012.49 ND  
a not determined. 
b Denominates a peptide plus label 
 
We also performed photoaffinity labeling of truncated loop 13 with 1 mM 3-AP in the 
presence of 15 µM phlorizin under the same conditions that were employed in the other 
photolabeling experiments. MALDI- mass spectrum of photolabeled truncated loop 13 did not 
show any additional peak in intact truncated loop 13 and also no additional peak was present 
in the Trypsin digested samples. 
 In order to further strengthen our results that labeling of residue Arg (602) is specific and it is 
not an artifact, we chemically modified the guanidino moiety of arginine with phenylglyoxal 
treatment. Photoaffinity labeling of arginine-modified protein with 3-AP did not resulting any 
additional peak in the MALDI- mass spectrum of trypsin digested photolabeled protein.  
Taking these evidences into consideration we can claim that the ortho position of ring B of 
phlorizin labeled amino acid Arg-602 of truncated loop 13, which thus forms part of a 
phlorizin-binding site. 
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5. Discussion 
 
Integral membrane proteins such as channels and transporters are essential for all living 
organisms as they mediate the passage of ions and molecules across the membrane. The 
understanding of how membrane proteins work in health and disease has been restricted 
hitherto largely due to lack of purified protein. Most membrane proteins are present in very 
low concentrations in their native tissue, and their over-expression is a prerequisite for 
purification. The use of eukaryotic expression system has illuminated mechanistic features of 
human membrane proteins, but these are unsuitable for their large-scale purification (Fleming, 
2000; Tate, 2001). In addition, genetic disorders of membrane proteins are frequently caused 
by improper trafficking in cells, and it is not known whether missorted proteins retain their 
catalytic activity. 
The first crystal structures of membrane proteins were obtained with proteins isolated from 
naturally abundant sources, and recombinant proteins still represent minority of the membrane 
proteins that have been crystallized to date. In the case of soluble proteins, over 90% have 
been crystallized using recombinant protein, which is in contrast to the 21 recombinant of 50 
total structures for membrane proteins (Loll, 2003). Only three mammalian membrane 
proteins to date have had crystal structures determined using recombinant protein: 
prostaglandin H2 synthase-2 (COX-2), produced in insect cells (Barnett et al., 1994; 
Kurumbail et al., 1996), monoamine-oxidase B, produced in yeast (Binda et al., 2002) and 
fatty acid amide hydrolase, produced in bacteria (Bracey et al., 2002). All three proteins are 
monotopic membrane proteins and therefore have little hydrophobic surface. It should also be 
noted that the only GPCR crystallized to date, bovine rhodopsin, was obtained from natural 
source, from bovine retina where it is found in large amounts. These statistics reflect the fact 
that active recombinant membrane proteins are difficult to obtain. 
It is not surprising that heterologous production of membrane proteins poses big challenges. 
Unlike their cytoplasmic counterparts, membrane proteins have a longer way to the fully 
functional form. Once their synthesis begins, the complicated secretory machinery is engaged 
in order to achieve proper targeting and insertion into the membrane. The majority of proteins 
synthesized in many cells are cytoplasmic proteins; such cells have no sufficient capacity to 
handle large amounts of newly synthesized membrane proteins. Therefore, when produced in 
a heterologous system, membrane proteins can “saturate” the secretory pathway of cell, 
leading to protein aggregation inside different cell compartments. 
Therefore, the choice of expression system is a crucial step towards obtaining large amounts 
of transporter in its active form. Devising a successful strategy for its subsequent purification 
is nonetheless important.  For the expression of hSGLT1, various animal heterologous 
expression systems have been widely used but major disadvantages associated with these 
systems are that modified protein are frequently not trafficked properly to plasma membrane 
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(Lam et al., 1999; Lostao et al., 1995; Martin et al., 1997; Martin et al., 1996) and that it is 
costly to produce sufficient amounts of protein for structural studies. Recently functional 
expression of hSGLT1∆N-GFP was reported in E. coli (Quick and Wright, 2002), but 
hSGLT1 expression in E. coli was not reproducible in our lab as reported in the results 
section. 
5.1. E. coli as an expression host 
Among the many systems available for heterologous protein production, the Gram-negative 
bacterium E. coli remains one of the most attractive because of its ability to grow rapidly and 
at high density on inexpensive substrates, its well-characterized genetics and the availability 
of an increasingly large number of cloning vectors and mutant host strains. Taking advantages 
of E. coli expression system into consideration, first we attempted expression of hSGLT1 in 
this system. For the expression of hSGLT1, we used two types of vectors, pET22b (T7 
promoter based) and pBAD24 (PBAD promoter), both having some advantages and 
disadvantages. We constructed different clones of hSGLT1 in pET22b and pBAD24 and 
tested hSGLT1 expression in different E. coli strains and at different conditions (Table 4.1) 
but we were not able to express hSGLT1 in E. coli. 
5.1.1. Probable reasons for not getting hSGLT1 expression in E. coli 
There are some probable reasons for not getting expression of hSGLT1 in E. coli. 
5.1.1.1. Codon usage 
E. coli and indeed all cells, use a specific subset of the 61 available amino acid codons for the 
production of most mRNA (Zhang et al., 1991). So-called major codons are those, which 
occur, in highly expressed genes, whereas the minor or rare codons tend to be in genes 
expressed at low level. The hSGLT1 gene was directly amplified from human genome and 
cloned into different expression vectors in E. coli, therefore, the codons of this gene are not 
optimized for E. coli expression host. Codon degeneracy analysis shows that the hSGLT1 
gene contains 23% codons, which cannot be translated efficiently, due to the low frequency of 
the corresponding tRNAs in E. coli. Therefore, a special host strain Rosetta (DE3) was used 
for the expression of hSGLT1 in prokaryote. Rosetta host strains are BL21 derivatives, 
designed to enhance the expression of eukaryotic proteins that contain codons rarely used in 
E. coli. These strains supply tRNA genes for AGG (Arg), AGA (Arg), AUA (Val), CUA 
(Leu), CCC (Pro), GGA (Gly) on a Col-E1 compatible chloroamphenicol-resistant plasmid. 
Thus, the Rosetta strains provide for “universal” translation, which is otherwise limited by the 
codon usage of E. coli. Transcription of the tRNAs genes is driven by their native promoters. 
The use of this strain did not solve the problem of expression. Thus, codon usage does not 
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appear to be a hurdle for the expression of hSGLT1. This signifies the importance of some 
other factors, which are responsible for the expression of human membrane proteins in E. coli. 
5.1.1.2. Signal sequences 
Signal sequences or signal peptides are a well-characterized but heterogeneous group of 
cleavable N-terminal peptide extensions that direct the newly synthesized proteins to specific 
subcellular compartments. In E. coli ~20 aa signal peptides direct secretion of proteins to the 
periplasma and outer membrane (Arkowitz and Bassilana, 1994; Driessen, 1994; Driessen et 
al., 2001). In eukaryotes, signal peptides are more variable in length and direct secretion to the 
endoplasmic reticulum lumen and the general secretory pathway (Sakaguchi, 1997). There are 
however, distinctions between the prokaryotic and eukaryotic systems; most notable are 
differences in the amino acid sequences of the signal peptide itself (Nielsen et al., 1997). In 
addition there are differences in the process of secretion: i.e., the function of the signal 
recognition particle (SRP), a more highly evolved secretion apparatus, and the use of different 
chaperones (Pohlschroder et al., 1997). If E. coli signal sequences were not working for 
hSGLT1 protein we should get hSGLT1 expression either in the form of aggregated protein in 
inclusion bodies, or in degraded forms, but our results indicate that this was not the case since 
we could not detect any sign of protein expression in the E. coli expression system. We also 
attempted expression of hSGLT1 at different conditions by changing the protein inducer and 
temperature from 37 to 16°C to change folding and degradation, but in all cases no expression 
was observed. Therefore in our experiments it seems that some phenomena other than those 
mentioned above could be the real cause for not getting expression of hSGLT1 in E. coli. 
5.1.1.3. Degradation of hSGLT1 mRNA in E.coli 
As already shown by the results obtained by SDS-PAGE analysis of β- subunit of E. coli 
ATPase expression in pET22b-Unc-F and pET22b-Unc-F-hSGLT1 plasmids (Figure 4.3), the 
expression of this protein was completely abolished when simultaneous expression of both the 
β-subunit and hSGLT1 was attempted. Subsequent computational analysis of the mRNA 
sequence of hSGLT1 revealed that it contains 5 potential RNase E sites at position 576, 600, 
1488, 1500, and 1558 (Table 4.2). The position 576 (ACAAUUACAG) and 600 
(GUGAUUUACA) contains the preferred nucleotide sequence (Figure 5.1) for degradation by 
RNase E but they are lacking a stem-loop structure adjacent to the cleavage site. RNase E 
prefers AU rich nucleotide sequences with adjacent secondary structure (stem-loop) for 
degradation. So these two sites may not be all that prone for RNase E degradation.  The three 
predicted RNase E sites at position 1488 (GGGAUUUCAC), 1500 (UAUGAUUACU), and 
1558 (GAUUAUCUGU) (Table 4.2) contain extended stem loop structures adjacent to these 
sites (Figure 5.2), so these sites are highly susceptible for degradation by RNase E. Once the 
RNase E degradation process is initiated in E. coli, it activates other exonucleases which 
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further degrade mRNA of the Unc-F gene. Thus the lack of hSGLT1 expression may be due 
to the instability of the mRNA. 
The role of cyclic nucleotide regulation of Na+/glucose cotransporter (SGLT1) mRNA 
stability for the expression in LLC-PK1 cells was reported in the literature (Lee et al., 2000), 
same observations for the effect of mRNA stability on glucose transporter (GLUT1) gene 
expression were also mentioned in previous studies in mammalian cell lines (Qi and Pekala, 
1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Part of hSGLT1 mRNA secondary structure indicating the positions of RNase E sites. 
Nucleotide sequences in this structure marked as 576, I (ACAAUUACAG); 600, II (GUGAUUUACA); 1488, III 
(GGGAUUUCAC); and 1500, IV (GAUUAUCUGU) indicates the positions of RNase E susceptible site in the 
mRNA of hSGLT1. 
To our knowledge, this is the first time that possible implications of mRNA stability of 
hSGLT1 on its expression into E. coli are reported. The reason given by most of membrane 
protein molecular biologists to explain their unsuccessful attempts is that the membrane 
protein is synthesized in E. coli but due to the absence of specialized membrane protein 
folding machinery (Molecular Chaperones) and proper membrane targeting machinery in 
bacteria, expressed protein either accumulates as insoluble aggregates of improperly folded 
species called inclusion bodies, or proteolytic degradation of newly synthesized protein takes 
place due to improper targeting of protein. In our opinion, this statement does not hold true in 
I  
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all conditions and the major culprit of our failure for hSGLT1 expression in E. coli is the 
mRNA stability of hSGLT1. 
 
 
Figure 5.2 Part of hSGLT1 mRNA secondary structure indicating the position of RNase E site. Nucleotide 
sequence 1558 of hSGLT1 mRNA marked as V (GAUUAUCUGU) in this structure is highly prone for RNase E 
degradation due to presence of very high stem-loop structure adjacent to this site. 
According to our mRNA degradation hypothesis, cDNA of hSGLT1 is transcribed into 
mRNA of hSGLT1 without any problem. At this point as mentioned above since hSGLT1 
mRNA contains 5 RNase E sites, RNase E and other endoribonucleases start to degrade 
hSGLT1 mRNA from the 5´-3´ end. RNase E degradation also activates other exonucleases 
like PNPase, RNase II, and RNase R. These active exonucleases start mRNA degradation 
from 3´-5´ end of oligoribonucleotides generated by RNase E degradation into smaller parts. 
These smaller parts are further degraded into mononucleotides by oligoribonucleases. 
5.1.1.4. Comparison to other attempts to express hSGLT1 in E. coli  
In the year 2002, Quick and Wright (Quick and Wright, 2002) reported functional expression 
of hSGLT1 in E. coli. The authors of this study claimed that they obtained 1 mg functional 
hSGLT1 protein from 3-liters of bacterial culture. These results are only apparently 
contradictory to the results we obtained in E. coli expression host in the present study. We 
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analysed their plasmid construction strategy and results in a step by step manner to find out 
the probable reasons for their success. They used pTMH-6FH expression vector (Quick and 
Jung, 1998), a derivative of pT7-5 (lacY) (Bibi and Kaback, 1990) and it works under the lac 
promoter/operator (Bibi and Kaback, 1990; Quick and Jung, 1998), which is a mild promoter. 
Use of mild promoter does not seem to be real reason for their success because we also used 
pBAD expression vector, which works on the mild promoter PBAD of the araBAD operon. The 
second important thing in their methodology was the use of growing temperatures below 20°C 
and the use of BL21 E. coli strains but we employed same growth conditions with same and 
different E. coli strains and could not get expression of hSGLT1 even in a small amount.  
The most interesting and important aspect of their study is that, they shortened the N-terminal 
of hSGLT1 by 16 amino acids (sequence of hSGLT1 from 12-28 aa), this deletion increases 
the amount of hSGLT1 inserted into the membrane of E. coli by about fivefold. They reported 
that bacterial cotransporters possess significantly shorter N-terminal hydrophobic extensions 
than those in eukaryotes (Turk and Wright, 1997) so this deletion makes hSGLT1 more 
similar to its bacterial counterpart and its helps in hSGLT1 proper insertion into membrane. 
Another reason behind the fivefold increment in hSGLT1 expression and insertion into the 
membrane might, however, be stability of ∆N12-28hSGLT1 mRNA. Deletion of 48 
nucleotide sequences at the N-terminal of hSGLT1 resulted in a secondary structure, which 
contains stem-loops at the N-terminal of gene (Figure 5.3). These N-terminal stem-loop 
structures prevent or delay the mRNA degradation by RNase E. Recently with the help of 
stem-loop addition at 5´end of mRNA, increased expression of genes has been described, 
which are either not possible to express (Paulus et al., 2004) or express at very low-level 
(Carrier et al., 1998; Carrier and Keasling, 1997a; Carrier and Keasling, 1997b; Carrier and 
Keasling, 1999; Smolke et al., 2000; Smolke and Keasling, 2002) in E. coli. Another 
important point of their strategy is the addition of glycophorin A transmembrane span (as a 
15th transmembrane domain in hSGLT1 sequence) and of the green fluorescence protein 
(GFP) at the 3´end of hSGLT1 gene. It is a well-documented fact that GFP mRNA does not 
contain any RNase E sites (Smolke and Keasling, 2002). Presence of stem-loop structure at 
the 5´of ∆N12-28hSGLT1-Gly-GFP gene, protects it from RNase E degradation and due to 
the addition of GFP at the 3´of gene, provides protection to the gene from the exoribonuclease 
degradation, which acts from 3´-5´end. There are again evidences that indicate that mRNA 
stability was the decisive factor. 
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Figure 5.3 Secondary structure of a part of hSGLT1 mRNA, and ∆N12-28 hSGLT1 mRNA. (A) mRNA of 
hSGLT1 does not contains any stem-loop structure at its N-terminal so it is highly susceptible for RNase E 
degradation. (B) Deletion of amino acids from N-terminal of hSGLT1 results in a secondary structure, which 
contains stem-loop at N-terminal of gene, and these stem-loop structure protects the RNase E sites from RNase E 
degradation. 
5.2. P. pastoris as an expression host 
The methylotropic yeast P. pastoris is a powerful tool for the heterologous expression of 
protein (Cereghino and Cregg, 2000). This system combines several advantages of 
prokaryotic and eukaryotic expression systems. The techniques needed for molecular genetic 
manipulation are similar to those well established for S. cerevisiae. P. pastoris can be easily 
grown to high cell densities using defined minimal media and is able to introduce eukaryotic 
posttranslational modifications. Another advantage of the P. pastoris expression system for 
structural analysis is the possibility of 13C labeling of expressed proteins for nuclear magnetic 
resonance analysis. Feeding 13C labeled methanol provides a cost-effective possibility to 
achieve incorporation levels of up to 98%. 
5.2.1. Expression of hSGLT1 in P. pastoris 
For the functional expression of hSGLT1 in P. pastoris FLAG tag was introduced in hSGLT1 
by changing the native peptide sequence D574 AEEEN to D574YKDDDDK and a 10 amino 
acids long spacer was placed at C-terminal. Addition of spacer at C-terminal helps in the 
proper targeting of hSGLT1 in the membrane because if the His tag is directly present at the 
C-terminal of hSGLT1 it interferes with the insertion of proteins into the membrane (Turk et 
al., 2000) after its synthesis in the cytosol and we observed degradation of most of the protein 
under this condition.  P. pastoris GS115 harboring a plasmid with hSGLT1 cDNA under the 
control of the AOX promoter proved to be most suitable for the high-level expression and 
stability of recombinant hSGLT1. The transporter was detected in the yeast cells by using a 
A B
Discussion 81
FLAG antibody against the engineered FLAG epitope (Figure 4.9B), and it is active as judged 
by sodium-stimulated sugar (D-glucose) uptake. 
5.2.2. Protein purification 
For the purification of hSGLT1 we adopted a new strategy, which includes washing of 
hSGLT1 containing membranes with 4 M urea to get rid of most of peripheral and outer 
membrane proteins, which helps in the enrichment of hSGLT1. As judged by Western blot 
analysis during different stages of hSGLT1 purification, the hSGLT1 was properly inserted 
into the membrane because in the supernatant (Figure 4.9B, lane S1) and in urea washing 
(Figure 4.9B, lane UW), we could not detect any hSGLT1 protein, whereas all hSGLT1 was 
present in the pellet (Figure 4.9B, lane P1), and could be released into supernatant (Figure 
4.9B, lane S4), which was obtained after solublization of membranes in 1.2% FosCholine-12.  
A variety of molecular signals or mechanisms have been reported for the specific localization 
of particular membrane proteins to specific membrane compartments (Bibi et al., 1992; Matter 
et al., 1992; Sandoval and Bakke, 1994; Weinglass and Kaback, 2000) but the mechanism by 
which hSGLT1 inserts into the membrane is still unclear. Recently, Quick and Wright (Quick 
and Wright, 2002) showed that shorter N-terminal of hSGLT1 increases the amount of 
hSGLT1 inserted into the E. coli membrane because bacterial cotransporters posses 
significantly shorter N-terminal hydrophilic extensions than those in eukaryotes (Turk and 
Wright, 1997). However in P. pastoris most of hSGLT1 inserted into membrane without any 
modification at its N-terminal as judged by Western blot analysis (Figure 4.9B). These results 
indicate that signal sequences encoded within hSGLT1 sequence are fully functional in the P. 
pastoris.  
Purified hSGLT1 shows an apparent molecular mass of 55 kDa, which corresponds to the 
nonglycosylated transporter. Despite the apparent nonglycosylated status of hSGLT1 in P. 
pastoris, its shows biochemical properties that are indistinguishable from glycosylated 
hSGLT1. This finding also supports previous observations that N- glycosylation is not 
required for hSGLT1 activity (Quick and Wright, 2002; Turk et al., 1996).  
Recombinant hSGLT1 was purified by Ni-affinity chromatography on a Protino column to 
more than 95% purity as judged by Coomassie Blue staining SDS-PAGE gel (Figure 4.9A). 
No degradation product was observed in the purified hSGLT1 (Figure 4.9A and B). About 3 
mg of hSGLT1 was purified from 1 liter of P. pastoris culture. The yield of hSGLT1, which 
we obtained in this study, was higher than those reported for other membrane protein in P. 
pastoris expression system. The yield for other membrane protein reported in literature are as 
following, 2 mg of multidrug resistance protein1 (Cai et al., 2001), 0.7 mg of ATP-binding 
cassette transporter (Cai and Gros, 2003), 2.2 mg of NOP-1 (Bieszke et al., 1999), and 1 mg 
of 5HT5A-serotoninergic receptor (Weiss et al., 1998). 
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5.2.3. Reconstitution and functional analysis of recombinant hSGLT1 
Purified recombinant hSGLT1 was reconstituted into performed detergent-destabilized 
liposomes made of 90% (w/v) asolectin soy lecithin and 10% (w/v) cholesterol with a 
detergent concentration adjusted to the onset of solublization (Jung et al., 1998; Panayotova-
Heiermann et al., 1999; Rigaud and Levy, 2003). 100 mM sodium stimulated uptake of 50 
µM α-MDG is completely blocked by 10 µM phlorizin (Figure 4.10, Figure 4.11, Figure 4.12, 
and Figure 4.13).  In order to further characterize recombinant hSGLT1 in proteoliposomes, 
we performed competitive uptake studies of 100 µM α-MDG in the presence of inhibitor (100 
µM phlorizin) high-affinity substrates (10 mM D-glucose and D-galactose) and low-affinity 
substrates (10 mM 2-Deoxy-D-glucose, mannose, allose, and L-glucose) inhibited sugar 
uptake according to their affinity towards transporter (Table 4.3). hSGLT1 in proteoliposomes 
exhibits substrate specificity in the following order, Phlz >> α-MDG ≈ D-Glc ≈ D-Gal >> 
2Doglc > Man > All > L-Glc. Catalytic turnover of hSGLT1 based on the Vmax of 3.4 µmol × 
mg hSGLT1-1 × min-1 is 6 s-1 (Table 4.4), which is in good agreement with that obtained in 
previous studies (Quick and Wright, 2002) and other Na+-dependent transporters [e.g., the 
Na+/ glucose transporter of Vibrio parahaemolyticus (vSGLT) (Turk et al., 2000), and Na+/ 
proline transporter of Escherichia coli (PutP) (Jung et al., 1998)]. The kinetics of recombinant 
hSGLT1 in intact cells or membrane vesicles, and reconstituted proteoliposomes, mirror those 
determined for hSGLT1 in native tissue and Xenopus oocytes. 
5.2.4. Reasons for getting functional expression of hSGLT1 in P. pastoris  
One obvious question that comes into mind, if mRNA of hSGLT1 is unstable in E. coli and 
contains five potential RNase E sites why did we get expression of hSGLT1 in P. pastoris. 
The best possible explanation of this question is that the mRNA half-life and underlying 
degradation mechanisms are different in P. pastoris as compared to E. coli. In yeast, the 
degradation of the transcript begins with the shortening of the poly (A) tail at the 3´end of 
mRNA (Muhlrad and Parker, 1992; Shyu et al., 1991). Shortening of the poly (A) tail 
primarily leads to removal of the 5´-cap structure (decapping), thereby exposing the transcript 
to digestion by a 5´-3´exonuclease. In addition to decapping and 5´-3´decay, transcripts can 
also be degraded in a 3´-5´direction following deadenylation (Anderson and Parker, 1998; 
Muhlrad et al., 1995). This process is catalyzed by a conserved complex of multiple 3´-
5´exonucleases, termed the exosome that also performs a wide variety of RNA processing 
events. Currently, the available data suggest that the major mechanism of mRNA decay in 
yeast is by decapping and 5´-3´degradation (Beelman et al., 1996). Yeast mRNA can also be 
degraded by mechanisms that involve specific cleavage of transcript independent of prior poly 
(A) shortening. 
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Decapping is a key step in the yeast mRNA degradation for several reseaons. First, in the 5´-
3´pathway of mRNA degradation, it both precedes and permits the decay of the transcript 
body. Second, since individual mRNAs are decapped at different rates, decapping is also an 
important control point in mRNA decay. Third, decapping also plays a critical role in the 
process of mRNA surveillance wherein aberrant mRNAs containing nonsense codons are very 
rapidly decapped and degraded in a 5´-3´direction. The major difference in the mRNA 
degradation mechanism in E. coli and P. pastoris is that the decapping is the most crucial step 
in the mRNA degradation in yeast but in bacteria this step is not necessary for mRNA 
degradation. Average half-life of mRNA in yeast is around 3 h while in case of bacteria it is 
only 1.5 min. 
Second explanation for hSGLT1 expression in P. pastoris can be given on the basis of 
difference in the codon usages in both expression systems. As mentioned previously, codon 
usage in E. coli are ~23% bias for hSGLT1 gene as compared to H. sapiens, while codon 
usage in P. pastoris are only 9.7% bias as compared to H. sapiens. Third possible explanation 
is that P. pastoris as a eukaryote organism shares many similarities with H. sapiens at the 
cellular level and molecular mechanisms underlying transcription, translation and membrane 
trafficking of membrane proteins compared to their prokaryote counterpart E. coli. 
5.2.5. Advantages of our expression method 
Our method of expression of hSGLT1 in P. pastoris has certain advantages over other 
methods of hSGLT1 expression. We expressed full-length hSGLT1 protein without any 
significant modification in hSGLT1 as compared to previously reported hSGLT1 in E. coli 
(Quick and Wright, 2002), in which N-terminal of hSGLT1 was shortened by deleting amino 
acid residues 12-28 and GFP was fused to its C-terminal but in our opinion hSGLT1∆N-GFP 
is not suitable for most of the biochemical and biophysical applications due to its very high 
molecular weight (≈100 kDa) and due to intense modifications in it. The amount of hSGLT1 
(3 mg hSGLT1 per 1-liter of yeast culture) obtained in our expression system is the highest 
yield reported so far for hSGLT1 protein expression. The yield obtained in E. coli is only 1 
mg of purified recombinant protein per 3-liter of cultured bacterial cells. For the better 
immunological detection and to provide ease in the purification two affinity tags are present in 
our protein. Our protein purification method is very simple and efficient. The initial step 
involving washing of the protein pellet with 4 M urea resulted in a much more enriched 
hSGLT1 protein pellet which was further solublized in 1.2% FosCholine-12. Thus resultant 
solublized supernatant gave more than 95% purified hSGLT1 protein without any degradation 
product on Ni-affinity purification on a Protino column, while the other reported procedure 
includes two steps protein purification, immuno-affinity chromatography followed by gel 
filtration (Quick and Wright, 2002). Advantages of our hSGLT1 expression methods clearly 
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demonstrate that our method is novel and unique, as it provides purified protein in less time 
with less expenditure. 
5.3. Photoaffinity labeling of truncated loop 13 
A photoaffinity probe should satisfy the following criteria for its successful utilization in 
target site identification. It should be small, so as not to cause unacceptable steric perturbation 
to the system under examination. It should be stable in the dark, and highly susceptible to 
light at a wavelength that does not cause photolytic damage to the biological sample. Finally, 
the reaction with biological targets should lead to stable products to enable their isolation, 
purification and analysis. Both diazirine and benzophenone based photo probes exhibit these 
major advantages over frequently used azido photoprobes (Bayley and Knowles, 1978; Gibbs 
et al., 1982; Lin et al., 1982). TIPDG, 6-AG and BzG come closer to satisfying the chemical 
and biological criteria required for most photo reagents (Brunner et al., 1980; Delfino et al., 
1993; Dorman and Prestwich, 1994; Fang et al., 1998; Hatanaka et al., 1994; Nassal, 1984; 
Platz et al., 1991; Prestwich et al., 1997). All three photoprobes TIPDG, 6-AG and BzG can 
be photolysed at 350-360 nm, avoiding protein-damaging wavelengths. In TIPDG the electron 
withdrawing trifluoromethyl group may lead to an increased stability of the C-I bond. That 
this type of iodinated phenyldiazirine makes promising photolabeling reagents is inferred also 
from a number of studies with 3-(trifluoromethyl)-3-(3-[125I]iodophenyl) diazirine, a reagents 
widely used in the past for labeling of the apolar phase of membranes (Brunner, 1989; 
Brunner and Semenza, 1981; Brunner et al., 1983). The superb selectivity of this reagent in 
labeling integral (versus peripheral) proteins may be a direct reflection of the C-I bond 
stability during diazirine photolysis.  
Despite the early concerns about the photochemistry of aliphatic as opposed to aromatic 
diazirines (Brunner, 1993), they have now been successfully employed in the design of 
minimally perturbing photoaffinity probes (Kipp et al., 1997; Liessem et al., 1995). We, 
therefore, recently developed a novel photoreactive aliphatic diazirine-containing photoprobe 
6-AG that mimic glucose, a high-affinity substrate transport by hSGLT1. In contrast to the 
bipolar azido group, no polarization of the aliphatic diazirine group can be observed. The 
carbon atom of the three membered aliphatic diazirine ring has a chemical shift of  ~15 ppm 
in 13C NMR spectra, and the hydrogen atoms of vicinal methyl group have a chemical shift of 
~1 ppm in 1H NMR spectra. This data is typical for the chemical shifts usually observed in 
nonpolar alkyl groups. The nonpolar character of 6-AG seems to have a special benefit for the 
binding of modified substrates to hydrophobic membrane proteins.  
BzG exhibits three distinct chemical and biochemical advantages over previously reported 
azido derivatives of phlorizin (Gibbs et al., 1982; Lin et al., 1982), which gave very 
inconsistent poor labeling results due to harsh photolysis conditions and low labeling 
efficiency caused by undesired side reactions. First BzG is more stable than azido derivatives 
Discussion 85
of phlorizin. Second BzG can be manipulated in ambient light and can be activated at 350-360 
nm. Third BzG reacts preferentially with unreative C-H bonds, even in the presence of solvent 
water and bulk nucleophiles. The relative inertness of the BzG triplet state to the water should 
guarantee that no BzG photoaffinity label will be lost to reaction with water, in contrast to 
carbene photoaffinity labels, where immediately or delayed hydrolysis has frequently been 
observed (Galardy et al., 1974; Hexter and Westheimer, 1971; Shafer et al., 1966).    
Aryl azides are the most widely used photochemical reagents in the strategy of photoaffinity 
labeling receptors sites on proteins. Photoactivation of aryl azide yields several reactive 
intermediates, including singlet (half-life on the order of milliseconds) plus small fractions of 
the relatively long-lived triplet nitrenes. Special attention must, therefore, be given to 
minimize spurious labeling attendant with reactive species that can migrate from the original 
binding sites. Nitrenes are also thought to react preferentially with nucleophilic groups and 
rarely are involved in random, near-neighboring hydrogen extractions and insertion into C-H 
bonds. However, this feature is not necessarily a disadvantage in the employment of the 
phlorizin aryl azide derivative. For example, the receptor for 3-AP probably includes a polar 
group that serves as the specific interaction site for the –N3 moiety. Our rationale for the 
synthesis of 3-AP photoprobe was based on previous results reported by Diedrich group 
(Diedrich, 1990; Gibbs et al., 1982; Hosang et al., 1981), using 4-azidophlorzin that 
introduction of the azido group into the phlorizin backbone neither changes its interactions 
mode with Na+/D-glucose cotransporter nor its inhibition kinetics. 
The synthesis of the new photoactivable analogue of arbutin 9 features several noteworthy 
steps: (a) regioselective introduction of an iodine atom into the aromatic ring of compound 1 
(Figure 3.2) in the presence of excess HgO affording aryl iodide 2 in high yield (Brunner et 
al., 1980; Hatanaka et al., 1994), (b) O-Demethylation of 2, followed by coupling of phenol 3, 
in the presence of mercuric cyanide to give keto compound 5 in very high yield (Ambroise et 
al., 2000). Regioselective introduction of the iodine atom into the aromatic ring of TIPDG can 
also serve the purpose of producing a radioactive analogue of TIPDG with a high specific 
activity by using the tritiodeiodination reaction (Ambroise et al., 2000) To check this 
possibility, we performed hydrodeiodination of TIPDG in the presence of molecular hydrogen 
and 10% Pd/C, which gave non iodinated form of TIPDG within 1 h without any significant 
loss of the diazirine moiety. Ambroise (Ambroise et al., 2000) synthesized [(4’-(3’’-
trifluoromethyldiazirinyl)phenoxy]-D-galactopyranoside by stannic tetrachloride-catalyzed 
glycosylation of β-D-galactose pentaacetate with [3-(4-hydroxyphenyl)-3-(trifluoromethyl)-
3H-diazirine in 43% yield. The phenol [3-(4-hydroxy phenyl)-3-(trifluoromethyl)-3H-
diazirine was synthesized in six steps by the previously reported procedure (Hatanaka et al., 
1994), but the major drawback of this synthesis was the low yield (26%) of demethylation of 
[3-(4-methoxyphenyl)-3-(trifluoromethyl)-3H-diazirine with trimethylsilyl iodide and a 
prolonged reaction time 65 h (Hatanaka et al., 1994). In our method, demethylation of 3-Iodo-
4-methoxy-trifluoroacetophenone 2 with LiCl gives phenol 3 in 88% yield and the coupling 
Discussion 86
reaction of phenol 3 with α-D-acetobromoglucose 4 in the presence of mercuric cyanide gives 
[(2’-Iodo-4’-trifluoroacetyl)phenoxy]-2,3,4,6-tetra-O-acetyl-D-glucopyranoside 5 in 75% 
yield. Thus, our method provides a simple and versatile approach for the synthesis of different 
sugar based photoaffinity probes.   
The results on Na+-dependent glucose uptake show that TIPDG (Figure 4.20), BzG (Figure 
4.19), 3-AP, and 6-AG (Figure 4.21) interact with the high affinity Na+/D-glucose 
cotransporter. It was further demonstrated that the Ki values of TIPDG (22 ± 5 µM) and its 
prototype compound arbutin (25 ± 6 µM), BzG (12 ± 2 µM) and its respective model 
compound phlorizin (8 ± 1.2 µM), 3-AP (8.6 ± 1.6 µM) and its parent compound phlorizin (8 
± 1.2 µM) and of 6-AG (40 ± 5 µM) and its sibling D-glucose (1 mM) were essentially 
identical. Modification of phenyl ring OH group in arbutin into a trifluoromethyl diazirine 
group and mono iodination of its phenyl ring neither altered the affinity to the Na+/D-glucose 
cotransporter nor the mode of inhibition. 
 To further test the potential of TIPDG and BzG as a selective photoaffinity probe for SGLT1, 
we labeled the truncated loop 13 (amino acid 564-638 of SGLT1 amino acid sequence). 
MALDI-mass spectrometry analysis of photoaffinity labelled truncated loop 13 protein with 
TIPDG and with BzG clearly indicates that our probes successfully labeled the part of SGLT1 
protein.  
Site-directed mutagenesis studies suggest that a hydrophobic region located in the C-terminal 
loop 13 (amino acids 604-610) is critically involved in the binding of phlorizin (Novakova et 
al., 2001). The binding of phlorizin to loop 13 could be confirmed in solution by monitoring 
phlorizin-dependent fluorescence quenching of the endogenous tryptophan residue (Trp-561). 
It has been further demonstrated that the phloretin (but not the glucose) moiety of phlorizin 
interacts with loop13 (Xia et al., 2003). Phlorizin consists of a pyranoside ring and two 
aromatic rings joined by an alkyl spacer. The conformation of phlorizin in aqueous solutions 
was previously studied by two-dimensional NMR and pharmacophore analysis by Wielert-
Badt (Wielert-Badt et al., 2000). Their model indicates that the interactions via hydrogen 
bonds from the 2-, 3-, 4-, and 6-hydoxyl groups of the pyranoside and the 4- and 6-OH groups 
of aromatic ring A are essential for phlorizin binding. This information can now be combined 
with the Trp fluorescence data (Raja et al., 2003) to estimate the dimensions of the phlorizin-
binding and recognition region. We can assume that phlorizin binds to the region very close to 
position 611 by H-bonding probably with 4-OH group by acceptor/donor atom O-4 of 
aromatic ring A. Thus, position 611 is supposed to be very important in phlorizin recognition, 
as also suggested by the lower affinity of D611W mutant. The H-bonding of any one 
hydrophobic amino acid located in region 606-609 with 6-OH group by acceptor/donor atom 
O-6 of aromatic ring A of phlorizin also causes a strong interaction. 
The combination of photoaffinity labeling, SDS-PAGE, enzymatic fragmentation, and 
MALDI-mass spectrometry analysis with resulting allocation of the attachment site of the 
ortho position of ring B of phlorizin to amino acid Arg-602 now defines directly the phlorizin 
Discussion 87
binding site in loop 13. Thus, an interaction of this region with the B ring of phlorizin can be 
assumed.  Thereby the binding pocket could accommodate the phlorizin molecule in the 
predicted conformation.  On the basis of photoaffinity labeling pattern of truncated loop 13 
with 3-azidophlorizin, we could provide a generalized mechanism by which phlorizin inhibits 
sugar transport by SGLT1. According to our assumption, a phlorizin-binding region in 
SGLT1 is located between amino acids 601-611, in this region aromatic rings (A and B) of 
phlorizin interact with hydrophobic amino acids and the glucoside moiety of phlorizin is free 
to interact with sugar interaction sites of SGLT1 (Lo and Silverman, 1998; Panayotova-
Heiermann et al., 1997). 
In summary, this study provides first example of large-scale functional expression and 
purification of full-length human Na+/D-glucose cotransporter. Recombinant hSGLT1 retains 
full functionalities when reconstituted into proteoliposomes. The ability to purify functional 
cotransporter enables a battery of biochemical and biophysical experiments to probe the 
structure and function of hSGLT1, with results possibly relevant to other cotransporters in the 
SGLT family. We hope that our method of functional human membrane protein expression in 
P. pastoris   presented in this study may also provide guidelines for the expression of other 
medically important human membrane proteins which thus far could not be expressed in 
prokaryote hosts. 
5.4. Future prospective 
In the life of a membrane protein molecular biologist the happiest day is the day when he/she 
gets functional expression of target protein. Our success in the functional expression of 
hSGLT1 open doors of new opportunities to work on hSGLT1. It would be an interesting and 
challenging task to decipher the molecular basis of the sugar transport and inhibitor binding. 
What are the responsible amino acids in the protein for sugar transport and inhibitor binding? 
What would be sugar translocation and inhibitor binding mechanisms? These and many other 
questions can now be readily answered because now we have an expression system, which 
provides sufficient amount of functional hSGLT1.  
Photoaffinity labeling provides a promising approach for the identification of sugar 
translocation pathway and inhibitor binding sites (Raja et al., 2004; Raja et al., 2003; Tyagi 
and Kinne, 2003), so it would be a challenging and interesting task to performed equilibrium 
and time-dependent photoaffinity labeling studies with reconstituted recombinant hSGLT1 for 
the identification of critical amino acids responsible for sugar selectivity, uptake and for 
inhibitor binding.  
It would be interesting to address the questions related to sugar translocation pathway and 
inhibitor binding mechanism by means of luminescence spectroscopy, which has proven 
informative in the case of some other transporter (Vazquez-Ibar et al., 2003) and which could 
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ultimately provide interesting insight concerning molecular mechanisms responsible for 
transport activity. 
The ultimate goal of protein biologist working on structure-functional relationship of protein 
is to get the information about target protein structure by X-ray crystallography or Nuclear 
magnetic resonance spectroscopy, so it would be interesting and challenging tasks to work on 
this aspect of hSGLT1 structure with the help of protein obtained from our expression system. 
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6. Summary 
 
Human sodium/D-glucose cotransporter (hSGLT1) is a member of solute carrier family 
(SLC5) and plays a central role in the homeostasis of glucose, salt, and water. During the 
course of this work, first the production of recombinant hSGLT1 transporter in E. coli and P. 
pastoris was evaluated. 
A number of different expression vector constructs of hSGLT1 for its production in E. coli 
were prepared. Various affinity tags were appended to the transporter C-terminal to enable 
transporter detection and purification. We attempted expression of transporter in different 
expression vectors, in different conditions and in different E. coli strains but we could not get 
the expression of hSGLT1. During this process, we constructed clone pET22b-Unc-F-
hSGLT1 containing Unc-F gene (encoding the β-subunit of E. coli ATP synthase), in this case 
also we could not find out any hSGLT1 expression but also no expression of β-subunit of the 
E. coli ATP synthase, which was expressed in large amounts in the control clone (pET22b-
Unc-F). This finding along with the fact that hSGLT1 mRNA contains 5 RNase E sites 
suggests that in E. coli hSGLT1 mRNA is unstable and all mRNA is degraded by RNase E 
and other exoribonucleases before its translation into protein.  
Heterologous expression of hSGLT1 was also carried out in P. pastoris. hSGLT1 gene 
containing  FLAG tag and a 10 amino acids long spacer at its C-terminal was cloned into 
pPICZB plasmid and the resulted expression vector pPICZB-hSGLT1 was transformed into P. 
pastoris strain GS115 by electroporation. Purification of recombinant hSGLT1 by Nickel-
affinity-chromatography yields about 3 mg of purified recombinant hSGLT1 per 1-liter of 
cultured P. pastoris cells.  The purity of the hSGLT1 was more than 95% pure, as judged 
from Coomassie stained gels.  Purified hSGLT1 migrates on SDS-PAGE at an apparent mass 
of 55 kDa, which corresponds to that of the nonglycosylated transporter. Reconstitution of 
purified hSGLT1 yields proteoliposomes active in Na+-dependent glucose uptake and sodium-
stimulated uptake of 50 µM α-MDG is completely blocked by 10 µM phlorizin. The 1 min 
time course of α-MDG uptake in the proteoliposomes demonstrated a characteristic overshoot 
in the presence of Na+, indicating that sugar was concentrated within the proteoliposomes and 
that uptake was energised by Na+electrochemical gradient.  In order to further characterize 
recombinant hSGLT1 in proteoliposomes, we performed competitive uptake studies of 100 
µM α-MDG in the presence of inhibitor (100 µM phlorizin) high-affinity substrates (10 mM 
D-glucose and D-galactose) and low-affinity substrates (10 mM 2-Deoxy-D-glucose, 
mannose, allose, and L- glucose) that inhibited sugar uptake according to their affinity 
towards the transporter in cells and membranes. hSGLT1 in proteoliposomes exhibits 
substrate specificity in the following order, Phlz >> α-MDG ≈ D-Glc ≈ D-Gal >> 2Doglc > 
Man > All > L-Glc. Recombinant reconstituted hSGLT1 shows sterospecificity as its 
preferred D-Glu over L-Glu, D-Glu inhibited 75% of α-MDG uptake L-Glu, inhibited only 
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2%. The equatorial orientation of the OH-group at the positions C-2 and C-3 of the D-glucose 
seems to be important for its recognition by hSGLT1 since the presence of mannose, 2-
Deoxy-D-glucose and allose significant inhibitory effect on α-MDG uptake was observed. 
The 78% inhibition of α-MDG uptake in the presence of D-galactose indicates the orientation 
of OH-group at C-4 (equatorial in D-glucose and axial in D-galactose) is not that important 
for their recognition by cotransporter because D-Glu and D-Gal inhibited sugar uptake by 
transporter upto equal extent. Phlz inhibited 84% of α-MDG uptake in proteoliposomes.  
Catalytic turnover of hSGLT1 based on the Vmax of 3.4µmol × mg hSGLT1-1 × min-1 is 6 s-1. 
These results clearly indicate that purified recombinant hSGLT1 posses the full functionalities 
in this reconstituted system.  
For the identification of sugar-binding sites and phlorizin interactions sites in the transporter 
four new photoprobes were synthesized and subsequently evaluated for their effects on 
SGLT1 mediated α-MDG transport in rabbit small intestine brush border membrane vesicles.  
Results of these experiments shows that [(2’-Iodo-4’-(3’’-trifluoromethyldiazirinyl) 
phenoxy]-D-glucopyranoside (TIPDG), [(4´-Benzoyl) phenoxy]-D-glucopyranoside (BzG), 3-
Azidophlorizin (3-AP), n-Methyl-6C-(Azimethyl)-D-glucopyranoside (6-AG) inhibit α-MDG 
uptake. The Ki values of TIPDG (22 ± 5µM) and its prototype compound arbutin (25 ± 6µM), 
BzG (12 ± 2µM) and its respective model compound phlorizin (8 ± 1.2µM), 3-AP (8.6 ± 
1.6µM) and its parent compound phlorizin (8 ± 1.2µM) and of 6-AG (40 ± 5µM) and its 
sibling D-glucose (1 mM) were essentially identical. Photoaffinity labeling were performed 
with a functional domain of SGLT1 (amino acids 564-638 of the SGLT1 amino acid 
sequence, loop 13) with TIPDG, BzG, and 3-AP clearly demonstrated that our probes 
successfully labeled part of the SGLT1 protein.  
3-AP was further used to identify phlorizin-binding sites in the truncated loop 13 by the 
combination of photoaffinity labeling, SDS-PAGE, enzymatic fragmentation, and MALDI-
mass spectrometry analysis. The attachment site of the ortho position of ring B of phlorizin 
could be allocated to amino acid Arg-602, thus, an interaction of this region with the B ring of 
phlorizin can be assumed.  Thereby the binding pocket could accommodate the phlorizin 
molecule in the previously predicted conformation. 
To summarize, this study provides first example of large-scale functional expression and 
purification of full-length human Na+/D-glucose cotransporter. Recombinant hSGLT1 retains 
full functionalities when reconstituted into proteoliposomes. The ability to purify functional 
cotransporter enables a battery of biochemical and biophysical experiments to probe the 
structure and function of hSGLT1, with results possibly relevant to other cotransporters in the 
SGLT family. The synthesis of four new photoaffinity probes provides tools for the 
identification of sugar translocation pathway and inhibitor binding in the recombinant 
hSGLT1. 
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Der humane Na+/D-Glucose Kotransporter (hSGLT1) gehört zur Transporerfamilie SCL 
(solute carrier) 5 und spielt eine zentrale Rolle bei der Homöostase von Glucose, Salz und 
Wasser.  
Ziel der vorliegenden Arbeit war zunächst die heterologe Expression des Transporters in E. 
coli und P. pastoris. Für die Expression in E. coli wurden verschiedene Expressionsvektoren 
verwendet und zur Detektion und Reinigung des Transporters unterschiedliche Affinitäts Tags 
an dessen C-Terminus angehängt.  
Wir haben die Expression des Transporters mit verschiedenen Expressionsvektoren und E. 
coli Stämmen unter zahlreichen Bedingungen versucht, ohne dass die Expression von 
hSGLT1 gelang. Während dieser Versuche haben wir den Klon pET22b-Unc-F-hSGLT1 
hergestellt, welcher das Unc-F Gen für die β-Untereinheit der E. coli ATP Synthase enthält. In 
diesem Fall konnten weder hSGLT1 noch ATPase Expression nachgewiesen werden, obwohl 
letztere in hohem Ausmaß im Kontrollklon (pET22b-Unc-F) exprimiert wurde. Zusammen 
mit der Tatsache, dass die mRNA des hSGLT1 5 RNasE Sequenzen enthält, lässt dies den 
Schluß zu, dass die mRNA des hSGLT1 in E. coli instababil ist und dass die mRNA durch 
RNase E und andere Exoribonucleasen abgebaut wird, noch bevor die Translation zum 
Protein erfolgen kann. 
Desweiteren wurde die heterologe Expression von hSGLT1 in P. pastoris durchgeführt. Das 
hSGLT1 Gen wurde mit einem C-terminalen FLAG Tag und einem 10 Aminosäuren langen 
Spacer in das Plasmid pPICZB kloniert. Mit dem erhaltenen Expressionsvektor pPICB-
hSGLT1 wurde der P. pastoris Stamm GS115 durch Elektroporation transformiert. Durch 
Aufreinigung des hSGLT1 mittels Nickel-Affinitätschromatographie konnten 3 mg 
gereinigtes rekombinantes hSGLT1 Protein pro Liter P. pastoris Kultur angereichert werden. 
Die Reinheit des hSGLT1 lag bei über 95%.  
Gereinigter hSGLT1 hat in SDS-PAGE Gelen ein scheinbares Molekulargewicht von 55 kDa, 
welches der Größe eines nicht-glykosilierten Transporters entspricht.  
Nach Rekonstitution des gereinigten SGLT1 in Proteoliposomen konnte eine 
natriumgetriebene Akkumulation von α-Methyl-D-Glucose (α-MDG) nachgewiesen werden, 
die vollkommen durch 10 µM Phlorizin gehemmt wurde.  
Um rekombinanten hSGLT1 in Proteoliposomen näher zu charakterisieren, wurden 
kompetitive Aufnahmestudien mit 100 µM α-MDG in der Gegenwart von Inhibitor (100 µM 
Phlorizin), Substraten mit hoher Affinität (10 mM D-Glucose und D-Galactose) und 
Substraten mit geringer Affinität (10 mM 2-Deoxy-D-Glucose, Mannose, Allose und L-
Glucose) durchgeführt, welche die Zuckeraufnahme entsprechend ihrer Affinität zum nativen 
Transporter inhibierten. 
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hSGLT1 in Proteoliposomen weist folgende Substratspezifität auf: Phlz >> α-MDG ≈ D-Glc 
≈ D-Gal >> 2DoGlc > Man > All > L-Glc.  
Die katalytische Umsatzrate des hSGLT1 beträgt 6 s-1 auf der Basis von Vmax =  3,4 µmol × 
mg hSGLT1-1 × min-1. Diese Ergebnisse zeigen deutlich dass gereinigter rekombinanter 
hSGLT1 in dem verwendeten System volle Funktionalität aufweist.  
Für die Identifizierung der Bindungsstellen des Transporters für Zucker und der 
Interaktionsstellen mit Phlorizin wurden vier neue Photo-Proben synthetisiert und deren 
Wirkung auf den SGLT1-vermittelten α-MDG Transport in Vesikeln der 
Bürstensaummembran des Kaninchen-Dünndarms untersucht. Die Ergebnisse zeigten dass 
[(2’-Iodo-4’-(3’’-trifluoromethyldiazirinyl) phenoxy]-D-glucopyranoside (TIPDG), [(4´-
Benzoyl) phenoxy]-D- glucopyranoside (BzG), 3-Azidophlorizin (3-AP), n-Methyl-6C- 
(Azimethyl)-D- glucopyranoside (6-AG)  die α-MDG Aufnahme inhibierten. Die Ki Werte 
der Ausgangsverbindungen und deren Derivate waren nahezu identisch; 25 ± 6 µM für 
Arbutin und 22 ± 5 µM für TIPDG,  8 ± 1,2 µM für die Ausgangsverbindung Phlorizin und  
12 ± 2 µM für BzG und 8,6 ± 1,2 µM für 3-AP als deren Derivate und 1 mM für die 
Ausgangsverbindung D-Glucose und 40 ± 5 µM für 6-AG.  
Photoaffinitäts-Markierungen wurden mit einer funktionellen, rekombinant exprimierten 
Domäne des SGLT1 (Aminosären 564-638 des loop 13) mit TIPDG, BzG und 3-AP 
durchgeführt. Es konnte deutlich gezeigt werden, dass die Proben erfolgreich Teile des 
SGLT1 Proteins markierten. 
Um die Phlorizin-Bindestellen des Loop 13 zu identifizieren wurde im weiteren 3-AP in einer 
Kombination von Photoaffinitäts Markierungen, SDS-PAGE, enzymatischer Fragmentierung 
und MALDI Massenspektrometrie verwendet. Die Anlagerungsstelle des Ring B von 
Phlorizin konnte der Aminosäure Arg-602 zugeordnet werden. Folglich kann eine 
Wechselwirkung dieser Region mit dem Phlorizin B-Ring angenommen werden. Dadurch 
könnte die Bindungstasche das Phlorizinmolekül in der zuvor vorhergesagten Konformation 
beherbergen. 
In dieser Studie konnte zum ersten mal der humane Na+/D-Glucose Kotransporter in großem 
Maßstab funktionell exprimiert und gereinigt werden. Dabei konnte gezeigt werden, dass 
rekombinanter hSGLT1 bei der Rekonstitution in Proteoliposomen die volle Funktionalität 
beibehält. Die Fähigkeit den funktionellen Kotransporter zu reinigen, eröffnet viele 
Möglichkeiten die Struktur und Funktion des hSGLT1 mit Hilfe biochemischer und 
biophysikalischer Methoden zu untersuchen. Durch die Herstellung von vier neuen 
Photoaffinitäts-Proben ist es in Zukunft möglich den Transportweg von Zucker zu verfolgen 
und Inhibitor Bindestellen zu identifizieren. Die daraus resultierenden Erkenntnisse sind 
möglicherweise übertragbar auf andere Ko-Transporter der SGLT Familie. 
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